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ABSTRACT OF DISSERTATION

THE PHARMACOKINETICS OF METAL-BASED ENGINEERED
NANOMATERIALS, FOCUSING ON THE BLOOD-BRAIN BARRIER
Metal-based engineered nanomaterials (ENMs) have potential to revolutionize diagnosis,
drug delivery and manufactured products, leading to greater human ENM exposure. It is
crucial to understand ENM pharmacokinetics and their association with biological
barriers such as the blood-brain barrier (BBB). Physicochemical parameters such as size
and surface modification of ENMs play an important role in ENM fate, including their
brain association. Multifunctional ENMs showed advantages across the highly regulated
BBB. There are limited reports on ENM distribution among the blood in the brain
vasculature, the BBB, and brain parenchyma.

In this study, ceria ENM was used to study the effect of size on its pharmacokinetics.
Four sizes of ceria ENMs were studied. Five nm ceria showed a longer half-life in the
blood and higher brain association compared with other sizes and 15 and 30 nm ceria had
a higher blood cell association than 5 or 55 nm ceria. Because of the long circulation and
high brain association of 5 nm ceria compared with other sizes, its distribution between
the BBB and brain parenchyma was studied. The in situ brain perfusion technique
showed 5 nm ceria (99%) on the luminal surface of the BBB rather than the brain
parenchyma.

For biomedical applications in the central nervous system (CNS), it is vital to develop
stable and biocompatible ENMs and enhance their uptake by taking advantage of their
unique properties. Cross-linked nanoassemblies entrapping iron oxide nanoparticles
(CNA-IONPs) showed controlled particle size in biological conditions and less toxicity in
comparison to Citrate-IONPs. CNA-IONPs considerably enhanced MRI T2 relaxivities
and generated heat at mild hyperthermic temperatures (40 ~ 42°C) in the presence of
alternating magnetic field (AMF). Numerous researchers showed mild whole body
hyperthermia can increase BBB permeability for potential brain therapeutic application.
Compared to conventional hyperthermia, AMF-induced hyperthermia increased BBB
permeability with a shorter duration of hyperthermia and lower temperature, providing
the potential to enhance IONP flux across the BBB with reduced toxicity.

Overall, ENMs with optimized physicochemical properties can enhance their flux across
the BBB into the brain with desirable pharmacokinetics, which provide great potential for
diagnosis and therapy in the CNS.

KEYWORDS: Metal-based engineered nanomaterials (ENMs), blood-brain barrier
(BBB), ceria ENM, iron oxide nanoparticles, pharmacokinetics
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Chapter 1 Introduction and Objectives
28B

1.1. Introduction and Statement of the Problem
Rapid expansion of nanotechnology has allowed metal-based engineered nanomaterials
(ENMs) to be used with broad application. These applications include drug delivery
devices (1), imaging agents (2), catalysts (3) and sensors (4). Metal-based ENMs are very
attractive for academia and industry, because of the dramatic increase in human exposure
and unusual physicochemical properties such as their size and shape-dependent
optoelectronic properties (5). Little is known about metal-based ENM distribution or
persistence in the vascular system and their association with biological barriers such as
the highly regulated blood-brain barrier (BBB).

Previous studies reported that the blood and biological distribution of metal-based ENMs
was size-dependent. For example, after iv injection of gold ENMs (15, 50, 100 and 200
nm), 15 and 50 nm showed higher concentration in the blood and the most widespread
organ distribution, including the brain compared with the other sizes 24 hours after
injection (6). Our previous research showed that the blood cerium concentration was 0.56
and 1.3 mg/L after a 1 h infusion of 50 or 250 mg/kg of an ~ 30-nm commercial ceria
ENM to rats (7). In contrast, 1 h after infusion of 100 mg/kg of an in-house manufactured
5-nm ceria ENM it was 370 mg/L (8), suggesting that the rate of metal oxide ENM
clearance from blood was size dependent. However, little is known about the influence of
size on the distribution in, and clearance from, blood of metal-based ENMs.
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To investigate the persistence and distribution of a model ENM in blood, we utilized
ceria (CeO2, ceric oxide). Numerous studies reported ceria ENM to be neuro- and
cardioprotective, suggesting it has therapeutic utility in medical disorders caused by
reactive oxygen species (9-17). On the other hand, there are reports of ceria-induced
toxicity (toxicity: a cascade of events starting with exposure, proceeding through
distribution and metabolism and ending with interaction with cellular macromolecules
and the expression of a toxic end point (18)) associated with increased oxidative stress
(19-24). Nanoscale ceria is a catalyst, marketed as a diesel fuel additive in the Eolys®
system (25). There have been limited studies of the biodistribution of nanoscale ceria (26,
27).

Despite what has been done previously, there is a lack of knowledge of the

pharmacokinetics of ceria ENMs in blood other than our report that a commercial ~ 30nm ceria had an initial t ½ of ~ 0.125 h (7). It is vitally important to understand the
pharmacokinetics of ENMs in relation to their potential therapeutic applications and/or
toxicity.

How ENMs interact with living tissues, particularly biological barriers including the
BBB, after they distribute in the blood will determine their distribution and potential
applications in the central nervous system (CNS). The tightly regulated BBB plays a
crucial role in safeguarding the brain from endogenous and exogenous compounds
circulating in the blood (28). ENMs are being extensively investigated as an approach to
deliver drugs to the CNS based on their unique physicochemical properties, such as tight
junction disruption, increased retention at the brain capillaries combined with adsorption
to the capillary walls and receptor mediated transcytosis (29, 30). Several studies
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indicated that metal ENMs altered BBB integrity and increased ENM brain accumulation
(6, 7, 31). After oral gavage, 25 nm ceria appeared in the brain 1 day later and was still
present in the brain at day 7 (32). Although these studies indicated that some metal oxide
ENMs have the potential to cross the BBB, most studies on brain ENM uptake did not
separate the capillary endothelial cells from the brain cells, making it difficult to
determine whether the ENMs entered the brain or if their distribution was limited to the
capillary endothelial cells and blood in the brain vasculature. For drug delivery into the
brain, the capability of ENMs across the BBB into the brain will determine whether they
can increase the drug in specific brain tissues such as brain tumor. Meanwhile, a better
understanding of non-brain targeting ENMs in the BBB and the brain tissue will provide
crucial information for their potential side effects in the CNS. In general, for
toxicological consideration or biomedical application in the CNS, it is important to
understand the distribution of ENMs between the BBB and/or brain tissue.

After studying the pharmacokinetics in blood and interaction with the BBB of ceria
ENMs, multifunctional ENMs with desirable physicochemical and pharmacokinetic
properties were developed and investigated for potential biomedical application in the
CNS. Iron oxide nanoparticles (IONPs) have drawn increasing attention as magnetic
resonance imaging (MRI) contrast agents to evaluate blood-brain barrier dysfunction
related to tumors and other pathologies in the CNS (e.g. brain tumor, stroke, and carotid
atherosclerosis) in clinical and preclinical studies (33, 34). IONPs can also be used as a
heating source for hyperthermia as they generate heat in the presence of an alternating
magnetic field (AMF: a varying magnetic field. In an AMF, induced currents are
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generated in IONPs and as a consequence, heat is generated in the metal (35)) to increase
temperature in solutions or localized tissues, thereby killing cancer cells in a controlled
manner (36-38). A problem with most metal-based ENMs including IONPs is their
tendency to agglomerate in aqueous solutions unless their surface is properly modified,
resulting in plasma protein binding in vivo and rapid clearance by the mononuclear
phagocyte system (MPS) (39). Several studies showed that IONPs, either bare or surfacemodified, could cause cell toxicity and oxidative stress in vitro and in vivo (40-42).
Therefore, it is crucial to improve particle stability and biocompatibility of IONPs in
biological environments.

In order to prevent agglomeration of IONPs, citric acid and surfactants are frequently
used to stabilize IONPs in aqueous solutions (43-45), but these stabilizers often cause
problems. For example, our previous study on citric acid-coated-ceria showed that
agglomerated ENMs were cleared into and persisted in the MPS, which could potentially
cause toxic effects over time (8, 27). Other research on citric acid IONPs demonstrated
similar results (46, 47). Biocompatible polymer nanoparticles and water soluble polymers
have been used as less toxic and more stable alternatives to these stabilizers (35, 48).
Among these polymer-based formulations, polymeric micelles prepared from amphiphilic
block copolymers are an attractive choice to develop IONP formulations for cancer
imaging and hyperthermia (49, 50). Micelles can embed IONPs and achieve considerable
MRI contrast enhancement as a result of the collective effects of IONP clusters (51-53).
One of the critical problems associated with conventional polymeric micelles is particle
stability, particularly in dilute conditions (e.g. blood and other biological environments)
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as polymer micelles can dissociate below the critical micelle concentration (54). To solve
these problems, cross-linked nanoassemblies (CNAs) from biocompatible poly(ethylene
glycol)-poly(aspartate) [PEG-p(Asp)] block copolymers were used in my study, which
have the potential to provide stable nanoparticles that can entrap charged, hydrophobic,
and amphiphilic payloads without changing particle sizes optimized for accumulation in
certain tissues such as the CNS (55-57).

For CNS application of IONPs, it is important to increase their flux across the BBB and
brain entry. Numerous researchers have shown mild whole body hyperthermia can
increase BBB permeability, which has potential for therapeutic application in the brain
(58). Whole body hyperthermia (42 ºC for 0.5 h) significantly increased adriamycin flux
delivered in a temperature sensitive liposome across the BBB in vitro and in vivo (59).
However, whole body hyperthermia led to heat stress in vivo and caused toxicity to the
CNS such as edema (58, 60). CNA-IONPs provide the potential to serve as a stable and
biocompatible IONP delivery system to generate local hyperthermia to increase BBB
permeability and brain accumulation for diagnosis and therapy.

1.2. Objectives
1B

The overall objective of this dissertation was to gain a better understanding of the
influence of size on the distribution in and clearance from blood of metal-based ENMs,
interaction between metal-based ENMs and the BBB and develop a stable and
biocompatible magnetic ENM for the controlled delivery of heat to enhance BBB flux of
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ENMs. Four projects were involved in this dissertation and the hypotheses of each
project are described as follows:
1. “Ceria engineered nanomaterial distribution in and clearance from blood: Size matters”
Hypotheses:
a. The fate of a metal oxide ENM in blood is different than its constituent metal
b. ENM size influences its persistence in and distribution within the major
components of blood.

The cerium ion and four sizes of cubic or polyhedral citrate-coated ceria ENMs will
be iv infused into rats. Blood will be repeatedly withdrawn up to 4 h later, and in
some cases up to 30 days. An aliquot of each blood sample drawn up to 4 h after
ceria infusion will be allowed to clot. By comparison of cerium in whole blood,
serum, and the clot we could determine pharmacokinetic parameters of ceria
distribution in and clearance from blood. This study informs about the effects of
ceria ENM size on distribution and clearance from blood, which cannot be predicted
from the cerium ion and size plays an important role on pharmacokinetics and cell
associations.

2. “ Brain microvascular endothelial cell association and distribution of a 5 nm ceria
engineered nanomaterial”
Hypothesis:
c. A 5 nm ceria ENM can associate with brain capillary cells and enter the brain.
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The in situ brain perfusion method will be used to evaluate BBB integrity and
determine brain entry rate at different perfusion flow rates, ceria ENM concentrations
and perfusion durations. Eight brain regions and a choroid plexus will be collected to
test regional differences in BBB integrity and ceria ENM brain entry rate. The
capillary depletion method will be used to evaluate ceria ENM distribution between
capillary and brain tissues. Light and electron microscopy (LM and EM) will be
employed to investigate the localization of ceria nanoparticles. This research will
provide the first data on the kinetics of ceria nanoparticle interaction with the BBB
and choroid plexus. This information will be important for the design of ceria ENMs
as a therapeutic agent as well as for a comprehensive toxicology assessment.

3. “Block copolymer cross-linked nanoassemblies improve particle stability and
biocompatibility of superparamagnetic iron oxide nanoparticles”
Hypothesis:
d. CNAs containing carboxyl groups in the core would simultaneously create,
entrap, and protect IONPs as iron ions (Fe2+ and Fe3+) co-precipitate inside the
nanoassembly core, thus suppressing IONP agglomeration and improve the
biocompatibility of IONPs without losing their superparamagnetic properties.

CNA-IONPs will be developed using the co-participation method. Particle stability
and biocompatibility will be determined with or without AMF exposure at room, body,
and hyperthermic temperatures. Cytotoxicity of the particles will be investigated using
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brain endothelial-derived cells. To evaluate potential imaging applications, T2weighted MRI enhancement of CNA-IONPs and AMF-induced heating properties of
CNA-IONPs will be evaluated. CNAs with a cross-linked anionic core have potential
to improve particle stability and biocompatibility of IONPs, which would be
beneficial for future MRI and AMF-induced remote hyperthermia applications.

4. “Alternating magnetic field enhanced the blood brain barrier association and
paracellular flux of superparamagnetic iron oxide nanoparticles”
Hypothesis:
e. AMF-induced hyperthermia would significantly increase the paracellular and/or
transcellular flux of IONPs, and influence the BBB cell association with IONPs
compared with conventional hyperthermia.

CNA-IONP uptake flux across the BBB, and effects will be evaluated in in vitro BBB
models

at

body

temperature,

conventional

hyperthermia,

or

AMF-induced

hyperthermia. The paracellular flux changes induced by conventional hyperthermia or
AMF-induced hyperthermia will be monitored by Lucifer yellow (LY), a paracellular
flux maker. Using transmission electron microscopy (TEM), the cellular localization of
the iron oxide core of the studied nanoparticles will be investigated. Results of this
study will provide a better understanding how AMF-induced hyperthermia influences
IONP BBB cell association and flux across the BBB, which will be beneficial for IONP
future application for the CNS and insight into the difference between conventional
hyperthermia and AMF-induced hyperthermia on the BBB permeability and IONP flux.
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This dissertation starts with an introduction and objectives in Chapter 1. Chapter 2
contains background on metal-based ENMs, which includes an introduction to metalbased ENMs, a discussion on how their physicochemical properties influence the
pharmacokinetics and the BBB association of ENMs, and a review of previous work on
ceria and iron oxide ENMs on pharmacokinetics and the BBB association and their
problems. Chapters 3, 4, 5 and 6 present the results and discussion for each project
described above. Finally the conclusions and future studies are presented in Chapter 7.

Portions of the introduction was reproduced with permission from Dan M, Scott D,
Hardy P, Wydra R, Yokel R, Hilt J, Bae Y. Block copolymer cross-linked
nanoassemblies improve particle stability and biocompatibility of superparamagnetic
iron oxide nanoparticles. Pharmaceutical Research 2013, 30(2):552-61. Copyright ©
2013 Springer Science+Business Media, LLC. Dan M, Tseng M, Wu P, Unrine JM,
Grulke EA, Yokel RA. Brain microvascular endothelial cell association and
distribution of a 5 nm ceria engineered nanomaterial. International Journal of
Nanomedicine, 2012, 7, 4023-4036. Copyright © 2012 Dan M, Tseng M, Wu P, Unrine
JM, Grulke EA, Yokel RA. Dan M, Wu P, Grulke EA, Graham UM, Unrine JM,
Yokel RA. Ceria engineered nanomaterial distribution in and clearance from blood:
Size matters. Nanomedicine, 2012, 7(1), 95-110. Copyright © 2012 Future Medicine
Ltd.

Copyright © Mo Dan 2013
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Chapter 2 Background
29B

2.1. Metal-based engineered nanomaterials and their biomedical applications
2B

Engineered nanomaterials are normally defined as being smaller than 100 nm on one
external dimension or internal structure (62). However defining the size of ENMs is
debatable. An ENM has typically been referred as any particle less than 1 µm. Such a
small size gives the ENM an unusual surface area, size distribution, surface modification
(surface groups, inorganic or organic coatings, surface charge etc.), solubility, shape, and
potential aggregation compared to bulk material. The unique physicochemical properties
of ENMs provide great potential for biomedical applications.

The application of ENMs is a burgeoning field with immense biomedical potential. In
2006, a global survey on biomedical application of ENMs was conducted by the
European Science and Technology Observatory. This survey found that more than 150
companies were developing nanoscale therapeutics; and 24 nanotechnology-based
therapeutic products were already approved for clinical use with sales exceeding $5.4
billion (62). Biomedical nanotechnology sales were expected to grow to $70-160 billion
by 2015 worldwide (63). Most metal-based ENMs have unique physical properties which
can be dictated for certain biomedical applications, giving them a strong potential for
diagnosis and therapy. For example, the optical properties of gold nanorods are directly
related with their shape and aspect ratio, which were used for contrast imaging and
photothermal therapy (64).
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Although the concept of metal-based ENMs was introduced in recent years, humans
started to synthesize and use metal nanoparticles hundreds of years ago. Gold
nanoparticles were used as part of ancient ayurvedic medicine in India 2000 years ago
(65). Although previously used, the first scientific study on metal nanoparticles has been
credited to English physicist and chemist Michael Faraday in 1857. Faraday studied and
reported the size dependent optical properties of gold colloids (66). The application of
metal-based ENMs has expanded in recent years as a result of significant developments
in the synthesis process. It has become possible to design and engineer metal-based
ENMs to produce specific and desired properties for different applications. I summarized
the major novel biomedical applications below.

2.1.1 Photothermal therapy
Photothermal therapy has been actively investigated to localize cancer treatment, with
promising potential to minimize damage to non-cancerous tissue. Metal-based ENMs
can be “tuned” to serve as either strong absorbers or scatters of near-infrared light, which
enables their use for photothermal therapy.

Gold nanoshells have been extensively

studied for this application (67). For example, the therapeutic efficacy of photothermal
therapy induced by gold nanoshells was tested in mouse tumors. The gold nanoshell was
delivered via tail veil injection and the tumors were irradiated with near infrared (NIR)
lasers at 808 nm wavelength at a power of 4 W/cm2 for 3 min. Several weeks after
treatment, all mice in the treatment group were free of tumors. Meanwhile, they also
showed that the gold nanoshell showed dramatic contrast enhancement for optical
coherence tomography (OCT) imaging (68). Through this study gold nanoshells
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demonstrated their effectiveness in imaging and ablating tumors in vivo. This could allow
integration of gold nanoshells into diagnostic and therapeutic technologies.

2.1.2. Radiotherapy
Metal-based ENMs provide an advantage in radiotherapy because of their optical
properties, surface resonance and wavelength tunability. Gold ENMs are the most studied
metal-based ENMs for use in radiotherapy. The intrinsic radioactive properties of gold
(Au-198 and Au-199) ENMs can be tuned, which make them ideal candidates for
radiotherapy (69). Dose and size dependent cytotoxicity of silver and gold ENMs were
demonstrated on glioma cells in combination with radiation. And 20 nm silver ENMs and
50 nm gold ENMs showed the most effective radiosensitization at low radiation doses
compared with other sizes (70). A recent report studied the radiosensitization application
of gold ENMs using a size range of 14-74 nm. They demonstrated that both the size and
the amount of uptake of ENMs into cells affect radiosensitization. Their results also
showed that 50 nm gold ENMs displayed the utmost enhancement compared to 14 and 74
nm (71). For radiotherapy application, it will be critical to develop ENMs with the
desirable size to enhance their radiosensitization ability.

2.1.3. Imaging
Their optical, magnetic, and other properties have made metal-based ENMs very
attractive for imaging.

Numerous studies have demonstrated that gold ENMs are

excellent contrast agents. This is due to the fact that the intensity of absorption and
scattering of gold ENMs is significantly higher than most organic dyes (72).
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The

applications of gold ENMs for in vivo imaging can be summarized as: 1) Optical
coherence tomography; 2) Two-photon luminescence; 3) Photoacoustic tomography; 4)
Surface enhanced Raman scattering; 5) X-ray computed tomography imaging. The details
about these five applications were reviewed in 2011(73). Another most investigated and
widely used metal-based ENM for MR imaging is IONP, due to their unique magnetic
properties. More detail about this application will be reviewed and discussed in 2.5.

2.1.4. Drug delivery
The unique properties of metal-based ENMs have allowed for various controlled delivery
systems to be developed such as pulsed laser induced gold-thiol bond cleavage (74) and
hyperthermia-triggered release (75). Multifunctional metal-based ENMs were also
developed for combination treatment, such as hyperthermia plus chemotherapy or
theranostics, by combining drug delivery and imaging (73). For example, tumor necrosis
factor alpha (TNF-α) can covalently conjugate to gold ENMs resulting in the
combination of TNF-α and gold-induced hyperthermia. This combination of TNF-α
therapy with gold hyperthermia resulted in an increase in tumor recession (76).
Thermally crosslinked IONPs have been developed for use in drug delivery and MR
imaging. The polymeric shell of IONPs loaded with doxorubicin was efficient in
detecting Lewis lung carcinoma, and delivering sufficient drug to tumor tissues with
lower toxicity in other organs (77). These studies demonstrated that metal-based ENMs
can be incorporated in drug delivery systems, which provide the possibility to control
drug release and increase efficacy of nanomedicine by combining different therapeutic
strategies.
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2.2. Effect of size and surface modification on pharmacokinetics of metal-based
3B

engineered nanomaterials
There have been several physicochemical candidates identified that influence the
pharmacokinetics of ENMs such as chemical nature, size, shape, surface chemistry,
charge, presence of surface lattice defects, surface curvature, and the atomic arrangement
of the crystalline facets and agglomeration potential (78-80). ENM size plays a very
important role in the pharmacokinetics because of their effects on margination dynamics
(lateral drifting from the vessel core to the walls), vascular adhesion, protein corona
(protein coating) and escape routes from the vasculature (81). In this section, how size
influences the pharmacokinetics of metal-based ENMs will be summarized.

Different margination dynamics are desirable for different ENM applications. For tissue
targeting ENMs, the fast margination and interaction with the endothelium may be
needed to target with selective cells with a high adherence. On the other hand, low
margination leads to long circulation without being trapped by cells. Mathematical
modeling and experiments in vitro demonstrated that certain ENMs within the critical
size showed the maximum margination time (82). For different applications, ENMs
should have size at the certain critical size range in order to circulate in the blood stream
and/or interact with the endothelium cells (83). Adhesion was also studied in vitro using
different sizes of silica ENMs. The strength of adhesion of the spherical ENMs reduces
as their diameter increases (84). Despite these important findings, it is more than likely
these previous mathematical modeling and experiments in vitro have oversimplified the
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vasculature architecture in vivo. More studies are needed to define how different sizes of
ENMs change their interaction with the vasculature in vivo.

It has been shown that different ENMs influence their interactions with proteins in blood
both quantitatively and qualitatively. For example, the protein corona changes the halflife and biodistribution of ENMs (82, 85, 86). ENM aggregation was induced by the
proteins in blood, which can be trapped in the first capillary bed encountered, such as rat
or mouse lung following tail vein injection (82). Furthermore, the protein corona on the
surface of ENMs also facilitated recognition and clearance from the blood by circulating
phagocytes and macrophages in the hepatic Kupffer cells and the marginal zone and redpulp macrophages in the spleen (87, 88). A previous study has shown that the size of
ENMs changed the protein corona, which influence the ENM’s pharmacokinetics in the
blood (85).

Normally, ENMs leave blood circulation through opening fenestrations in the organs or
some disease conditions such as tumor (89). In the liver, the size of fenestrate can be as
large as 150 nm (90). Spleen filtration is also size dependent. ENMs need to be small
enough to avoid the splenic filtration process at intercellular slits in the walls of venous
sinuses (91). The width of interendothelial cell slits is approximately 200-250 nm,
providing a mechanism to target the spleen (92). Alternatively, the size of longercirculating ENMs should not exceed 200 nm to bypass spleen filtration. Studies have
shown that tumors have a characteristic leaky vasculature pore size of 200 nm to 1.2 μm
(93). However, the average size recommended for tumor targeting is less than 200 nm to
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take advantage of the enhanced permeability and retention (EPR) effect (94, 95). This
doesn’t mean that the smaller ENMs will have desirable pharmacokinetics. ENMs less
than 10 nm can leave the blood circulation through the permeable vascular endothelium
in lymph nodes (96, 97).

Furthermore, very small ENMs tend to be cleared by

glomerular filtration very fast. Quantum dots were used to define the renal filtration
threshold in rodents. They showed that when the diameter is less than 5.5 nm, the ENMs
were cleared through urinary excretion rapidly (98). In order to target specific tissue or
change the ENM’s clearance pathway, it is critical to design ENMs with desirable sizes.

Another factor that influences the rate of ENM clearance from blood and their
distribution is their surface chemistry, including charge and surface coating. A zeta
potential greater than + 30 or less than -30 mV decreases the potential for agglomeration
in the medium due to repulsive electrostatic forces (99). ENMs are often coated with
polymers such as polyethylene glycol or oxygen-rich ions such as citrate. These coatings
increase ENM hydrophilicity and stabilize ENM dispersions through the electrostatic
repulsion mechanism, which may reduce their clearance by the reticuloendothelial system
(100-103). Citrate, an endogenous molecule present in the blood and an integral
component of the tricarboxylic acid cycle, is one of the most commonly used surface
coatings to minimize agglomeration. Although citric acid forms a stable chelate with
ENMs, it is not sufficient to prevent agglomeration and precipitation in the presence of
multivalent counter ions (magnesium or calcium) and serum proteins (104-107).
Biocompatible polymer ENMs and water soluble polymers have been used as less toxic
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and more stable alternatives to these stabilizers (48, 108). More detail about
biocompatible polymer stabilizers will be discussed in 2.3.3.2.

2.3. Effect of physicochemical properties of engineered nanomaterials on their
blood-brain barrier association
2.3.1. The blood-brain barrier and the translocation mechanisms to the brain
The microenvironment of the brain is tightly regulated by the BBB. It relies on brain
endothelial cells, pericytes, astrocytes and neurons to generate and maintain the unique
barrier properties regulating cerebral blood flow and barrier performance. Selected
molecules pass the BBB from the bloodstream to the brain by either the passive diffusion
pathway or a specific transporter pathway.

Lipid-soluble agents and small gaseous

molecules enter into the brain through the effective transcellular passive diffusion
pathway, but not the paracellular pathway because of the tight junctions between the
endothelial cells (109). Carrier-mediated transport systems facilitate transport of nutrients
into the brain including glucose, galactose, amino acid, nucleosides, purines,
monocarboxylate, choline, vitamins and hormones (29). Glucose transporters (such as
GLUT1 and GLUT3) provide the major energy source, glucose, for the brain.
Monocarboxylate

transporters

(MCTs)

are

responsible

for

the

transport

of

monocarboxylates (lactate, pyruvate, acetoacetate). MCTs are of great significance for
brain energy metabolism (110).

Receptor-mediated transport systems can facilitate

endogenous proteins and hormones to cross the BBB. The transporters for insulin,
insulin-like growth factors, angiotensin II, and transferrin (Tf) have been identified (111,
112). However, under normal physiological conditions, the presence of interendothelial
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tight junctions and absence of a vesicular transport system restrict the entry of proteins,
ions, lipid insoluble non-electrolytes and circulating hematogenous cells into the brain
(113, 114). ATP-binding cassette (ABC) transporters, efflux transporters, are found at
the luminal membrane of the brain endothelium. The multidrug resistance transporter Pglycoprotein (P-gp or ABCB1) is an ATP-dependent efflux pump which mediates rapid
removal of ingested toxic lipophilic metabolites, such as many amphipatic cationic drugs
(115). Other efflux transporters (ASCT2, NET, OAT3) have the potential to work
together to reduce penetration of xenobiotics into the brain and increase their efflux from
the brain (116). In general, the BBB has not only a physical barrier but also metabolic
mechanisms to eliminate the xenobiotics and maintain brain homeostasis.

2.3.2. Conventional strategies to cross the BBB and their limitations
Because of the insufficient delivery of therapeutics into the brain, aggressive research
efforts have focused on the development of new strategies to more effectively deliver
drugs to the CNS for decades. The major approaches and their limitations are
summarized below (117).

Invasive approaches have been used to mechanically breach the BBB to deliver drug to
the brain including: 1) Intra-cerebro-ventricular (ICV) infusion: ICV showed
pharmacologic effects if the target of the drug is close to the ventricles (118).

2)

Convention-enhanced delivery (CED): a small catheter was inserted into the brain
parenchyma and infusate is actively pumped into the brain. CED demonstrated promising
results recently on animals. However, it is still challenging to place the catheters

18

precisely and optimize the infusion parameters for delivery (119). 3) Intra-cerebral
injection or implants: the drug concentrations in the brain tissue depend on the diffusion
principle. The distribution of drugs in the brain by diffusion decreased exponentially with
distance (120). 4) Disruption of the BBB: the tight junctions were disrupted to increase
the BBB permeability. Osmotic disruption, MRI-guided ultrasound BBB disruption and
whole body hyperthermia are commonly used techniques. Hypertonic mannitol solution
was used in the clinic to increase drug concentrations in the brain (121). Ultrasound
demonstrated the capability to disrupt the BBB in animal models. Numerous researchers
have shown that mild whole body hyperthermia can increase BBB permeability (58).
However, these approaches are expensive and lead to potential brain toxicity (58, 60).

Medicinal chemistry approaches have been utilized to modify the physicochemical
properties of molecules to increase their BBB permeability. The small molecules to enter
the brain should have molecular weight less than 500D, low hydrogen bounding
capabilities and hydrophobic properties (122, 123). For example, N-docosahexaenoyl
can be conjugated with small molecules to increase their BBB permeability (124).
However, structure modification has the potential to reduce, or even lose, the central
nervous activities of small molecules. Furthermore, hydrophobic molecules serve as good
candidates for the efflux pump P-glycoprotein in the BBB (125).

One promising approach to access the brain is to take advantage of the receptors and
transporters on the BBB. As I described in 2.3.1, essential substances such as glucose,
insulin and growth hormone can be recognized and transported into the brain using the
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receptors or transporters on the BBB. For example, transferrin-conjugated therapeutic
agents can cross the BBB using receptor-mediated transcytosis (82). The limitation of
this strategy is a lack of full understanding of certain transporters and/or receptormediated mechanisms to cross the BBB. For example, the transferrin receptor has been
the most studied receptor to target receptor-mediated brain uptake (126). Despite this
plethora of research on the transferrin receptor, there has been little work done on brain
uptake of transferrin-modified agents, and most of the research was focused on the
improvement of diagnostic and therapeutic effects (2, 127). Some studies showed that the
brain delivery of the transferrin ligand led to limited transcytosis using a healthy animal
model (128). In order to take advantage of transporter and receptor mediated mechanisms,
a better understanding of these physiological processes is needed.

2.3.3. Engineered nanomaterial translocation into the brain
ENMs have been shown to have multiple mechanisms to cross the BBB and overcome
some of the previous limitations mentioned in the above section. Numerous studies have
shown that ENM uptake into the brain can occur through a variety of mechanisms (Figure
2.1). 1) Passive diffusion: ENMs adhered to the endothelial cells of brain capillaries,
increased the concentration gradient, then were transported by passive diffusion (129).
ENMs also can prolong their circulation time in blood and be recognized by the MPS,
increasing the passive targeting capability of ENMs (29). 2) Endothelial cell membrane
lipid solubilization: surfactant coated ENMs can increase BBB permeability by
solubilizing the endothelial cell membrane lipids (130). 3) Open the tight junctions:
ENMs open the tight junctions between the brain capillary endothelial cells, and increase
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the penetration into the CNS (30). 4) Receptor-mediated endocytosis: Polyethercopolyester-coated nanoparticles are taken up into the brain via clathrin and caveolin
mediated endocytosis mechanisms (131). Transferrin-coated ENMs enter the BBB via the
caveolae pathway (132) and clathrin-coated pathway (133). Plasma protein, especially
apolipoprotein E (Apo-E), coated nanoparticles are mistaken for low-density lipoprotein
(LDL) particles by the cerebral endothelium and internalized by the LDL uptake system
(134). 5) Inhibition of efflux systems: ENMs can inhibit the drug efflux system, i.e.,
Polysorbate-coated nanoparticles modulate P-glycoprotein on the BBB, to increase the
ENMs flux across the BBB (135). 6) Absorptive transcytosis: positively-charged ENMs
interact with the negatively charged plasma membrane surface through electrostatic
interaction (136). Because of the unique physicochemical properties of ENMs, they can
potentially cross the BBB by multiple mechanisms. That’s why nanoparticles are
versatile platforms for drug delivery systems with potential to treat brain diseases. It is
very important to understand how different physicochemical properties can affect BBB
translocation and brain uptake of ENMs. The previous research on how size and surface
modification influence ENMs flux across the BBB is summarized below.
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Figure 2.1. A schematic diagram of the main pathways that ENMs have potential to
increase the brain uptake of ENMs or drugs. a) ENMs increased passive diffusion by
creating a sink condition. b) ENMs inhibit a drug efflux system. c) ENMs open tight
junctions. d) ENMs are taken up by receptor-mediated endocytosis and transcytosis. e)
Positive charged ENMs are taken up by adsorptive mediated transcytosis. Adapted from
(137).

2.3.3.1. Size
37B

The size of ENMs has a profound effect on pharmacokinetics, biodistribution and passive
targeting (See Section 2.2.). Tight junctions can block ENMs larger then 4 nm diameter
under normal physiological conditions (138). However, except paracellular penetration,
endocytosis and transcytosis are important ways to cross the BBB, especially for ENMs.
Clathrin and caveolae-mediated endocytosis and adsorptive transcytosis are the main
mechanisms for ENM uptake into the BBB (139, 140). Size plays a very important role in
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these endocytosis pathways. There are different views on the average size of the
endocytic vesicle, 100 nm (141) or 120 nm (142) for clathrin-mediated endocytosis, 50
nm-100 nm (141, 143) or 60 nm-80 nm (142, 144) for caveolae-mediated endocytosis.
However, most of this research is focused on fundamental biological processes. The
differences between the fundamental biological research and particle uptake research lead
to the finding of a difference in optimal size when looking at ENM drug delivery via the
endocytosis pathway. Rejman et al investigated size-dependent internalization of
nanoparticles from 50 nm to 1000 nm. Their results showed that when a diameter was
less than 200 nm, clathrin-mediated endocytosis was the dominant pathway. With
increasing size, a shift to caveolae-mediated endocytosis was observed, and caveolaemediated endocytosis became the predominant pathway for 500 nm particles (145). The
cell types and their states of differentiation can also determine the choice of pathway
(78).

Metal-based ENMs have been shown to have the ability to cross the BBB.

However, most published studies show indirect evidence of nanoparticle flux across the
BBB into the brain by monitoring fluorescent and radioactive drugs (146, 147), or
therapeutic efficacy of drugs in animal models of brain tumors (148). A better
understanding of nanoparticle association with biological barriers, such as the tightly
regulated BBB, and their flux across them, is urgently needed.

Previous research demonstrated that having a optimal particle radius would accelerate
wrapping of ENMs and their cell uptake (78). The critical size for ENMs to have
properties different from solution and bulk chemistry is ~ 15 to 50 nm. The critical size
of ENMs has been studied on cell internalization and their function in biological systems.
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Reactive oxygen species (ROS) generation in an acellular system, to which titania ENMs
ranging in size from 4 to 195 nm were added, was negligible up to and including 10 nm
then increased up to ~ 30 nm when it reached a plateau (149). Gold ENMs with a
diameter of 50 nm were taken up by mammalian cells at a rate and concentration that was
faster and higher, respectively, than 14, 30, 74, and 100 nm gold ENMs (150). The
optimal wrapping of transferrin-coated gold ENMs occurs at about 50 nm and the
interaction between the receptor and 50 nm gold ENMs can produce enough free energy
to drive the ENMs into the cell (151). It is crucial to design an ENM system within the
critical size range for biomedical applications.

Numerous studies have already been done to investigate how crucial the size of metalbased ENMs is to cross cell barriers (150, 152, 153). Size also plays an important role for
the translocation of inhaled nanoparticles to the CNS via olfactory neurons (154) and
toxicity such as ROS generation (149). However, how size influences the ability of
nanoparticles to cross the BBB still hasn’t been systematically studied. Even though we
could try to predict how size might affect the ability to cross the BBB using results about
ENMs, our predictions are limited because the BBB is a tightly regulated special
membrane barrier with tight junctions and efflux transporters. More research needs to be
done to have a better understanding whether size influences ENM association with the
BBB and entry into the brain, not only for drug delivery of ENMs, but also for human
risk assessment.
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2.3.3.2. Surface modification
38B

Surface coatings are widely used to change the physicochemical properties of metalbased ENMs to cross the BBB and target the brain. Surface modifications can change
nanoparticle size, charge and uptake mechanism etc, which can lead to a wide variety of
biomedical applications. This can also make them hard to investigate due to their
complicated system and toxicity issues.

Surface modifications are commonly used in the ENM industry to tailor the dispersion
characteristics of the ENMs to specific applications. PEGylation of ENMs has become
the most widely used approach to increase the circulation lifetime of ENMs (155).
PEGylated conjugated fluorescein-doped magnetic silica ENM (PEGylated FMSNs)
could penetrate the BBB and spread into the brain parenchyma. However, FMSNs
without PEG were easy to agglomerate, which resulted in a rapid clearance from blood
circulation and subsequent capture by the MPS (156). In addition, this increased brain
penetration was achieved without modification of the BBB permeability. No toxic effect
arising from the PEGylated nanoparticles or from their degradation products has been
detected toward the permeability of the BBB (157). Polyether-copolyester (PEPE)
dendrimers internalized efficiently into brain vascular endothelial cells utilizing several
pathways, but the major contributers were clathrin- and caveolin-mediated endocytosis.
The PEPE dendrimers permeated across an in vitro BBB model in high amounts without
significant disruption of the tight junction properties (131). Trimethylated chitosan
(TMC) surface-modified PLGA nanoparticles enhanced the brain uptake of PLGA
nanoparticles superior to the PLGA nanoparticles with negligible cytotoxicity (158).
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Polysorbate 80-coated nanoparticles with brain diffusion capability were found to induce
permeabilization of the BBB, likely due to toxic effects of free polysorbate 80, not the
polysorbate 80-coated nanoparticles (157).

In general, most of these surface

modifications showed that they are promising candidates to increase the stability, change
the physicochemical properties, and help to cross the BBB with less toxicity. However,
most ENM research has shown indirect evidence of their flux across the BBB by
analyzing extractions of the whole brain without excluding the ENMs in the brain vessels
and BBB cells, or through therapeutic efficacy of drugs in animal models of brain tumors.
There is an urgent need to understand how metal-based ENMs associate with and
transcytose across the BBB in vitro and in vivo. When ENMs enter biological fluid, their
surface properties interact with proteins leading to the exposure of new epitopes, altered
function, and/or avidity effects (85, 159). By mimicking endogenous molecules we can
investigate how surface modifications impact the uptake and fate of ENMs to the CNS.

Endogenous surface modifications are widely used to target specific receptors or
translocation mechanisms. Tf-ENMs were found to be highly adsorbed by the BBB cells
and endocytosed using an energy-dependent process compared with blank ENMs and
BSA-ENMs. Tf-ENMs interact with the cells in a specific manner and enter the BBB via
the caveolae pathway. Tf also prevented the aggregation of ENMs with less toxicity
compared with chemical stabilizers such as Tween 20 and Tween 80 (132). However, the
actual extent of Tf transcytosis is still unknown. Some studies showed that only a
miniscule amount of Tf is trancytosed across the brain capillary endothelial cells and
accumulated in the brain (160, 161). Albumin ENMs with covalently-bound ApoE were
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detected in brain capillary endothelial cells and neurons; whereas, no uptake of ENMs
occured without Apo E. Apo-E coated ENMs were taken up into the cerebral
endothelium by an endocytic mechanism followed by transcytosis into the brain
parenchyma (162). However, binding of apolipoproteins has been shown to correlate with
rapid uptake into the liver and the spleen, and clearance of the particles by the MPS, a
negative effect if one is attempting to increase circulation and retention time of the ENMs
in the body (163). Angiopep-2, one of the peptides derived from the Kunitz domain,
targets the low-density lipoprotein receptor-related protein-1 (LRP1). Several studies
demonstrated that Angiopep-2 possessed a higher brain penetration capability both in an
in vitro model of the BBB and in situ brain perfusion in mice (164, 165). Angiopepmodified polyamidoamine dendrimers showed higher efficiency in crossing the BBB than
unmodified ENMs in vitro and in vivo. LRP1-mediated endocytosis may be the main
mechanism of cellular internalization of angiopep-modified ENMs (166). According to
our knowledge from the literature, no significant toxicity of angiopep-2 was reported and
Angiochem Inc. has started clinical development with angiopep peptides for the transport
of therapeutic agents in two Phase I clinical trials (117). In general, endogenous surface
coatings are used as stabilizers to prevent agglomeration, gain functions to target specific
targets, and reduce toxicity. We know little about the distribution, stability, and
persistence of endogenous surface coated nanoparticles. At the same time, the
endogenous surface coating may fall off or cause a loss of function, which may lead to
agglomeration or enhance the rate of protein fibrillation (167).

2.4. Ceria ENMs
5B
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Ceria ENMs have many current commercial applications and potential therapeutic
applications in the CNS, because of their redox capability. Ceria ENM is highly insoluble
and can be observed under TEM, which makes it a good model to study particle
pharmacokinetics in blood and their distribution. In this dissertation, citrate-coated ceria
ENMs were chosen as a metal-based ENM model to study the effect of size on their
pharmacokinetics in blood and their blood distribution in vivo. Furthermore, the BBB
association of ceria ENMs and their flux across the BBB were investigated, which
provide important information for their potential CNS applications.

2.4.1. Definition and their applications
39B

Cerium is a lanthanide metal and a member of the rare earth metals. Ceria ENM has
multiple commercial applications, such as a diesel fuel catalyst in Envirox® (Oxonica
Ltd.) (25). Nanoscale ceria has been nominated by the National Institute of
Environmental Health Sciences (NIEHS) for toxicological consideration due to its
widespread and expanding industrial uses, limited toxicity data, and lack of toxicological
studies (168). Cerium (IV) (stable form) and cerium (III) oxidation states coexist,
producing a redox couple that is responsible for catalytic activity (169). The reduction of
Ce3+ is compensated by a corresponding number of oxygen vacancies. The defect
concentrations of Ce3+ ion and oxygen vacancies are larger at the surface of ceria than in
the bulk (170, 171). Therefore the surface of cerium oxide contains defects, such as, Ce3+
ions and oxygen vacancies (172). Ceria ENM has higher Ce3+ concentration and
enhanced redox activity with respect to larger particles, given the increase in the surface
to bulk ratio (172). For these reasons, ceria ENM has been targeted as a potential
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antioxidant agent to regenerate the initial oxidation state through redox cycling reactions
(173). An autoregenerative mechanism for ceria was demonstrated (Figure 2.2) (174).
The anti-oxidative stress ability of ceria ENMs showed a size-dependent pattern. With
decreasing ENM size, the anti-radical ability increased, which was consistent with the
Ce3+ concentration increase on the surface of the ENMs (175). Because of all these
properties, numerous studies reported ENM ceria to be neuroprotective, suggesting it has
utility in medical disorders caused by ROS (10, 12, 13, 17). The tetravalent state cerium
(Ce4+) is more stable than the trivalent state (Ce3+). Meanwhile, a few studies reported
that ENM ceria can increase oxidative stress (22, 176). It is very important to know
whether

the

physicochemical

properties

of

ceria

ENMs

will

change

their

pharmacokinetics, biodistribution or how they interact with the biological barrier such as
the BBB, regardless if you want to look at potential therapeutic applications or the
toxicity of ceria ENMs.
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Figure2.2. Schematic Detailing the Regenerative Properties of Ceria ENM and probable
mechanism of Cerium oxide nanoparticles’ free radical scavenging property and autocatalytic behavior. Adapted from (174).

2.4.2. Fate of ceria ENMs
40B

The uptake of ceria ENMs of different sizes and concentrations has been previously
studied using human lung fibroblasts in vitro. The study found that ceria ENMs were
contained inside single or multiple lipid bilayer vesicles in the cytoplasm. They also
showed that the size of the ceria ENMs affected the cell uptake greatly. With the increase
of size, the cell uptake of ceria ENMs was significantly increased. However, small ceria
ENMs agglomerated rapidly and cells can absorb agglomerates effectively. Large ENMs
agglomerate slowly because of low number densities and can penetrate into the cells
much more efficiently (152). This study demonstrated the importance of size on cell
uptake of ceria ENMs. Furthermore, it is crucial to develop stable ENMs in the biological
relevant system to study their cell association compared to micrometer size agglomerates.

For therapeutic applications, ceria ENMs need to be delivered through systemic
administration rather than oral or inhalation in vivo. This is due to the fact that ceria
ENMs are poorly absorbed through oral or inhalation routes.

Twenty-eight days after

inhalation a variety of concentrations were detected in various tissues, 1 x 10 -5 % of the
dose in the brain, 1 x 10-3 % in the kidney, 1 x 10-2 % in the spleen, and 1 x 10-1 % of the
dose in the liver (32). A 7 nm ceria (5 mg/kg) was orally administrated. Only ~ 1 x 10 -4
% of the dose was detected in the liver and less than 1 x 10-5 % was in the heart, spleen,
kidney, brain, testicle, and lung 1 to 7 days later (177). Ceria was found in lung and
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spleen, but not brain, heart, kidney, or liver of mice after 5 weekly oral doses of 0.5
mg/kg of a 3 to 5 nm ceria (178). For systemic administration of ceria ENMs, their
pharmacokinetics in blood needs to be defined. In this dissertation, it is the first time that
the influence of size on the distribution in and clearance from blood of ceria ENMs was
investigated.

Our lab studied the biodistribution through iv infusion of 5, 15, 30 and 55 nm citratecoated ceria. Of the ceria in the blood, brain, liver and spleen, ≥ 98% of the ceria was
retained in the liver and spleen 20 h after its iv infusion, from which it was not
significantly cleared over 30 days. Electron microscopy revealed only occasional ceria
ENM beyond the BBB (179). The reasons for the lack of ceria ENM in the brain were
unknown. One possibility is that ceria ENMs were rapidly coated by proteins in the blood
that changed their physicochemical properties, resulting in their rapid clearance by the
MPS (180, 181). Another possibility is that the ENMs agglomerated very rapidly in the
blood or on a biological surface, changing their distribution and cell interaction (78, 182184), so that the agglomerated ceria became too large or unavailable to penetrate the
intact BBB. How ceria ENMs interact with brain capillary endothelial cells is relevant to
the therapeutic use and toxicological consideration of ceria ENMs. In this dissertation, 5
nm ceria was used to study its association with the BBB.

2.5. Iron oxide nanoparticles
6B

The pharmacokinetic study of ceria ENMs helped me to have a better understanding of
the blood distribution of different sized citrate coated metal-based ENMs and their BBB
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association. According the results of the ceria ENM project, I designed a novel IONP
which has potential to improve the stability and the biocompatibility of IONPs. And its
BBB association and flux across the BBB was tested, which will provide important
information for its potential applications in the CNS.

2.5. 1. Definition and their applications
41B

IONPs are superparamagnetic materials, which can be activated only in the presence of
an external magnetic field, enabling various bionanomedical applications (185, 186).
IONPs can be visualized in T2-weighted MRI sequences as a hypointense signal
(negative contrast enhancement), which is the most widely investigated MRI contrast
agent (187). IONPs have been approved by the Food and Drug Administration as MRI
contrast agents including Lumiren® for bowel imaging (188), Feridex IV® for liver and
spleen imaging (26), and Combidex® for lymph node metastases imaging (189). IONPs
activated by AMF lead to a localized hyperthermia above 41-42 ºC resulting in cancer
cell death (190). The particle sizes of IONPs can be tailored to accumulate in specific
organs, contributing to early detection of human malignancies with blood vessel
disruption such as brain tumor (191-193).

Numerous studies have shown that multifunctional IONPs can be used for brain tumor
diagnosis and therapy. When comparing traditional gadolinium (Gd)-based MRI contrast
agents to IONPs, it has been found IONPs are eliminated slower from the circulation
(194). IONPs reside within brain tumors much longer than Gd-based agents (the half-life
of Gd-DTPA is ~ 20 min in blood (195)) and can be imaged from 24 and 72 h. More
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importantly, IONPs have revealed more intense MRI contrast enhancement compared
with Gd-based contrast agents (100). Previous research also demonstrated that
multifunctional IONPs can conjugate with chemotherapeutic drugs. Such drug-loaded
IONPs can accumulated in brain tumors and facilitate monitoring drug delivery via MR
imaging (196). Another promising application of IONPs is hyperthermia induced by
AMF, which can be utilized for thermotherapy of brain tumors. The first in vivo report on
IONPs inducing local hyperthermia to kill glioma cells was in 1997 using T-9 glioma
cell, injected to Fisher F344 rats (36). After 1997, lots of studies have been done to test
IONPs generating hyperthermia on glioma tumors in vivo (192). A hydrogel with iron
oxide nanoparticles was tested using human glioblastoma cells (M059K). Cell death was
observed where hydrogel was applied but not the surrounding region (43). Some studies
also investigated the synergistic effects of combined gene and thermal therapy (197, 198).
Most of the in vivo studies bypassed the BBB to deliver the IONPs to the tumor in the
brain by intratumoral injection or implanting the tumor cells outside the brain regions
(192).

As I described in section 2.3, the BBB is the tightly regulated barrier to eliminate

therapeutics from brain. It is necessary to understand whether multifunctional IONPs
cross the BBB and increase their brain accumulation for brain tumor therapy.

A major challenge for effective delivery of IONPs to the CNS is the BBB. Many
strategies have been developed to increase the flux of ENMs across the BBB as described
in 2.3.3. IONPs can generate local hyperthermia by AMF. Mild hyperthermia
demonstrated their ability to increase the BBB permeability and drug transport across the
BBB (58). For example, previous research showed that the flux of liposomes across the
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BBB increased significantly by whole body hyperthermia using 42 ºC water bath for 30
min in vivo (59). However, whole body hyperthermia led to potential toxicities to the
brain such as edema (58). In this dissertation, I hypothesize that multifunctional IONPs
have the potential to generate local hyperthermia to open the BBB and decrease the side
effects of conventional hyperthermia by locally using AMF.

2.5.2. Biocompatibility of IONPs
42B

Because of the favorable biocompatibility and biodegradability, IONPs have widespread
biomedical applications (199, 200). However, surface modification of IONPs change the
toxicity of IONPs dramatically. Bare IONPs led to oxidative stress in the lungs after
intranasal instillation using two-sizes of IONPs (22 and 280 nm) (201). After inhalation
of bare IONPs, neuron fatty degeneration occurred in the CA3 area of the hippocampus
in the CNS (202). However, dextran surface modified IONPs showed no measurable
LD50 (200). Even though retention of dextran-coated iron oxide NPs in the liver and
spleen was observed in mice, but no histopathology alterations, including damaged cells,
were found in the analyzed organs (203). In addition, IONPs are easily oxidized,
transforming from magnetite (Fe3O4) to maghemite (γFe2O3), leading to a broad spectrum
of particle size, shape, stability, and magnetic properties (108, 204). Particle stability also
influences IONP toxicity and biological applications. For example, surfactants, typically
prepared from multivalent polymers, have been developed to stabilize IONPs in vivo, yet
they can get detached from IONPs due to an unclear mechanism by which ligand
exchange occurs in metal chelates (205-207). Importantly, these IONP formulations,
which change particle stability over time in vivo, could potentially cause toxic effects in
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vivo (46, 47). Therefore, it is crucial to improve particle stability and biocompatibility of
IONPs in biological environments.

Biocompatible polymers improve the stability of IONPs in aqueous solutions and avoid
undesirable interactions with cells in the human body. Among these polymer-based
formulations, polymer nanoassemblies are promising choices to improve the
biocompatibility and stability of IONPs. For MRI contrast application, the signal-to-noise
(S/N) ratio of contrast agents is very important for tumor imaging. Polymer
nanoassemblies provide a stable nanocarrier without leakage of contrast agents during
blood circulation, which leads to less blurring of cancer images (208). Micelles can
embed IONPs and achieve excellent MRI contrast enhancement as a clustered IONP (5153). However, a major disadvantage of self-assembling conventional micelles is their
thermodynamic nature, which leads to instabilities, particularly in dilute conditions (e.g.
blood and other biological environments) as polymer micelles can dissociate below the
critical micelle concentration (54). To solve this problem, cross-links can be used to
stabilize conventional micelles. Dr. Bae’s lab developed CNAs from biocompatible PEGp(Asp) block copolymers. They showed improved particle stability in biological related
environments. Furthermore CNAs can entrap charged, hydrophobic, and amphiphilic
payloads including drugs and contrast agents without changing particle sizes (55). CNAs
have the potential to provide a stable and biocompatible platform to deliver IONPs for
diagnosis and therapy.

2.6. Summary
7B
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The application of metal-based ENMs in medicine is an emerging field and has the
potential to revolutionize the development of drug delivery, imaging, and diagnosis in the
CNS. A variety of metal-based ENMs have been developed and engineered to cross the
BBB for specific applications in the CNS. Because of the inherent complexity of the CNS
and the safety concerns of metal-based ENMs, the fundamental understanding on the
pharmacokinetics of metal-based ENMs, especially their BBB association will provide
critical knowledge for further development of noble metal-based ENMs, which can be
tuned to be effective therapeutic and diagnostic agents with low toxicity.

Portions of sections 2.4 and 2.5 were reproduced with permission from Dan M, Tseng M,
Wu P, Unrine JM, Grulke EA, Yokel RA. Brain microvascular endothelial cell
association and distribution of a 5 nm ceria engineered nanomaterial. International
Journal of Nanomedicine, 2012, 7, 4023-4036. Copyright © 2012 Dan M, Tseng M, Wu
P, Unrine JM, Grulke EA, Yokel RA. Dan M, Wu P, Grulke EA, Graham UM, Unrine
JM, Yokel RA. Ceria engineered nanomaterial distribution in and clearance from blood:
Size matters. Nanomedicine, 2012, 7(1), 95-110. Copyright © 2012 Future Medicine Ltd.
Dan M, Scott DF, Hardy P, Wydra RA, Yokel RA, Hilt JZ, Bae Y. Block copolymer
cross-linked nanoassemblies improve particle stability and biocompatibility of
superparamagnetic iron oxide nanoparticles. Pharmaceutical Research 2013, 30(2):55261. Copyright © 2013 Springer Science+Business Media, LLC.
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Chapter 3 Ceria engineered nanomaterial distribution in and clearance from blood:
30B

Size matters

The hypothesis of the present work is that the fate of a metal oxide ENM in blood is
different than its constituent metal and ENM size influences its persistence in and
distribution within the major components of blood. The kinetic endpoints include
absorption (uptake), distribution, biotransformation (and protein corona), re-distribution
(translocation), and elimination. These appear to be greatly influenced by the
physicochemical properties of nanoscale materials. As noted in recent reviews of the
pharmacokinetics of carbon-based and quantum dot ENMs (209, 210), they are not
amenable to classical pharmacokinetic parameter estimations due to their differences
from the solution chemistry of their components. In this chapter, we will characterize
different sized ceria ENM distribution in and clearance from blood compared to the
cerium ion. The results of this study will provide critical knowledge to engineer ENMs
with desirable pharmacokinetics.

3.1. Introduction
8B

There has been much research to develop ENMs. Polymer ENMs are being developed as
drug delivery systems (211, 212), and some metal and metal oxide ENMs are being
developed as therapeutic agents. Human exposure may also come from occupational and
environmental sources. Little is known about ENM distribution or persistence in the

37

vascular system. We were unable to find published studies of the distribution of metal or
metal oxide ENMs among blood compartments.

Little is known about the influence of size on the distribution in and clearance from blood
of metal and metal oxide ENMs. We found that the blood cerium concentration was 0.56
and 1.3 mg/L after a 1 h infusion of 50 or 250 mg/kg of an ~ 30-nm commercial ceria
ENM to rats (7). In contrast, 1 h after infusion of 100 mg/kg of an in-house manufactured
5-nm ceria ENM it was 370 mg/L (8), suggesting that the rate of metal oxide ENM
clearance from blood was size dependent. The present study was conducted to test this
hypothesis.

The present work was conducted to test the hypotheses that the fate of a metal oxide
ENM in blood is different than its constituent metal and that ENM size and shape
influence its persistence in and distribution within the major components of blood. We iv
infused the cerium ion, four sizes of cubic or polyhedral citrate-coated ceria ENMs, and a
mixture of cubic and rod-shaped ceria to rats. Blood was repeatedly withdrawn up to 4 h
later, and in some cases up to 30 days. An aliquot of each blood sample drawn up to 4 h
after ceria infusion was allowed to clot. By comparison of Ce in whole blood, serum, and
the clot we could determine pharmacokinetic parameters of ceria distribution in, and
clearance from, blood.

3.2. Materials and methods
3.2.1. Materials
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Cerium chloride heptahydrate (Sigma-Aldrich #228931, 99.9% metal basis), cerium
nitrate hexahydrate (Sigma-Aldrich # 22350, >99.0%), sodium hydroxide (Fisher #S3181, certified ACS pellets), ammonium hydroxide (Fisher # 3256, ACS, 28-30%),
hexadecyltri-methylammonium bromide (CTAB, Sigma-Aldrich #H9151, ~99.0%),
deionized ultra filtered water (DIUF, Fisher #W2-20), and citric acid monohydrate (EMD
Chemicals Inc # CX1725-1, GR ACS) were used without further purification.

3.2.2. Ceria ENM synthesis
Five nm ceria ENM was synthesized as described (213). Typically a 20 ml aqueous
mixture of 0.5 M (0.01 mol) cerium chloride and 0.5 M (0.01 mol) citric acid was added
to 20 ml of 3 M ammonium hydroxide. The latter was in excess of that needed for
complete reaction of the cerium chloride to cerium hydroxide. The final product was an
un-buffered ceria dispersion with a pH of 8 to 9. After stirring for 24 h at 50 C, the
solution was transferred into a Teflon-lined stainless steel bomb and heated at 80 C for
24 h to complete the reaction. The cerium concentration in samples taken from the top
and bottom of two ceria dispersion samples that were un-disturbed for > 2 months were
within 2.5% of each other, demonstrating dispersion stability. Settling of the 5 nm ceria
dispersion was not observed over at least three months and dynamic light scattering
estimates of 5 nm ceria particle size distributions were similar to those obtained initially.
The dispersed ceria ENM was infused intravenously without any further treatment.

Fifteen nm ceria ENM was synthesized using a hydrothermal procedure (214). In a
typical procedure, 2 ml ammonium hydroxide was drop-wise added into 20 ml aqueous
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mixture of 1.5 mmol cerium nitrate and 0.5 mmol CTAB and kept stirring for 0.5 h to
form a brown emulsion. The emulsion was transferred into a Teflon-lined stainless steel
bomb and heated at 120 C for 24 h to complete the reaction. The fresh product was
washed with water three times to remove free cerium, dialyzed three times with fresh
citric acid aqueous solution, and dried at 55 C for 24 h. The final 15 nm citrate-modified
ceria powder was re-dispersed into water to prepare a ~5 wt% aqueous suspension. The
pH of the resulting un-buffered ceria dispersion was 3.5.

Thirty nm ceria was synthesized using a hydrothermal approach (215). Generally, 20 ml
aqueous mixture of 1 mmol cerium nitrate and 105 mmol sodium hydroxide was stirred
for 0.5 h to get a milky suspension. The suspension was transferred into a Teflon-lined
stainless steel bomb and heated at 180 C for 24 h. After the hydrothermal treatment,
fresh white precipitates were washed with deionized water three times and then ethanol
three times to remove the free cerium and organic impurities. Then the wet precipitates
were dispersed into 0.05 M citric acid aqueous solution with stirring overnight, followed
by washing with water 5 times. The resulting dispersion had a pH of 3.9.

The mixture of 30 nm cubic ceria ENMs with nanorods was synthesized using a
hydrothermal method (216). Typically, 0.9 mmol cerium nitrate was dissolved into 15 ml
9 M sodium hydroxide solution with stirring for 0.5 h. The suspension was transferred
into a Teflon-lined stainless steel bomb and heated at 140 C for 48 h. After the
hydrothermal treatment, fresh precipitates were separated by centrifugation, and washed
with deionized water three times. The wet precipitates were dispersed into 0.06 M citric
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acid aqueous solution overnight, washed with water for several times until the final
suspension had a pH around 7.

Fifty-five nm ceria ENM was synthesized by a method (217) modified with controlled
thermal treatment to achieve the desired ceria particle size (unpublished results). It was
re-dispersed in citrate solution and washed three times in doubly distilled water to
remove free cerium and citrate. The resulting dispersion had a pH of 7.

3.2.3. Ceria characterization
The morphology, crystallinity, and phase purity of each citrate-coated ceria ENM were
determined

in

our

laboratories

using

high

resolution-transmission

electron

microscopy/scanning transmission electron microscopy and X–ray diffraction (XRD)
analyses. Primary particle size distributions were determined by TEM analysis (184). The
crystallinity of all ceria ENMs were determined by XRD (Siemens 5000 diffractometer).
Particle size distributions in aqueous suspension were determined using dynamic light
scattering (90Plus Nanoparticle Size Distribution Analyzer, Brookhaven Instruments
Corp, Holtsville, NY). To indicate the stability of the ceria dispersion when infused into
the rat, the zeta potential was measured for each ENM (except the mixture of ceria
nanoparticles and nanorods) using a Zetasizer nano ZS (Malvern Instruments,
Worchestershire, UK). The Zetasizer estimates the surface charge of nanoparticles based
on the assumption that the correlations are generated from spheres, but nanorods have an
elongated axis and different mobility from spherical nanoparticles; the instrument
therefore often fails to provide consistent and accurate estimation for nanorods and
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mixtures that include rods. Since all of the ceria ENMs had hydrodynamic diameters <
200 nm, the Hückel approximation was used to calculate zeta potential from
electrophoretic mobility. To estimate the extent of citrate surface coating each of the ceria
ENMs was washed at least three times with water before drying. As separation of the 5
nm ceria by centrifugation required ~12000 rpm for 12 h due to their small size, they
were

agglomerated

by

decreasing

the

pH

to

4,

enabling

centrifugation.

Thermogravimetric analysis (Perkin-Elmer TGA7 Analyzer) was then performed to
investigate the weight loss of citrate-coated ceria ENMs over the temperature range of
150 to 300°C under which decomposition of citric acid occurs. The extent of citrate
surface coating was estimated based on the assumption that all the ceria NPs were
spherical and had uniform size. The free cerium concentration in the ceria dispersions of
the unwashed 5 nm ceria and each of the washed ENMs was determined using Amicon
Ultra-4 centrifugal 3000 molecular weight cut-off filter devices and centrifugation at
3000 g to obtain filtrate, which was analyzed for cerium by inductively coupled plasma
mass spectrometry (ICP-MS).

3.2.4. Animals
Data were obtained from 101 male Sprague Dawley rats, weighing 325 ± 30 g (mean ±
SD), that were housed individually in the University of Kentucky Division of Laboratory
Animal Resources facility. All animal studies were approved by the University of
Kentucky Institutional Animal Care and Use Committee. The research was conducted in
accordance with the Society of Toxicology’s Guiding Principles in the Use of Animals in
Toxicology (http://www.toxicology.org/ai/air/air6.asp).
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3.2.5. Cerium ion and ceria ENM administration
Rats were prepared with 2 cannulae, surgically inserted into femoral veins under
ketamine/xylazine anesthesia, which terminated in the vena cava, and were connected to
infusion pumps via a flow-through swivel. This enabled conduct of the study in the
awake, mobile rat. All samples were sonicated to ensure dispersion prior to
administration. The day after cannulae implantation the un-anesthetized rat was infused
via the longer cannula with cerium ion (as the chloride), a ~ 5% ENM dispersion in
water, or water. A pilot study was conducted with the cerium ion and each of the ceria
ENMs to determine tolerability following iv infusion. A 100 mg cerium ion/kg infusion
was lethal. Rats were infused with ~250 or 175 mg/kg of the 5 nm ceria; 3 of 8 died. A
dose of ~250 mg of the 15 nm ceria/kg was tolerated. Infusion of 100 mg/kg of the 30 nm
ceria resulted in some evidence of mild distress (tachypnea, skittish behavior, and not
resting well). Dyspnea and lethargy were seen in rats given 250, 100 or 78 mg of the 55
nm ceria/kg. Therefore the target doses were 100 mg/kg for the 5, 15, and 30 nm ceria
and 50 mg/kg for the 55 nm ceria ENM and the cerium ion. ICP-MS analysis of cerium in
replicate samples of the dosed materials showed the doses to be 70 to 100% of the target
doses. Each was infused over 1 h, except for the cerium ion that was infused over 2 h.
Control rats received water adjusted to the pH of the paired ceria ENM or cerium ion. To
compensate for the iv administration of a considerable volume of grossly hypotonic
infusion, concurrent iv infusion of an equal volume and rate of 1.8% sodium chloride in
water was delivered into the second, shorter, cannula. Each fluid was delivered at ~ 0.6
ml/h.
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3.2.6. Sample collection
After the infusion, 0.6 ml blood was withdrawn at 0.167, 0.5, 0.75, 1, 2 and 4 h from the
cannula that had not delivered ceria from 3 rats that had received infusion of the cerium
ion, 6 that received the 30 nm ceria ENM, and 5 that received the 5, 15, 55 or 30 nm ceria
cube + rod ENM. The blood sample was immediately separated volumetrically into two
0.3 ml aliquots to enable determination of Ce in whole blood in one and in the serum and
clot fractions of the other. A blood clot is formed by platelets and blood proteins,
including fibrin, and traps the blood’s red and white cells. It may have some serum
trapped in it; therefore the clot fraction may over-estimate the percentage of Ce
associated with cells. To determine the distribution of Ce in the serum and clot fractions
the 0.3 ml sample of whole blood was allowed to clot at room temperature, the clot given
time to contract, and serum withdrawn into a digestion vessel. The clot was withdrawn
and placed in another digestion vessel and the remaining serum added to the serum
sample. This enabled determination of the mass amount of Ce in the two major
compartments of blood; serum and, from the clot fraction, association with the formed
elements (red cells, white cells and platelets). This approach was taken to avoid
centrifugation to generate the serum sample because we found that centrifugation at 1600
g for 10 min, as used to generate serum, resulted in loss of ~ 75% of a 30-nm ceria ENM
from the serum sample (7).
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Blood was also obtained from some rats 20, 168 (1 week) or 720 h (30 days) after ceria
ENM administration. An equal volume of saline was infused after each blood withdrawal
to replace the fluid volume. Blood was obtained at termination of all rats.

3.2.7. Cerium analysis
To determine Ce in whole blood, the sample was transferred into a 55 ml TFM
(polytetrafluoroethylene) digestion vessel (CEM) to which 6 ml trace-metal grade nitric
acid and 3 ml 30% H2O2 were added, digested in a CEM MARS Xpress microwave at
180 °C for 10 min to convert all ceria to dissolved Ce4+, diluted with 18 MΩ water to 50
ml, and subsequently further diluted dependent on the Ce concentration.

Cerium concentration was determined in whole blood, serum and clot by ICP-MS
(Agilent 7500cx, Santa Clara, CA, U.S.). Following ceria ENM administration, Ce
concentration is believed to reflect the Ce in ceria ENM because ceria ENMs are quite
inert and persist as an ENM in the rat for months (27), and the Ce levels in non-Ce
treated rats is very low. We determined a method detection limit (MDL) of Ce for blood
and serum samples of 0.018 mg/L (7). No samples in this study had Ce concentrations
below this MDL. Seven samples, containing whole blood, serum or clot, were analyzed
in duplicate and were spiked with 8.3 ng Ce/ml. Results of duplicate analysis showed a
range of 0 to 4% between the two determinations. Recovery of the Ce spike ranged from
93 to 114%, averaging 105%.

45

3.2.8. Data analysis and statistics
Blood, serum and clot Ce concentrations were normalized to an infusion dose of 100 mg
ceria/kg for all rats, based on determination of the actual Ce content of the infusions by
ICP-MS analysis, and because a few materials were given at doses other than 100 mg/kg,
as noted above. This enabled direct comparison of results from the cerium ion, ceria
ENM sizes, and shapes. Outliers, identified using the Grubbs test, were not included in
the data analysis. Four percent of the 600 whole blood, serum and clot samples were
outliers by this test.

Pharmacokinetic modeling. Non-compartmental and compartmental analyses of the
whole blood Ce concentration vs. time results were conducted using WinNonLin, a
pharmacokinetic analysis program (Pharsight®, St. Louis, Missouri). For noncompartmental analysis, AUC (h*mg/L), Cmax (mg/L), half life (t 1/2, h), and mean
residence time (MRT, h) were calculated. The squared correlation of distances (Rsq) and
correlation between time (X) and Ce concentration (Y) (Corr-XY) were used to measure
the goodness of fit. For compartmental analysis, one and two compartments were
evaluated to determine the best model fit. AUC (h*mg/L), Cmax (mg/L), half life (t 1/2, h),
mean residence time (MRT, h), clearance (CL, ml/h/kg) and apparent volume of
distribution at steady state (Vdss) were calculated. Various weightings were evaluated,
including 1, 1/y (y: ceria concentration, which weights higher values more heavily), 1/y2
(which weights lower values more heavily), 1/predicted concentration (iterative
reweighting), and 1/predicted concentration2. Goodness of fit was based on visual
inspection, weighted corrected sum of squares, sum of square residuals, weighted sum of
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square residuals, random distribution of residuals, Akaike’s information criteria, and
Swartz criteria. The initial estimates for model parameters were calculated as below.
The semi-logarithmic plots of blood concentration vs. time data showed the one or two
compartment

kinetics

respectively.

model

as

,

represent intercepts on the concentration (Y) axis of the back-

extrapolated initial and terminal phases and

the initial and terminal slopes.

As blood sampling began after completion of the infusion, the iv bolus case was used.
was used to correct the infusion intercept values for the one
compartmental analysis and
compartment model.

and

is the infusion dose,

were used in the two

is the infusion rate.

was used

to calculate the volume of the central compartment. The micro rate constants were
determined as

;

.

k12 and k21

represent the rate constants between central and peripheral compartment, and k 10 is the
elimination rate constant from the central compartment. The elimination half-lives (t1/2)
were calculated as t1/2 1 =0.693/

1

and t1/2 2 =0.693/ 2. One-way ANOVA, followed by

Tukey’s multiple comparison tests (Prism 5.02 software, GraphPad, San Diego, CA), was
used to test for significant differences in pharmacokinetic parameters among the 6
treatment groups.

Quality analysis of the WinNonLin coefficients was conducted by determining whether
the ratio of the coefficient estimate to its average standard error was greater than the
appropriate p value < 0.05, using a two-tailed Student’s t-test (3.18 for n = 3, 2.78 for n =
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4), Excel and Systat. The results showed that the pharmacokinetic parameter estimations
using WinNonLin were acceptable for only the cerium ion and the 5-nm ceria ENM. Two
factors contributing to this were 1) that less than 2% of the dose of the other 4 ENMs was
circulating in the blood when the first sample to estimate the pharmacokinetic parameters
was obtained (0.167 h after completion of the infusion), and 2) the Ce concentration
increased in blood from 0.167 to 4 h after infusion of the 15- and 30-nm ceria, which is
not the elimination behavior for typical pharmacokinetic models. Therefore, the
pharmacokinetic data for ceria ENMs was compared directly to that of the cerium ion,
which is known to follow typical pharmacokinetic elimination models.

Ratio of Ce concentration in whole blood following infusion of ceria ENMs vs. the
cerium ion. The Ce ratio in ceria ENMs compared to the cerium ion was reported as
R

[Ce]ceria
, calculated for each of the six sample times. This provided the
[Ce]cerium (ion)

opportunity to see temporal differences between the ENMs and the cerium ion. The ratio
for each ENM was plotted as a function of time from 0 to 4 h. Linear, exponential, power
law, and 2nd order polynomial equations were used to evaluate the data over 4 h. Because
the linear, exponential, and power law equations required only two parameters for fitting,
they could be used to demonstrate common trends for small data sets (usually six points
over the 4 h time period). The partition ratio, R, for each ENM was evaluated to
determine whether there was a significant trend in the data. This was done by evaluating
fits of linear, exponential, and power law equations to the data over the time period, 0 < t
≤ 4 h. Quality of the fitted coefficients was evaluated by using the Student’s t-test
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criteria. For example, if the exponential factor for the model R

R 0 exp

t met the

t-test criterion, then the trend was described by an apparent first order process.

Ce partitioning between serum and clot. The quality of the data describing the
partitioning of Ce between the serum and clot fractions was screened using mass
balances. The total mass of cerium (or ceria) in the whole blood sample should equal the
sum of the cerium masses in the serum and clot phases. The cut-off for mass material
balance screening was taken to be ± 30%. If the sum of the masses of Ce in the serum and
clot phases was < 70 or > 130% of that in the mass in the whole blood sample, the
partitioning data were not used in the analysis or shown in the figure. No other screening
analyses, such as outlier evaluation, were applied.

The partitioning of cerium was

reported as the ratio of cerium in the serum phase to that in whole blood.

3.3. Results
9B

Particle morphologies are shown in Figure 3.1. Panel D in Figure 3.1 is part of a larger
image that shows the diameter and length of the rods in the mixture of 30-nm cubic and
rod ENMs were ~ 10 nm and 2 µm, respectively. The shape, surface area, zeta potential
in water, and estimated extent of the ENM surface that was coated with citrate are shown
in Table 3.1. All of the ceria ENMs had face-centered cubic (FCC) crystal structures with
the same Miller indices of (111), (220) and (311), and with lesser presence of (200),
(222) and (400), based on XRD crystal structure linked to known morphology. The 55
nm ceria had the lowest surface coating of citrate and a lower absolute surface charge (31.5 mV) than the other ENMs. The unwashed 5 nm ceria ENM had 11.6 ± 0.3% free
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cerium in the dispersion. The washed ceria ENMs were found to contain << 1% free
cerium.

Figure 3.1. HRTEM and STEM images of ceria used in this study: (a) TEM/STEM: 5nm polyhedral ceria; (b) TEM: 15-nm polyhedral ceria; (c) TEM: 30-nm cubic ceria; (d)
TEM: 30-nm cubic and rod ceria; (e) STEM: 55-nm polyhedral ceria.
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Table 3.1. Physico-chemical properties of the ceria ENMs. Shape delineation based on
TEM data. Dave (average primary particle diameter from number frequency distribution)
and standard deviation based on TEM measurements of diameter fitted using lognormal
distribution models (n = 100). Citrate loading expressed as % of monolayer coverage
(TGA analysis).

Ceria ENM
primary
size(nm)

shape

5

polyhedral

Dave, nm
(st. dev.)
[TEM, Lognormal
model]
4.6 (0.135)

15

polyhedral

30
55

zeta potential
in water at
pH~ 7.3 (mV)

extent of
surface citrate
coating

- 53 ± 7

~ 40%

12.0 (0.232)

- 57 ± 5

~ 27%

cubic

31.2 (0.478)

- 56 ± 8

~ 18%

polyhedral

55 (0.162)

- 32 ± 2*

~ 15%*

* Determinations made on a batch similarly-prepared to that administered to the rats

Ten min (0.167 h) after completion of the cerium ion or 5-nm ceria ENM infusion ~ 14
and 32% of the Ce remained in the circulating blood, respectively. This was calculated
from the measured blood Ce concentration compared to the Ce dose, based on the iv
infusion of 100 mg ceria/kg into the rat’s vascular system (~ 7% of its body volume),
which would introduce ~ 1163 mg Ce/l blood. In contrast, the 15-, 30- and 55-nm ceria
and mixture of 30-nm cubic + rod ceria were rapidly removed from circulation, so that
0.167 h after their infusion ≤ 2% was in blood (Figure 3.2).

Pharmacokinetic models were constructed using whole blood Ce concentrations from
each individual rat’s results. Non-compartmental models showed the best fits for the
cerium ion (Rsq 0.94 ± 0.08, Corr XY = 0.97 ± 0.04) and 5 nm ceria ENM (Rsq 0.89 ±
0.06, Corr XY = 0.94 ± 0.03). However, 15, 30 cubic, 30 cubic + rods, and 55 nm ceria
ENMs were poorly fitted by non-compartmental models. One and two compartment
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models showed the Ce concentrations in blood obtained 0.167 h to 1 week after cerium
ion infusion and 0.167 h to 30 day following infusion of 5-, 15-, and 30- nm ceria ENMs
were best fit by two compartmental models (biexponential decay). For the mixture of 30nm cubic + rod ceria and the 55-nm ceria ENMs, for which modeling was based on
results to 4 h after their infusion, the one compartment model provided the best fit.

Table 3.2 summarizes the pharmacokinetic parameters. Compartmental analysis showed
the cerium ion to have a greater AUC than the ceria ENMs, a higher C max compared to
the ≥ 15 nm ENMs, and a smaller Vdss than all of the ENMs. Surprisingly, the 15- and
30-nm cubic ceria materials showed increasing blood concentrations over the period 0 to
4 h after infusion, with estimated half-lives of this process of ~ 4 and 2.7 h, respectively
(Figure 3.2). Since conventional elimination models are always monotonically decreasing
in solute concentration, the WinNonLin fits were poor and the 15 and 30 nm ceria ENMs
model coefficients did not meet the Student’s t-test criteria for quality (the average
standard error was often larger than the estimated value of the coefficient).

With the exception of the 5-nm ceria ENM, the pharmacokinetic results are based on <
2% of ceria dose that was remaining in the blood 0.167 h after completion of the ceria
infusion, therefore the pharmacokinetic parameter estimates describe only a small
fraction of the dose of these ENMs. The two-compartment models for each of the rats
that received cerium ion or 5-nm ceria ENM infusions fit the data very well based on
visual inspection, weighted corrected sum of squares, sum of square residuals, weighted
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sum of square residuals, random distribution of residuals, Akaike’s information criteria,
and Swartz criteria.

Figure 3.3 shows the ratio of the whole blood Ce concentration after infusion of 5-, 15-,
30-, and 55-nm ceria ENMs vs. the cerium ion. The ratio, R, for 5 nm ceria ENM could
be modeled either by a power law dependence, R

R0 t d (R0 is a constant and d is the

power exponent for time t), or an exponential dependence, R R0 exp(d t) (R0 is the
Arrhenius-type factor and d is the process rate constant) for each of three animals. Trend
lines are shown for the power law dependence (Figure 3.3, top left panel) with d ~ -0.8.
Five-nm ceria ENMs are fitted by two-compartment models and their blood
concentrations showed time dependent decreases compared to cerium ion blood
concentrations. Over the time period, 0 to 4 h after infusion, it was cleared faster than the
free ion. On the other hand, R values for both 15 and 30 nm ceria increased over the 0 to
4 h time period and their exponential coefficients were similar (d = 0.41 h-1 and d = 0.45
h-1, respectively). The R value of 55 nm ceria showed no strong trend.

The Ce mass balance for cerium ion, calculated by comparing the cerium in the serum
plus clot samples to the cerium in whole blood, averaged 98 ± 7% over all samples. For
the 5-nm ceria ENM, the average mass balance was 83 ± 44%; 5 out of the total of 30
values from the 6 sample times were below the cutoff of 70% mass balance. These
ranged from 16 to 31% and were obtained 120 or 240 min after the ceria infusion, at a
time when Ce concentrations had decreased to an average of 8 and 0.4 microgram Ce in
the serum prepared from the 0.3 ml of blood. They were not used in the data analysis. For
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the remaining 25 values, recovery was 93 ± 40%. For the 15-, 30-, and 55-nm ceria
ENMs, 17, 16 and 11 of the 18 values from 3 of the rats met the material balance quality
control criteria and were used in the data analysis, respectively. For the 30-nm ceria
cubes and rods mixture, 12 values from 2 rats met the material balance quality control
criteria and were used in the data analysis.

Figure 3.4 shows the ratio of Ce distribution in blood serum vs. whole blood from 0.167
to 4 h after completion of the cerium ion or ceria ENM infusions. The ratio of Ce in
serum vs. whole blood shows its distribution between blood serum and the clot fraction
(associated with the red and white cells and platelets). Blood samples taken from 0 to 4 h
after infusion showed that the cerium ion, 5-, and 55-nm ceria ENMs did not
preferentially distribute into either the blood serum or clot (containing red, white cells
and platelets); there was no consistent time dependence of the ratio for all animals. The
30 nm cubic + rod mixture preferentially distributed to the clot fraction over a similar
period, also with no consistent time dependence of the ratio for all animals. However,
serum/clot partition data for 15- and 30-nm ceria showed that these ENMs migrated into
the clot fraction, and that partition ratio of ceria in the clot increased with time. Two of
the rats that received 15 nm and 4 that received 30 nm ceria showed a statistically
significant increase of Ce associated with the clot fraction.
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Table 3.2. Pharmacokinetic parameters for the cerium ion; 5-, 15-, 30- and 55-nm ceria ENMs; and mixture of 30-nm cubic and rod
ceria ENMs and after iv infusion to rats. Values are means ± SD, calculated from results obtained from times shown (after
completion of the infusion).
0.167 h to 7 days
0.167 h to 30 days
0.167 to 4 h
Parameter

cerium ion (n=3)

5-nm ceria
(n=3)

15-nm ceria
(n=4)

30-nm cubic
ceria (n=5)

30-nm cubic +
rods ceria (n=5)

55 nm ceria
(n=5)

25 ± 8a
20 ± 11a
26 ± 36a
1.6 ± 1.8a

1.5 ± 0.5a
0.78 ± 0.12a
2.2 ± 0.8a
1.5 ± 0.1a

Non-compartmental Analysis
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AUC (h* mg/L)
Cmax (mg/L)
t1/2 (h)
MRT (h)

326 ± 102a
163 ± 27a
2.7 ± 0.8a
1.5 ± 0.2a

2264 ± 1284b
278 ± 215b
80 ± 25b
7.1 ± 3.0a

361 ± 130a
0.95 ± 0.34a
41 ± 11b

2201 ± 1314b
6.5 ± 3.1a
15 ± 11a

Two Compartment Model
c

a

One Compartment Model
b

a

AUC (h* mg/L)
1377 ± 416
690 ± 181
152 ± 41
561 ± 256
72 ± 39b
1.9 ± 0.7b
Cmax (mg/L)
190 ± 29a,b
372 ± 317a
0.82 ± 0.45b
3.5 ± 1.7b
12 ± 5b
0.88 ± 0.44b
t1/2-α (h)
0.57 ± 0.13
0.44 ± 0.27
2.5 ± 2.6
12 ± 17
4.3 ± 1.8
1.9 ± 0.6
b
a,b
c
a
t1/2-β (h)
16 ± 3
124 ± 53
239 ± 56
140 ± 43
c
a,c
b
a
c
MRT (h)
21 ± 3
92 ± 53
343 ± 83
192 ± 57
6.3 ± 2.6
2.8 ± 0.8c
CL (L/h/kg)
0.078 ± 0.028a
0.15 ± 0.04a
0.71 ± 0.24a
0.22 ± 0.11a
1.4 ± 1.0a
46 ± 30b
Vdss (L/kg)
1.7 ± 0.8a
15 ± 12a
240 ± 8b
38 ± 12a
9.6 ± 3.9a
130 ± 42c
AUC, area under the concentration–time curve; t1/2-α , first half-life; t1/2-β , second half-life; Cmax, peak concentration; CL, Clearance;
MRT, mean residence time; Vdss, volume of distribution at steady state.
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Figure 3.2. Whole blood Ce concentration after completion of iv infusion of the cerium
ion, 5, 15, and 30 ceria ENM, a mixture of 30-nm ceria cubes and rods, and 55-nm ceria
ENM. All values are normalized to an equivalent dose of 100 mg ceria/kg. Results are
mean ± S.D. from 5 rats at each time point, except for cerium ion, where n = 3 for 5 nm
ceria ENM where n = 9, 10, 21, 10, 12, and 7 rats at 0.167, 0.5, 1, 2, 20 and 720 h; for 15
nm ceria ENM where n = 10 rats at 0.167, 0.5, 1, 2, and 4 h; for 30 nm ceria ENM were n
= 6 for all times except 1, 20 168 and 720 h where n = 10, 8, 3 and 11; and for the 55 nm
ceria ENM were n = 10 and 7 at 1 and 20 h, respectively. The horizontal line at the top
of each graph shows the calculated cerium concentration in blood representing 100% of
the dose.
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Figure 3.3. The ratio of Ce concentration in whole blood following iv infusion of 5-, 15-,
30- and 55-nm ceria ENMs from 0.167 to 4 h after their infusion, compared to the cerum
ion concentration. Each symbol represents a different rat.
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Figure 3.4. The ratio of cerium in serum to whole blood (as %), following iv infusion of
the cerium ion; 5-, 15-, and 30-nm ceria ENMs; mixture of 30-nm cubic + rod ceria
ENMs; and 55-nm ceria ENM. Each symbol shows results from a different rat. For the
15-nm ceria ENM the solid curve is the model for the rat shown by the open circle,
dashed line for rat shown by the closed square, and double curve for rat shown by the
closed diamond. For the 30-nm ceria ENM the solid curve is the model for the rat shown
by the closed square, dashed line for rat shown by the open circle, double curve for rat
shown by the closed diamond, and long dash dot curve for rat shown by the open triangle.
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3.4. Discussion
10B

The crystal structure of the ceria ENMs was as expected because the fluorite structure is
the only one for crystalline CeO2. The citrate coating was least dense on the 55 nm ceria,
suggesting it would be the most likely of the ENMs tested to agglomerate in aqueous
dispersion; a problem that was observed during its administration requiring frequent
agitation of the dispersion to prevent it from occluding the infusion line. Although nearly
12% of the total cerium in the 5 nm ceria ENM was free cerium in the aqueous phase,
comparison of the results after infusion of the 5 nm ceria ENM, the cerium ion, and the
other ceria ENMs shows the free cerium cannot account for the differences between the 5
nm and the larger ENMs.

In the present study ~ 14% of the cerium ion remained in the blood 0.167 h after
completion of a 1 h iv infusion. In a previous report Ce was determined in blood from 1 h
to 3 days following its iv administration as the chloride to mice and rats; however, the
author did not conduct a pharmacokinetic analysis of the results (218). Using WinNonLin
to conduct pharmacokinetic analysis, non-compartmental and compartmental calculations
of the Bjondahl results (218) showed similar AUC, MRT, Cmax, and CL results. The noncompartmental half-life (10 h) was the same as the terminal half-life obtained with a two
compartment model, which best fit the data for compartmental analysis. The initial halflife of the Bjondahl results (~ 3 h) was longer than we obtained (0.6 h) because our study
included samples taken as early as 10 min, whereas the first sample in the Bjondahl study
was obtained at 1 h.
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Ten min after completion of the iv infusion of ceria ENMs, ~ 32% of the 5-nm ceria but
< 2% of the larger ceria ENMs were present in the blood. The greater extent of citrate
coating on the 5-nm ceria (and therefore its greater hydrophilicity) may have contributed
to this. However, we do not know how long the citrate persisted on the surface of the
ceria ENM or if was covered (opsonized) by proteins. The rapid clearance of metal/metal
oxide ENMs from blood has been reported previously.

Little has been reported about the fate of systemic cerium, other than it is very slowly
eliminated, primarily in bile, resulting in prolonged retention in mammals, primarily in
the liver and skeletal system (219, 220). Our pharmacokinetic results showed that the
cerium ion had a smaller Vdss than the 5-nm ceria ENM. It also showed less retention in
reticuloendothelial tissues, but more in the lung (27). All the ceria ENMs showed a large
Vdss indicating great distribution in tissues, consistent with the intracellular
agglomerations we have seen, especially in reticuloendothelial cells (179). Ceria ENMs
have been seen in the cytoplasm of brain cells, phagosomes of macrophages, vesicles of
lung fibroblasts, spleen red pulp, Kupffer cells, hepatocytes and mesangial cells (7, 71,
221-224). Thirty days after ceria ENM infusion the greatest concentration was seen in the
reticuloendothelial tissues, including liver and spleen (7, 32, 224). It was reported that
lung, heart, and brain cerium did not decrease over 6 months following iv ceria ENM
dosing (221). A study with the 30-nm ceria ENM used in the present study showed no
significant decrease of ceria in 14 tissues up to three months after iv administration. The
highest concentrations were in reticuloendothelial tissues (spleen, liver and bone
marrow), followed by the lung, then other sites (27). We are not aware of any reports of
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ceria uptake into red or white blood cells or platelets other than our prior finding
suggesting a small amount of a 30 nm ceria ENM might have entered red blood cells after
1 h in vitro (7). It is unclear if the ceria ENMs would ever reach a constant blood level.
Up to the times studied in the present report, there was generally a decrease of blood
cerium. Given the persistence of ceria in the rat, one might expect a steady state to be
reached. However, 90 days after ceria infusion blood cerium concentration was higher
than earlier times (27).

The cerium ion was equally distributed between serum and clot fractions. A previous
study reported that 2 h after iv cerium ion administration ~ 28% of the cerium in the
blood was in cells and 72% in serum (225), similar to results in the present study that
showed ~ 70% in the serum fraction at 2 h. The distribution of ceria ENMs between
serum and clot varied with size and surface chemistry. The 5-nm ceria was evenly
distributed within the serum and clot fractions. We previously observed small
agglomerations of the 5-nm ceria in serum, presumably associated with proteins, and
agglomerations associated with the extracellular side of the erythrocyte cell membrane
after 1 h of incubation of the ceria in blood (224). The ability of ENMs to enter
erythrocytes, a non-phagocytic cell, has been observed for 78 nm polystyrene, 25-nm
gold, and 22-, 25- and 80-nm titania ENMs (226-228). However, we are not aware of
any studies of ceria ENM or other metal/metal oxide ENMs entry into white blood cells
or platelets.
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Although the extent of citrate coating might be expected to influence the fate of ceria
ENMs in vivo, the present results show no clear trends between the extent of citrate
surface coating and ceria ENM distribution between serum and the clot fraction initially,
or over time. For the cerium ion, and 5- and 55-nm and the mixture of 30-nm cubic + rod
ceria ENMs, we were unable to identify any trends in the percentage of Ce in the serum
vs. time.

The blood levels of the 15- and 30-nm ceria ENMs increased over the 4 h after their
infusion. As they were given by the iv route, this suggests a re-distribution of the ENM
over time. Re-distribution of ENMs has been previously recognized and discussed, e.g.
(229). An increase of ENM in blood within the first 2 h after iv administration has been
reported, although the increases appear to be within the variability of the reported
measure of the quantum dots in plasma or blood and neither report discusses the increase
(230, 231). The increase we saw may be influenced by protein corona and/or distribution
into and out of a non-central compartment, such as the lymphatic system, as noted by
(232). We also observed that the distribution of the 15- and 30-nm ceria ENMs within
blood compartments changed over the 4 h after completion of their infusion, when they
became more associated with the cells in the clot fraction. These results suggest their
surface chemistry changed during that period, which may be due to dissociation of the
citrate, association with proteins or blood cells, and/or cell entry and release. Nanoscale
materials are rapidly coated with plasma proteins and other circulating substances, which
create a corona around the ENM, increasing their hydrodynamic size (163, 180). It has
been shown that citrate-coated ENMs bind to the surface of cells (102) and can become
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opsonized with albumin (233). We speculate that the increase of the 15- and 30-nm ceria
ENMs in circulating blood and migration toward the clot fraction during the first 4 h after
their iv infusion is due to distribution out of, then back into, circulating blood, perhaps
associated with protein corona. This might be due to initial accumulation in blood vessels
or adsorption onto the luminal surface of vascular endothelial cells, followed by protein
modification and re-circulation in blood. However, we would not anticipate extensive
accumulations of ceria blocking the vasculature in the absence of cardio- and
cerebrovascular incident (MI and stroke) which we have not observed in these rats that
generally tolerated the target doses well.

Or the ceria ENMs may have distributed

outside of the vascular compartment, such as entrapment by reticuloendothelial organs
followed by their release back into blood, or entry into the lymphatic system, that drains
into the cardiovascular system. Particles up to 50 nm are able to rapidly enter the
lymphatic system (234, 235). From the results of the present study we do not have
evidence of the origin of the ceria ENMs that re-entered circulating blood during the first
4 h after their infusion. However, we have seen a net migration of Ce following 30-nm
ceria ENM administration from liver to spleen from 1 to 20 h after its infusion (181) and
into lung over 90 days, consistent with re-distribution of this ENM over time (27). As >
98% of the ceria dose was no longer in circulating blood when we started blood sampling
10 min after completion of the ceria infusion, the long terminal half-life and MRT and
large Vdss for the 5, 15 and 30 nm ceria ENMs, based on blood levels to 30 days, may
describe the very small fraction of the ENMs that had not yet distributed out of blood
and/or ceria re-distributing among storage sites. This speculation is based on the retention
of a very large percentage of the ceria ENM dose for a long time in the rat and evidence
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we (and others) have of re-distribution among sites over time. Similarly, there may have
been some re-distribution of the 5 nm ceria which was not seen above the much higher
level of ceria remaining in blood from the infusion during the first 4 h after its infusion.

The non-compartmental analysis could not estimate some of the pharmacokinetic
parameters for the 15 and 30 nm ceria ENMs probably because of the ceria concentration
increase at the first 4 h. Due to the lack of prior studies of metal and metal oxide ENMs
in blood, further studies of citrate-coated ceria ENMs are necessary to better understand
their fate in the vascular compartment, including the stability of the citrate coating; their
interaction with cell membranes; and the rate, extent and character of protein association.

The mean residence time (MRT) typically indicates the average time molecules stay in
the body. In our study, the MRT indicated how long ceria ENMs remained in blood, not
in the tissues, because MRT is derived from measurement of ceria (as Ce) in blood (236).
It has been previously noted that the blood half-life of an ENM may be short despite
prolonged body persistence, due to reticuloendothelial system entrapment and other
processes not typical of small inorganic and organic molecules (209). Noncompartmental and compartmental analyses produced quite different MRT results,
although the trends among the tested materials are similar across analysis. The lower
MRT values with the non-compartmental analysis may be due to its tendency to
underestimate MRT (237). Knowing that there are persistent accumulations of ceria
ENMs in multiple organs suggests the MRT results from the compartmental analysis
more closely reflects the whole body residence time of ceria ENMs. The results of the
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present pharmacokinetic calculations that one can have the most confidence in are those
obtained following infusion of the cerium ion and the 5-nm ceria ENM, due to the very
rapid clearance of the larger ENMs from circulating blood and the rise in Ce
concentration over 4 h following 15- and 30-nm ceria ENM infusion. Although the
results obtained with the cerium ion and 5, 15 and 30 nm ceria ENMs clearly show two
compartments, the values for the second compartment do not have a high degree of
precision due to the limited number of data points on which they are based.

It has been previously noted that some of the properties of ENMs, e.g., protein coating,
adhesion, and phagocytic uptake, may differ from small organic molecule disposition for
which pharmacokinetic modeling programs such as WinNonLin were created (209).
Pharmacokinetic and PBPK approaches have been used to model ENM distribution
among tissues and blood (232, 238). Most nanomaterials do not exhibit ADME profiles
typical of drugs (239), e.g. they are rapidly cleared from the blood, not metabolized, and
not rapidly eliminated, unless small enough to be filtered by the renal glomerulus. It has
been recognized that the toxicokinetics of ENMs are unlikely to follow the “rules” of
current approaches (240, 241). Further work is needed to develop a pharmacokinetic
model to predict the time-dependent changes of ceria ENM distribution in tissues and
blood.

There is considerable literature on the pharmacokinetics of polymer ENMs due to the
extensive research in developing them as drug delivery systems. Much less is known
about the pharmacokinetics of metal and metal oxide ENMs; particularly their
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distribution, residence time, and rate of clearance from the vascular compartment. The
present study informs about the effects of ENM physicochemical properties on
distribution and clearance from blood. The results show ceria ENMs have a
biodistribution and clearance pattern which cannot be predicted from the cerium ion. This
may be due to the very different physicochemical properties of the cerium ion and ceria
ENMs.

3.5. Conclusions
1B

To better understand the fate of ceria as a model ENM we compared the distribution
within, and rate of clearance from, blood of four different sizes of cubic or polyhedral
ceria nanoparticles, a mixture of cubes and rods, and the cerium ion after iv infusion into
rats. Table 3.3 summarizes the main findings of the present study. The kinetics and
distribution of the cerium ion did not predict those of the ceria ENMs. A 5-nm ceria
ENM, which was very resistant to agglomeration and settling in vitro, was cleared much
more slowly from blood than larger ceria ENMs, presumably because it was too large to
be cleared by glomerular filtration and perhaps too small or too hydrophilic to be readily
recognized by the reticuloendothelial system. Ceria ENMs larger than 5 nm were very
rapidly cleared from circulating blood. All the ceria ENMs had a much greater Vd ss than
the cerium ion, consistent with their extensive distribution and prolonged retention
throughout the rat. The 15 and 30 nm ceria ENMs showed concentration ratios increasing
vs. cerium ion over 4 h after infusion. The distribution of ceria ENMs between serum
and the blood clot was size dependent. The citrate-coated 30-nm ceria showed the
greatest distribution in the clot fraction. The fraction of 15 and 30 nm-ceria ENMs in the
clot fraction increased over 4 h, suggesting a change in their surface properties, perhaps
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due to protein corona. A further understanding of the rate and nature of ceria ENM
association with blood proteins and cells, and the process(es) of their clearance from
blood, is needed to fully interpret their fate in the vascular compartment.

Table 3.3. The whole blood compartment model, serum and clot partitioning, and ceria
ENM vs. cerium ion ratio results of the six materials studied.
[Ce]ceria
[Ce]cerium(ion)

Serum/whole
blood partitioning

Material

Compartment modeling

R

Cerium ion

Fits the two compartment
model

Not applicable

No strong trend

5 nm ceria

Fits the two compartment
model; longer persistence in
the second compartment
than the cerium ion

Time-dependent
reduction in [Ce]
relative to the ion;
1st order or other
process possible

No strong trend

15 nm ceria

Rapid loss during infusion;
Apparent re-distribution to
blood in 2-4 hours

Increase relative to
[Ce]ion; 1st order
process

Reduction in serum
levels with time;
1st order process
(protein corona?)

30 nm ceria

Rapid loss during infusion;
Apparent re-distribution to
blood in 2-4 hours

Increase relative to
[Ce]ion; 1st order
process

Reduction in serum
levels with time;
1st order process
(protein corona?)

Cubic +
rod ceria

Loss during infusion;
Apparent redistribution to
blood in 2-4 hours

No strong trend

No strong trend;
less than 50% in
serum

55 nm ceria

Rapid loss during infusion;
No apparent re-distribution
to whole blood in 2-4 hours

No strong trend

No strong trend
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3.6. Unsolved problems
12B

This study gave us a better understanding of pharmacokinetics of different sized ceria
ENMs in blood. Traditional pharmacokinetic modeling showed the best fit for 5-nm ceria
ENM and the cerium ion. Ceria ENMs larger than 5 nm were rapidly cleared from blood.
After initially declining, whole blood 15- and 30-nm ceria increased; results not welldescribed by traditional pharmacokinetic modeling. One possibility is that ceria ENMs
associated with the blood vessel and dissociated over time due to protein corona.
Following the distribution in and clearance from blood, the ceria ENM blood vessel
association and moving out of the vascular compartment will be the next crucial step
influencing their fate in biological systems. In the next chapter, the BBB was chosen to
investigate the association and flux of ceria ENMs across this biological barrier using the
in situ brain perfusion method.

Reproduced with permission from Dan M, Wu P, Grulke EA, Graham UM, Unrine JM,
Yokel RA. Ceria engineered nanomaterial distribution in and clearance from blood: Size
matters. Nanomedicine, 2012, 7(1), 95-110. Copyright © Future Medicine Ltd. Dan M
and Yokel RA drafted the published paper. Author’s contributions: Dan M did the most
of pharmacokinetic studies including modelling and animal studies. Wu P synthesized
and characterized the ceria ENMs except 55 nm ceria. Grulke EA helped with the
pharmacokinetics model and revised the paper critically. Graham UM synthesized the 55
nm ceria. Unrine JM analyzed all the samples using ICP-MS.

Copyright © Mo Dan 2013
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Chapter 4 Brain microvascular endothelial cell association and distribution of a 5
31B

nm ceria engineered nanomaterial

In this chapter, we will test our hypothesis that a 5 nm ceria ENM can associate with
brain capillary cells and enter the brain. The study will provide important information on
how ceria ENMs associate with endothelial cells, which is the first step for its cell uptake
or redistribution back into circulating blood. This is the first report on how ceria ENMs
distribute between the BBB and the brain parenchyma. The results will show the potential
biomedical applications in the CNS and provide explanation for the nontraditional
pharmacokinetics profile of ceria ENMs.

4.1. Introduction
Our previous findings showed 5 nm ceria ENM agglomerates in the brain capillary
lumen. Electron microscopy did not reveal ceria ENM inside microvascular endothelial
or brain cells. Ceria ENMs did not produce profound pro- or anti-oxidant effects in the
brain 1 or 20 h after a one h systematic intravenous infusion (8). The reasons for the lack
of ceria ENM in the brain were unknown. One possibility is that the protein corona in the
blood that changed ceria ENMs physicochemical properties, resulting in their rapid
clearance by the MPS (180, 181). Nanoparticles agglomerated very rapidly in the blood
or on a biological surface, changing their distribution and cell interaction (78, 182-184),
so that the agglomerated ceria became too large or unavailable to penetrate the intact
BBB. The present study utilized a controlled system to better understand how ceria
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ENMs interact with brain capillary endothelial cells. The results are relevant to the
therapeutic use and toxicological consideration of ceria ENMs.

The objective of this study was to investigate the brain capillary cell association and brain
entry rate of a 5 nm ceria ENM. We used the in situ brain perfusion method to evaluate
BBB integrity and determine brain entry rate at different perfusion flow rates, ceria ENM
concentrations and perfusion durations. Eight brain regions and a choroid plexus were
collected to test regional differences in BBB integrity and ceria ENM brain entry rate.
The capillary depletion method was used to evaluate ceria ENM distribution between
capillary and brain tissues. The localization of ceria nanoparticles was investigated by
LM and EM.

4.2. Materials and Methods
4.2.1. Materials
The chemicals used to prepare the ceria ENMs have been described (242). Cerium
chloride heptahydrate (Sigma-Aldrich #228931, 99.9% metal basis), ammonium
hydroxide (Fisher # 3256, ACS, 28-30%), deionized ultra filtered water (Fisher #W2-20),
and citric acid monohydrate (EMD Chemicals Inc # CX1725-1, GR ACS) were used
without further purification. All other chemicals were purchased from Sigma-Aldrich (St.
Louis, MO) unless otherwise noted.

4.2.2. Ceria ENM synthesis
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Synthesis of the 5 nm ceria ENM was described (224). It was synthesized using a
hydrothermal method (213) that produces monodisperse nanoparticles directly in the
reactor. Typically, a 20-ml aqueous mixture of 0.5 M (0.01 mol) ceria chloride and 0.5 M
(0.01 mol) citric acid was added to 20 ml of 3 M ammonium hydroxide. The latter was in
excess of that needed for complete reaction of the cerium chloride to cerium hydroxide.
After stirring for 24 h at 50 ºC, the solution was transferred into a Teflon-lined stainless
steel bomb and heated at 80 ºC for 24 h to complete the reaction. Ceria ENM was citrate
coated (capped) to improve their dispersity in water to stabilize dispersion through
electrostatic repulsion to prevent the agglomeration seen with uncoated ceria that occurs
in high ionic strength solutions, such as blood (102, 103, 243). Citrate was selected
because it is a commonly used surface coating agent for ENMs to inhibit agglomeration
(e.g., NIST’s reference materials 8011, 8012 and 8013), is a component of blood (present
at ~ 100 µM in humans), might coat bare ENMs circulating in blood, has been shown to
have no effect on erythrocyte response to a silver ENM, and citrate-coated ENMs interact
strongly with proteins, resulting in the rapid protein corona that occurs when ENMs enter
blood (233, 244, 245).

4.2.3. Ceria ENM characterization
The physico-chemical properties of the ceria ENMs were determined in our laboratories.
Most of the methods have been reported (242). Primary particle size distributions were
determined by TEM and scanning transmission electron microscope (200-keV field
emission analytical transmission electron microscope, JEOL JEM-2010F, Tokyo, Japan).
From the individual primary particle sizes measured from TEM images, number
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frequency cumulative distributions were constructed. These cumulative distributions
were best described by log-normal distribution models, characterized by a sample mean
and its standard deviation. All of these data sets were well-described by a single monomodal distribution, that is, one continuous distribution was observed, and no significant
secondary or tertiary peaks were noted. The reported ‘average’ diameter of each sample
was Dave

exp

, where µ is the mean of the log-normal probability distribution, and the

reported ‘standard deviation (S.D.)’ is the value from the fit of the log-normal
distribution to the data. For each sample, number-based differential frequency
distributions were constructed using the model coefficients. The particle size distributions
(PSDs) for each batch of as-synthesized ceria aqueous dispersion were determined using
dynamic light scattering (DLS; 90Plus NanoParticle Size Distribution Analyzer;
Brookhaven Instruments Corporation, Holtsville, NY). Zeta potential of the ceria ENMs
dispersion as infused into the rat was estimated from electrophoretic mobility
measurements using a Zetasizer nanoZS with a typical ceria concentration ~0.02 wt%
(Malvern Instruments, Worchestershire, UK). Because the particles had hydrodynamic
diameters < 200 nm, the Hückel approximation was used to calculate zeta potential from
electrophoretic mobility. The surface area of the dried powder was determined using a
BET surface area analyzer (Micromeritics Instrument Corporation, Norcross, GA, USA).
Thermogravimetric analysis (Perkin-Elmer TGA7 Analyzer) was then performed to
investigate the weight loss of citrate-coated ceria NPs over the temperature range of 150
to 300°C under which decomposition of citric acid occurs. The extent of citrate surface
coating was estimated based on the assumption that all the ceria NPs were spherical and
had uniform size.
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4.2.4. Nanomaterial
The 5 nm ceria ENM was synthesized using a previously reported method (8). The
physico-chemical properties of the ceria ENMs were determined in our laboratories. Free
cerium in the ceria ENM dispersion was removed by ultrafiltration using 3 kDa
molecular weight cutoff regenerated cellulose centrifugal filtration devices (Amicon
Ultra-4, Millipore). The 5 nm ceria (3.5 ml) was added to the Amicon Ultra Filter unit.
The unit was centrifuged at 4800 g for 35 min to obtain 3 ml filtrate and 0.5 ml
concentrated ceria ENM. The 3 ml filtrate (containing free cerium) was removed from the
centrifuge tube. Three ml sodium citrate (0.17 M) solution was added to the filtration
device to disperse the ceria ENM. After conducting this washing procedure 3 times,
sodium citrate solution (3 ml; 0.17 M) was added to the filtration device which was bath
sonicated for 15 min to redisperse the ceria ENM. The Ce concentrations of the 5 nm
ceria ENM dispersion and free cerium in the ultrafiltrate were analyzed by ICP-MS (8,
242).

4.2.5. Perfusate for in situ brain perfusion
The perfusate contained 30, 100 or 500 µg/ml ceria ENM in a solution of Na + (153 mM),
K+ (4.2 mM), Ca2+ (1.5 mM), Mg2+ (0.9 mM), Cl- (162 mM) and glucose (9 mM).
Gadolinium-diethylenetriaminepentaacetic acid (Gd-DTPA) (1 mM) was added to
determine BBB integrity. Gd-DTPA, a marker for vascular space, has been shown to not
significantly cross the intact BBB because of its charge and high molecular weight (246).
A significant increase of Gd-DTPA in brain samples indicates BBB damage. Following
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at least 1 h incubation at 37°C, the perfusate was bubbled for 2 min with 95/5 air/CO 2
and adjusted to pH 7.4 prior to its use (247).

4.2.6. Ceria ENM stability in the perfusate
Ceria ENM stability in the perfusate was determined from 1 to 230 min (after addition to
perfusate) using dynamic light scattering (DLS) (90Plus Nanoparticle Size Distribution
Analyzer, Brookhaven Instruments Corp, Holtsville, NY). The intensity-weighted
hydrodynamic diameter in the perfusate was measured at 1000 µg/ml at 37 ºC, and then
converted to number- and volume-weighted averages.

4.2.7. Animals
This study used 55 male Sprague-Dawley rats, weighing 330 ± 35 g (mean ± SD), that
were housed individually prior to study in the University of Kentucky Division of
Laboratory Animal Resources Facility. Animal work was approved by the University of
Kentucky Institutional Animal Care and Use Committee (Protocol 2008-0272). The
research was conducted in accordance with the Guiding Principles in the Use of Animals
in Toxicology.

4.2.8. In situ brain perfusion methods
We employed the modification of the brain perfusion technique that we previously
reported (247-249). Briefly, the rat was anesthetized under ketamine/xylazine anesthesia
(75 and 5 mg/kg), and its left carotid artery exposed. Following ligation of the external
carotid, occipital and common carotid arteries, PE60 tubing containing heparin (100
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U/ml, in 0.9% NaCl) was inserted into the common carotid. We used the heart-cut
modification of this technique and increased the perfusate flow rate to 20 ml/min (250).
The rat was decapitated to end the perfusion. The brain was harvested and cleaned of
meninges and surface vessels. Brain tissue (~ 20 mg from each brain region except the
choroid plexus, which averaged 0.9 ± 0.4 mg) was collected from the frontal cortex,
parietal cortex, occipital cortex, thalamus/hypothalamus, midbrain/colliculus, striatum,
cerebellum, hippocampus, and choroid plexus from the left hemisphere for measurement
of Gd-DTPA (as gadolinium) and ceria ENM (as cerium) by ICP-MS. Cerebrovascular
washout of perfusate was conducted to test the influence of ceria concentrations in the
vascular space on the brain uptake space. The cerebrovascular space was washed at the
same perfusion rate (n = 4 rats) for 20 s with ceria-free perfusate immediately following
100 µg ceria ENM/ml perfusion for 120 s at 20 ml/min. The results were compared to
those obtained without cerebrovascular washout using a two-way ANOVA. The brain
uptake space in the washout and non washout conditions did not show significant
differences after correcting for the vascular volume. Therefore, the rest of the studies did
not conduct washout except the capillary depletion experiment and 3 rats perfused for
LM and EM examination.

Flow-rate dependent uptake is a property of some carrier-mediated uptake systems, but is
not a property of diffusion (247). Therefore, to examine the effect of perfusion flow rate
on influx rate and the vascular and brain extracellular fluid volumes, 15 and 20 ml/min
flow rates (100 µg ceria ENM/ml) were tested in 4 and 5 rats, respectively. To determine
whether ceria ENM brain entry is concentration dependent, 3 ceria ENM concentrations
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(30, 100 and 500 µg/ml) were investigated using a perfusion rate of 20 ml/min and
duration of 120 s (n = 4, 6 and 5 rats, respectively). Ceria ENM brain entry during
different perfusion durations was investigated to determine how fast ceria ENM
associates with brain capillary cells or enters the brain. Perfusion durations of 20, 60 and
120 s, using a rate of 20 ml/min, and 30 µg ceria ENM/ml were studied in 4 treated
animals and 3 control animals in each group. Three animals were prepared for LM and
EM after perfusion with 100 µg ceria ENM/ml, 20 ml/min for 120 s, followed by 20 s
washout with ceria-free perfusate.

4.2.9. Capillary depletion method
The capillary depletion method was used to separate brain parenchyma from capillary
tissue (247, 251). After a 30 µg/ml, 120 s, 20 ml/min ceria ENM perfusion, a 20 s
washout was conducted. The forebrain from perfused hemisphere was isolated from 10
rats (2 control and 8 treated) and the lateral ventricle choroid plexus in the perfused
hemisphere was removed. The tissue was homogenized in 3.5 ml physiological buffer
containing 141 mM NaCl, 4 mM KCl, 2.8 mM CaCl2, 1 mM NaH2PO4, 1 mM MgSO4,
10 mM glucose and 10 mM HEPES at pH 7.4. Dextran (70,000 g/mol) was then added to
18% (w/v) and the sample further briefly homogenized. After centrifugation at 5400 x g
for 15 min at 4 ºC, the supernatant (brain rich fraction) and pellet (capillary rich fraction)
were carefully separated for measurement of ceria ENM by ICP-MS. The percentage of
the forebrain ceria ENM in the capillary rich fraction = mass amount of cerium in the
capillary rich fraction / mass amount cerium in the capillary rich fraction plus brain rich
fraction.

The percentage of the ceria ENM dose in the capillary rich fraction = mass
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amount of cerium in the capillary rich fraction / mass amount cerium in the total ceria
ENM dose

4.2.10. Cerium and gadolinium analysis
Cerium and gadolinium were analyzed by ICP-MS (Agilent 7500cx, Santa Clara, CA,
USA) as previously described (7, 224). The method detection limits of Ce and Gd in
tissue were 0.013 mg Ce/kg and 0.0004 mg Gd/kg, respectively.

4.2.11. Light and electron microscopy
Rats were decapitated at the end of the in situ-washout perfusion for brain removal. After
bisection, each hemisphere was immediately immersed in a fixative containing 2%
paraformaldehyde-2% glutaraldehyde in 0.1 M cacodylate buffer for 24 h at 4 ºC. Tissue
samples from pituitary gland, hippocampus, and choroid plexus were identified with the
aid of a dissecting microscope, and stored in 0.1 M cacodylate buffer. Samples were cut
to approximately 3 mm3 before being dehydrated in ascending concentrations of ethanol
and embedded in Araldite 502. After polymerization, blocks were sectioned at one
micron thickness, toluidine blue stained for screening, and selected blocks sectioned at 80
nm thickness for TEM viewing in a Philips CM 10 electron microscope operated at 80
kV.
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4.2.12. Data and Statistical Analysis
The distribution volume, or uptake space (Q), derived from the in situ brain perfusion
results, is the amount of brain tissue into which the substrate distributes during a given
perfusion duration. Q

ceria total

(ml/g) = ceria ENM in tissue (µg/g) / ceria per volume of

perfusate (µg/ml) (252). The mass amount of ceria ENM per gram of brain (µg/g) was
also calculated in order to compare the results of perfusion of the 3 ceria ENM
concentrations. Gd-DTPA uptake space (vascular and extracellular space) was used to
correct the ceria ENM brain uptake space results (247). QGd-DTPA = Gd-DTPA in tissue
(µg/g) / Gd-DTPA per volume of perfusate (µg/ml). Corrected brain Qceria ENM = Qceria total
– QGd-DTPA. The corrected mass amount of ceria ENM per gram of brain (µg/g) = (Qceria
total

– QGd-DTPA) (ml/g) X ceria per volume of perfusate (µg/ml). Grubbs' test was used to

determine outliers. Bartlett’s was used to test if samples have equal variances. Two - way
ANOVA followed by Bonferroni multiple comparisons was used to test for significant
differences among Gd-DTPA concentrations at 15 ml/min and 20 ml/min (treated and
control) flow rates and among the nine regions. Two - way ANOVA followed by
Bonferroni multiple comparisons was also used to test for significant differences among
three concentration groups of ceria ENMs and the nine regions or among three infusion
times of ceria ENMs and the nine regions (GraphPad Prism Version 3.00 for Windows,
GraphPad Software, San Diego, CA). The results of the statistical analysis for two-way
ANOVA will be reported as F(df (degrees of freedom) effect, df error) = F-value and Pvalue. The percentage of the capillary surface area that would be covered by ceria ENMs
was calculated as = (the number of ceria ENM particles in the perfused hemisphere X one
ceria particle cross sectional area)/the rat brain capillary endothelial cell surface area.
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This was based on the ceria average diameter, the ceria density = 7.132 g/cm3 and the
rat’s capillary surface area = 140 cm2/g brain (253). All results are reported as mean ±
SD.

4.3. Results
4.3.1. Nanoparticle characterization
The ceria ENM was polyhedral. The X-ray diffraction pattern showed the ceria to be
highly crystalline. It was face centered cubic with corresponding Miller indices of the
most common faces of (111), (220), and (311). Evaluation of a number of TEM images
(Figure 4.1A) showed that Dmean (average primary particle diameter from number
frequency distribution) and standard deviation based on TEM measurements of diameter
fitted using lognormal distribution models was 4.6 ± 0.1 nm. DLS results of a
representative batch of as-synthesized ceria dispersion showed that 98 percent of the
particles were in the range of 6.7 - 8.2 nm (Figure 4.1B). Zeta potential was -53 ± 7 mV
at pH ~ 7.35 in water. The ceria ENM surface area was 121 m2/g. The extent of surface
citrate coating was ~ 40% (8). Five percent free cerium ions were in the as-synthesized
ceria ENM. After the 3 filtrations, less than 0.05 % of the ceria ENM perfusate was free
cerium ions. Ceria ENM was stable in the perfusate at 37 ºC: no apparent agglomeration
was observed from 1 to 230 min. The particle size of the ceria ENMs was within +/- one
standard deviation after addition of the ceria ENM to the perfusate (Figure 4.2). The
stability of the ceria ENM in the perfusate is crucial for this experiment to understand
how the ceria ENM interacts with capillary cells and brain tissue.
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A
Figure 4.1. Ceria ENM morphology. (A) Ceria ENM imaged using TEM. The insert at
the top right shows the crystallinity of the ceria ENM. (B) Volume-based particle size
distribution for ceria ENM of a representative batch of as-synthesized ceria aqueous
dispersion.

Figure 4.2. Ceria ENM hydrodynamic diameter in perfusate. Hydrodynamic diameter
(intensity weighted average) of ceria ENM in the in situ perfusate from 1 to 230 min
(1000 µg/ml at 37 ºC) after ceria was added to the perfusate. Solid circles are DLS data
and black solid line is the average of all the data. Dotted lines represent the position of
average diameter +/- one standard deviation.

4.3.2. Flow rate dependency
Comparison of uptake space (Qceria ENM) using 15 and 20 ml/min flow rates did not show
a significant flow rate effect on brain ceria ENM uptake in any of the 8 brain regions or
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the choroid plexus. Furthermore, there was no significant difference in the vascular space
with these 2 flow rates or between control and treated groups. However, the choroid
plexus showed a significantly higher vascular space than the 8 brain regions (F(8,144) =
12, P < 0.0001) (Figure 4.3). The brain vascular space results were similar to those we
measured using [14C]-sucrose (247). A 20 ml/min flow rate was used for the rest of
study.
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Figure 4.3. Vascular space of the brain as measured by Gd-DTPA at 15 (n=4) and 20
(n=5) ml/min flow rate in control rats and 20 (n=10) ml/min flow rate in 5 nm ceria
treated rats.
* Significantly different from 8 brain regions, F(8,144) = 12, P < 0.0001.

4.3.3. Ceria ENM uptake
To investigate the 5 nm ceria brain entry rate, its uptake space (Q ceria

ENM)

was

determined for each brain region for each of the 3 ceria perfusate concentrations. Figure
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4.4A shows the uptake space significantly decreased with the increase of ceria ENM
concentration in the perfusate (F(2,108) = 118, P < 0.0001). In the 30 µg/ml group, there
were no significant differences among the nine regions. However, in the 100 and 500
µg/ml groups, choroid plexus uptake space was significantly higher than in the 8 brain
regions. In order to compare ceria ENM uptake among the three concentrations, we
calculated the mass amount of ceria uptake into the brain as µg/g (Figure 4.4B). There
were no significant differences among the 3 treatment concentrations. The mass amount
of ceria in the choroid plexus uptake space was significantly higher than in the 8 brain
regions and also significantly higher in the 100 and 500 µg/ml groups compared to the 30
µg/ml group. The average mass amount of ceria per brain hemisphere (0.85 g) (excluding
choroid plexus) was 4.2 ± 0.7 µg. To verify whether the uptake space of ceria ENM
rapidly saturates ceria uptake space was determined for 30 µg ceria ENM/ml for 20, 60
and 120 s perfusion durations. There were significant increases of uptake space to
multiple brain regions from 20 to 60 s (F(2,81) = 9, P < 0.0004) but no differences
between 60 and 120 s, suggesting the uptake space of this ceria ENM saturated between
20 and 60 s (Figure 4.4C). The increased uptake space of the 5 nm ceria ENM showed
that the ceria ENM either associated with capillary endothelial cells or entered the brain.
In the next step, ceria ENM distribution between cerebral capillary cells and brain
parenchyma was determined.

4.3.4. Isolation of cerebral capillaries
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Cerebral capillaries were isolated from brain parenchyma to investigate the distribution
of ceria ENMs between these two fractions. Less than 0.4% of the perfused ceria ENM

Figure 4.4. Ceria ENM uptake space at three concentrations and perfusion duration
times. Effect of ceria ENM concentration and perfusion duration on its uptake. (A) Q
uptake space (ml/g) of a 5 nm ceria ENM in 8 brain regions and the choroid plexus for 3
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concentrations, at a flow rate of 20 ml/min, and 120 s perfusion duration. (B) Mass
amount (µg/g) of 5 nm ceria ENM in 8 brain regions and the choroid plexus after brain
perfusion with 3 ceria concentrations, at a flow rate of 20 ml/min, and perfusion duration
of 120 s. (C) Q uptake space (ml/g) of 5 nm ceria ENM in eight brain regions and
choroid plexus after 20, 60 and 120 s perfusion at 30 µg/ml, at a flow rate of 20 ml/min.
Figure 4.4A, # = significantly different among three concentration groups, F(2,108) =
118, P < 0.0001; * = significantly different compared to the 8 brain regions at the same
concentration, P < 0.05. Figure 4.4B, # = significantly different compared to 30 µg/ml
concentration group; * = significantly different compared to the 8 brain regions, P < 0.05.
Figure 4.4C, # = significantly different between 20s and 60s perfusion duration groups,
F(2,81) = 9, P < 0.0004.

dose associated with cerebral capillaries and brain parenchyma. This separation revealed
that a great majority of the ceria ENM (99.4% ± 1.1% of the total ceria ENM in both the
capillary rich fraction plus brain rich fraction) was associated with the capillary
endothelial cells. Less than 0.003% of the ceria ENM dose was associated with the brain
tissue rich fraction (Figure 4.5). These results suggest that most of the 4.2 ± 0.7 µg ceria
ENM in the perfused brain hemisphere was associated with the capillary endothelial cells
and very little ceria ENM passed through the endothelial cells into brain extracellular
fluid or brain cells.

4.3.5. Ceria ENM localization using LM and EM
LM and EM were used to confirm BBB integrity and determine the localization of ceria
ENM in the endothelial cells and/or brain tissue. Light microscopic examination of
choroid plexus revealed the presence of a cuboidal epithelial cell layer surrounding a core
of capillaries with some surrounding loose connective tissue. There appeared to be no
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Figure 4.5. Capillary depletion results. The percentage of the ceria ENM dose in the
capillary rich fraction and brain rich fraction for 100 µg/ml, at a flow rate of 20 ml/min,
120 s perfusion duration, followed by 20 s washout.

physical injury from the exposure to the high perfusate flow rate (Figure 4.6A). A
capillary in the mid-CA1 region of the hippocampus is shown in Figure 4.6B. The
pyramidal cells appeared unaffected by in situ perfusion. In the posterior pituitary,
capillaries were not affected by the high perfusate flow rate (Figure 4.6C). At the
ultrastructural level, the endothelial lining of the choroid plexus appeared intact (Figure
4.7A). The adjacent ependymal cell layer was lined by tightly adhering cells with well
developed surface microvilli creating frond-like processes projecting into the ventricles.
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Figure 4.6. The capillaries in the choroid plexus (A), hippocampus (mid-CA1 region) (B) and pituitary (C) were not affected by the
high perfusate flow rate. Rats perfused with 100 µg ceria ENM/ml, at a flow rate of 20 ml/min, and perfusion duration of 120 s.
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Figure 4.7. A capillary with intact endothelial lining in the choroid plexus containing two ceria ENM agglomerates (arrows) (A). A
vessel in the hippocampus (B) and a vessel from the pituitary gland (C) associated with fine ceria ENM (arrows). Rats perfused
with 100 µg ceria ENM/ml, at a flow rate of 20 ml/min, and perfusion duration of 120 s.

Consistent with the high ceria concentration in the choroid plexus, electron dense ceria
ENM agglomerations were observed on the endothelial lining (Figure 4.7A). Meanwhile,
electron dense nonagglomerated ceria ENM particles adhered to the endothelial lining in
the hippocampal vessels (Figure 4.7B) and the pituitary gland vessels that lack a BBB
(Figure 4.7C). Ceria ENM associated with the surface of brain capillary endothelial cells.
No ceria ENM was observed in any brain tissue, consistent with our capillary depletion
results. The ultrastructural data lend support to the calculation that 2.4 ± 0.4 % of the
luminal surface area of the capillary endothelial cells would be occupied by the 4.2 ± 0.7
µg ceria ENM per hemisphere measured in our uptake study.

4.4. Discussion
The results demonstrate that this ceria ENM did not influence BBB integrity. Perfusate
flow rate and ceria ENM concentration did not influence ceria ENM uptake to brain
parenchyma, providing evidence for a non-diffusion mechanism. The uptake space of the
5 nm ceria ENM did increase compared to the vascular space, leading to the conclusion
that the 5 nm ceria ENM either associated with capillary endothelial cells or entered the
brain. The capillary depletion method showed that most of the ceria ENM associated with
the capillary cells. Association of the ceria with the brain endothelial cells was a very
rapid process that saturated between 20 and 60 s using a flow rate of 20 ml/min and ceria
ENM concentration of 30 µl/ml. Electron microscopy revealed the ceria ENM was
associated with the capillary luminal wall and was not seen inside the brain capillary
endothelial cells.
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Prior to the present studies how metal or metal oxide ENMs interact with or cross the
brain capillary endothelial cells was poorly understood. One of the issues relevant to
how nanomaterials interact with biological membranes is that “what the cell sees” may
not be the same as the ENM introduced into the study preparation (e.g., cells in culture,
intact mammal in this study). Several researchers showed that ENMs agglomerate in cell
culture media (22, 182). In blood, plasma proteins rapidly adsorb to nanoparticle
surfaces, to form a protein corona which can change the physicochemical properties and
influence the fate of ENMs (232, 254, 255). It is hard to interpret some in vitro and in
vivo nanoparticle studies because of their agglomeration in cell culture media and
development of the protein corona in blood. In our studies, we used a technique that does
not allow the nanoparticles to mix with blood. We determined the size distribution and
stability of our ceria ENM in the perfusate from 1 to 230 min. The results did not show
agglomeration, which was supported by EM images that did not show significant ceria
ENM agglomeration in rat brain. This is the first report of ceria ENM interaction with
the BBB in vivo under conditions that control ENM chemistry. This research helps us to
understand citrate-coated 5 nm ceria brain capillary cell association, potential brain entry
and redistribution. The in situ brain perfusion technique is a good experimental method to
investigate how the different physicochemical properties of ENMs interact with or cross
the BBB in the absence of major agglomeration and a protein corona. The research will
help us understand how certain physicochemical properties influence the ability of ENMs
to associate with or cross the BBB for therapeutic application.
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Our results showed that most of the ceria ENMs are associated with brain capillary cells
rather than brain cells. Several studies showed that metal and metal oxide ENMs cross
the BBB (7, 31, 256). However, without separating brain capillary cells from brain cells,
it is very possible that the ENMs in those studies were associated with endothelial cells
rather than entering brain parenchyma. For example, based on ICP-MS results of brain
metal content, bovine serum albumin-coated silver ENM was in the brain, compared with
control. Signs of silver-induced brain damage were observed. However, EM did not
reveal silver ENMs in the brain (257). It is possible that the silver ENMs associated with
the BBB and released silver ions to produce the toxicity rather than being an effect of
silver ENMs. A previous study using the in situ brain perfusion method reported that
polymer-based nanoparticles entered the central nervous system within 60 s without
influencing BBB integrity. However, the researchers did not separate the capillary cells
from the brain parenchyma. They showed an uptake space similar to results we obtained
at 20 and 60 s. Capillary association may also contribute to their brain uptake space
(258). Our previous studies showed only 0.02% of a 5 nm ceria dose in the brain 1 h after
iv infusion. However we didn’t observe any 5 nm ceria ENM in brain tissue (8). In light
of the results in this paper, the 0.02% ceria in the brain may be ceria ENM in blood and
associated with capillary cells. In this study, brain association (0.386% of the ceria ENM
dose) using in situ perfusion is 19 times higher than our previous report (0.02% of the
ceria dose) 1 h after iv infusion. The different timelines (in the prior study brain samples
were obtained 1 h after completion of a ceria infusion; in the present immediately after
completion of ceria perfusion) and routes (intravenous vs. intra-carotid artery) may
contribute to the ceria ENM brain capillary association differences. In the present studies
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using in situ brain perfusion ceria ENM did not mix with blood and avoided first pass
clearance. After intravenous administration ceria ENM agglomerated in the blood and
protein corona formation changed its physicochemical properties, resulting in rapid
clearance by the mononuclear phagocyte system (181, 259) . Ceria ENM may associate
with brain capillary cells at 120 s perfusion and dissociate over time. The above reasons
may explain the high brain capillary ceria ENM association compared with our previous
iv infusion study.

Our EM results showed that most of the ceria ENM is on the luminal surface of brain
capillary cells rather than inside these cells. Brain capillary cell association with this
negatively charged ceria ENM is in agreement with a previous kinetic study that reported
a negatively charged nanoparticle associated with the cell surface within seconds by
Langmuir adsorption through electrostatic interaction (260). After surface adsorption, the
next step may be dissociation and redistribution or cell internalization. The time course of
cell internalization of metal oxide nanoparticles is still under investigation. Anionic iron
oxide ENMs attached onto the cell membrane of Hela cells immediately after ENM
introduction to the cells. Early endocytic coated vesicles were observed at 10 min (260).
Most of the literature we are aware of showed cell line- and material-dependent ENM
internalization half lives more than a few min in vitro and in vivo (151, 260-263).
Fourteen, 50 and 74 nm gold nanoparticles had uptake half lives more than 1 h in three
different cancer cells (151). Flux of cationic arginine-vasopressin nanoparticles across the
BBB started at 15 min though absorptive-mediated endocytosis in mice (262). Because
of the nature of the in situ perfusion technique, perfusion duration in the present study

90

was not greater than 120s (252). More research will need to be done to understand what
happens after the ceria ENMs interact with brain capillary cells. However, no matter what
does happen, it is very important to know the rate and extent of cell surface adsorption;
because it is the initial step for ENM cell uptake and potential redistribution back into
blood.

In this study, capillary depletion results showed ceria ENM associated with brain
endothelial cells. Electron microscopy failed to find any 5 nm ceria in brain tissue,
however, nonagglomerated ceria ENM was observed to associate with the luminal wall of
brain capillary endothelial cells. Assuming all of the ceria associated with the capillary
surface without any agglomeration and based on the mass of ceria ENM we observed in
rat brain after arterial ceria ENM perfusion, our calculation showed that 2.4 ± 0.4 % of
the brain capillary surface area might be covered by the ceria ENM. We think that the 4.2
± 0.7 µg of ceria ENM per brain hemisphere seen in the present study might contribute to
ceria ENM redistribution or sustained release back to blood. Ceria ENM dissociation
from the brain capillary lumina over time may provide an explanation for findings in our
pharmacokinetic study where the circulating blood level of two sizes of ceria ENMs
increased from 2-4 hours after completion of their iv infusion, which cannot be explained
using conventional pharmacokinetics (259). A similar increase of ENM in blood within
the first 2 h after its intravenous administration has been reported for quantum dots,
however explanation of the increase was not discussed in these reports (230, 231). ENMs
that associate with, and subsequently disassociate from, the vascular wall might provide
an explanation. Another study showed that 100-200 nm ceria ENMs (primary size 3-5
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nm) were observed on the luminal surface of mice tail vein 30 days post intravenous
injection (223). It is not known if these agglomerated ceria nanoparticles were from
original association with the blood vessel or from redistribution over time. In general,
our results showed that ENMs can associate with capillary cells which may contribute to
nanoparticle redistribution back into the blood.

This is the first report that a ceria ENM has a higher concentration in the choroid plexus
compared with brain regions. Our vascular space results measured by Gd-DTPA showed
that the choroid plexus has a larger vascular space than brain tissues. The choroid plexus
showed a significantly higher uptake space compared with brain regions in the 100 and
500 µg/ml concentration groups rather than 30 µg/ml group. The uptake space of choroid
plexus did not change between 100 and 500 µg/ml concentration groups. Little is known
about how metal oxide nanoparticles interact with the choroid plexus. The choroid plexus
has larger surface area per weight, a leaky epithelial barrier, and different junction
proteins and transport protein expression compared to cerebral endothelium (264, 265).
The fundamental differences between the choroidal epithelium and the cerebral
endothelium may influence the ceria ENM association sites and determine the ceria ENM
saturation concentration. Ceria agglomerates (Figure 4.7) were observed in the choroid
plexus compared to fine primary ceria ENM on the surface of the brain endothelial cells,
providing evidence that ceria ENM may associate with choroid plexus differently than
the BBB, leading to higher concentrations in the choroid plexus.

Previous research

showed that the choroid plexus sequesters metal ions rapidly and that their concentrations
were more than 10 times higher than other brain regions (247, 266). Some polymer
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nanoparticles showed similar results as the present study. Poly (d,l-lactide-co-glycolide)
nanoparticles showed a high concentration in the choroid plexus (158). The choroid
plexus is considered to be a potential region to retain nanoparticles (267) and a pathway
to enter the CNS (158, 268). Our results provide the first evidence that ceria ENMs
interact significantly with the choroid plexus. Our data showed high variability in choroid
plexus. The choroid plexus in rats only weigh 1-2 mg, which might contribute for the
high variability. However, this results provides initial evidence of high ceria ENMs
association with choroid plexus, which is very important for toxicity concerns and
therapeutic application.

4.5. Conclusion
Brain uptake of a 5 nm ceria ENM was flow rate and perfusion concentration
independent, showing diffusion was not mediating its association with brain tissue. The
ceria ENM concentration was significantly higher in the choroid plexus than in 8 brain
regions. Brain ceria ENM association was a very rapid process that reached saturation
between 20 and 60 s. The capillary depletion method showed that the ceria ENM was
predominately associated with the brain capillary cells rather than brain parenchyma.
Furthermore, EM showed most of the ceria ENM associated with the luminal surface of
brain endothelial cells, rather than entering the cells. This research provides the first data
on the kinetics of ceria interaction with the BBB and choroid plexus. Ceria ENM
capillary cell surface association also provides a site from which it can dissociate,
redistribute or enter the capillary cells. This information will be important for design of
ceria ENMs as a therapeutic agent as well as for a comprehensive toxicology assessment.
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4.6. Unsolved problems
13B

This study showed that the brain entry of ceria ENMs is very limited. However, ceria
ENMs can associate with the BBB, which provides the possibility to enter the BBB for
therapeutic applications. Chapters 3 and 4 demonstrated that it is very important to design
biocompatible and stable metal-based ENMs for biomedical applications. Furthermore,
different strategies should be used to increase metal-based ENMs flux across the BBB. In
chapters 5 and 6, we designed CNA-IONPs which have the potential to improve the
biocompatibility and stability of IONPs and enhance IONP flux across using AMFinduced local hyperthermia compared to conventional hyperthermia.

Reproduced with permission from Dan M, Tseng M, Wu P, Unrine JM, Grulke EA,
Yokel RA. Brain microvascular endothelial cell association and distribution of a 5 nm
ceria engineered nanomaterial. International Journal of Nanomedicine, 2012, 7, 40234036. Copyright © 2012 Dan M, Tseng M, Wu P, Unrine JM, Grulke EA, Yokel RA.
Author’s contributions: Dan M did all the animal studies and drafted the published paper.
Tseng M generated the LM and EM images. Wu P and Grulke EA synthesized and
characterized the ceria ENMs. Unrine JM analyzed all the samples using ICP-MS. Yokel
RA revised the manuscript critically.

Copyright © Mo Dan 2013
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Chapter 5 Block copolymer cross-linked nanoassemblies improve particle stability
and biocompatibility of superparamagnetic iron oxide nanoparticles

As I described in 2.5.2, IONPs tend to agglomerate in aqueous solutions unless their
surface is properly modified, resulting in plasma protein binding in vivo and rapid
clearance by the MPS (39). Several studies showed that IONPs, either bare or surfacemodified, could cause cell toxicity and oxidative stress in vitro and in vivo (40-42).
Therefore, it is crucial to improve particle stability and biocompatibility of IONPs in the
biological environment. In this chapter, we hypothesized that CNAs containing carboxyl
groups in the core would simultaneously create, entrap, and protect IONPs as iron ions
(Fe2+ and Fe3+) co-precipitate inside the nanoassembly core, thus suppressing IONP
agglomeration and improve the biocompatibility of IONPs without losing their
superparamagnetic properties. CNA-IONPs would be beneficial for future MRI and
AMF-induced remote hyperthermia applications.

5.1. Introduction
14B

Aggregation of IONPs leads to altered magnetic properties or even complete loss of
magnetism (48). In addition, IONPs are easily oxidized, transforming from magnetite
(Fe3O4) to maghemite (γFe2O3), leading to a broad spectrum of particle size, shape,
stability, and magnetic properties (35, 204). Numerous efforts have been made to
suppress agglomeration and retain the superparamagnetic properties of IONPs for a
prolonged time (269-271). Citric acid is commonly used to stabilize IONPs in aqueous
solutions (43, 45, 272). Although citric acid forms a stable chelate with iron oxide, it is
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not sufficient to prevent agglomeration and precipitation in the presence of multivalent
counter ions (magnesium or calcium) and serum proteins (105-107, 273). Importantly,
these IONP formulations, which change particle stability over time in vivo, could
potentially cause toxic effects in vivo (46, 47).

To solve these problems, we recently developed CNAs from biocompatible PEG-p(Asp)
block copolymers, which provided stable nanoparticles that can entrap charged,
hydrophobic, and amphiphilic payloads without changing particle sizes optimized for
tumor accumulation (< 100 nm) (55-57). We hypothesized that CNAs containing
carboxyl groups in the core would simultaneously create, entrap, and protect IONPs as
iron ions (Fe2+ and Fe3+) co-precipitated inside the nanoassembly core, thus suppressing
IONP agglomeration (Figure 5.1). In this study, we tested our hypothesis and confirmed
that IONPs incorporated into CNAs improve their particle stability and biocompatibility
in aqueous solutions without compromising paramagnetic properties.

Particle stability and biocompatibility were determined with or without 30 min AMF
exposure in water, PBS, and a cell culture medium with 10% FBS at 22, 37, and 43 °C,
respectively. Cytotoxicity of the particles was investigated using a mouse brain
endothelial-derived cell line (bEnd.3). T2-weighted MRI enhancement of CNA-IONPs
was tested in water, PBS and a cell culture medium. AMF-induced heating properties of
1, 2.5 and 5 mg/mL CNA-IONPs were also evaluated in a cell culture medium for future
hyperthermia applications. Conventional citrate-coated IONPs (Citrate-IONPs) were used
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as control. Results of this study provide insight into potential applications of CNAIONPs, integrating MRI diagnosis and thermal therapy.

Figure 5.1. Citrate-coated iron oxide nanoparticles (Citrate-IONPs) and cross-linked
nanoassemblies entrapping IONPs (CNA-IONPs). (A: A chelate is formed between citric
acid and Fe3O4 iron oxide; B: CNA-IONPs entrap Fe3O4 in the core to protect the iron
oxide from agglomeration and protein binding; and C: Fe3O4 IONPs are stabilized in the
cross-linked core of CNAs.)

5.2. Materials and methods
15B

5.2.1. Materials
N,N′-Diisopropylcarbodiimide

(DIC),

N-hydroxysuccinimide

(NHS),

4-

(dimethylamino)pyridine (DMAP), β-benzyl L-aspartate, triphosgene, hexane, benzene,
tetrahydrofuran (THF), dimethyl sulfoxide (DMSO), ferrous chloride tetrahydrate
(FeCl2·4H2O), ferric chloride hexahydrate (FeCl3·6H2O), ammonium hydroxide
(NH4OH), citric acid monohydrate, and ethanol (100%) were purchased from Sigma-
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Aldrich (St. Louis, MO, USA). α-Methoxy-ω-amino poly(ethylene glycol) (PEG, 5 kDa)
was purchased from the NOF Corporation (Tokyo, Japan). Cell culture medium
Dulbecco's Modified Eagle Medium (DMEM), regenerated cellulose dialysis bags with 6
8 kDa molecular weight cut off (MWCO), sodium hydroxide (NaOH), and
hydrochloric acid (HCl) were purchased from Fisher Scientific (USA). FBS was
purchased from Atlanta Biologicals (Lawrenceville, GA, USA) and penicillinstreptomycin (Pen-Strep) was purchased from Invitrogen (Grand Island, NY, USA).

5.2.2. Synthesis of CNAs
CNAs were prepared by cross-linking poly(ethylene glycol)-poly(aspartate) [PEGp(Asp)] block copolymers as previously reported with slight modification (55). Briefly,
β-benzyl-L-aspartate N-carboxy anhydride (BLA-NCA) monomers were prepared by
reacting β-benzyl-L-aspartate with triphosgene (1.3 equivalent) in dry THF at 45 C until
the solution became clear. Anhydrous hexane was added to the BLA-NCA, which was
subsequently recrystallized at -20 C. As shown in Figure 5.2, BLA-NCA monomers were
polymerized using amino-terminated 5kDa PEG as a macroinitiator in DMSO (50
mg/mL) at 45 C under dry nitrogen for 48 h to synthesize PEG-poly(β-benzyl Laspartate) (PEG-PBLA). PEG-PBLA was collected from the reaction solution by
precipitation in diethyl ether and freeze drying from benzene. 1H-NMR (400 MHz,
Varian) spectra from PEG (3.5 ppm) and benzyl groups (7.3 ppm) was used to determine
the block copolymer composition. PEG-PBLA with 40 aspartate repeating units was used
for this study. The benzyl groups of PEG-PBLA were removed by 0.1 N NaOH. The
benzyl alcohol byproducts and excess NaOH were removed through dialysis, followed by
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desalination of the aspartate through the addition of HCl to the dialysis solution to yield
PEG-p(Asp). To prepare CNAs, PEG-p(Asp) was dissolved in DMSO to a final
concentration of 75 mg/mL followed by the addition of DIC, NHS, and DMAP (in a
molar ratio of 4:4:0.2, respectively) to the aspartate units of PEG-p(Asp). A 0.5 molar
equivalent of 1,8-diaminooctane was added to the reaction solution, which was placed at
50 C for 72 h. The CNAs were dialyzed against 100% DMSO, 50% DMSO, and finally
deionized water to remove impurities, followed by freeze drying. CNA purity was
characterized with gel permeation chromatography (GPC, Shimadzu LC20, Japan), which
was equipped with refractive index (RI) and ultraviolet (UV) detectors. PEG standards
were used to establish a calibration curve for molecular weight determination (Mn =
number molecular weight).

5.2.3. Preparation of Citrate-IONPs and CNA-IONPs
Citrate-IONPs were prepared by co-precipitating iron oxides and citric acid in an aqueous
solution as previously reported (186). As shown in Figure 5.2B, ferric chloride
hexahydrate (Fe3+) and ferrous chloride tetrahydrate (Fe2+) were dissolved in deionized
water (Fe3+ Fe2+ = 2:1), followed by adding ammonium hydroxide dropwise under an N2
atmosphere at 85 ºC. Citric acid (2 equivalent) was then added to prepare Citrate-IONPs.
After 1 h, the solution was placed on a magnet to collect black brown particles, which
were washed repeatedly using pure ethanol (274, 275). Citrate-IONPs were dried
overnight in a vacuum drying oven.
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Figure 5.2. Synthesis schemes for empty CNAs (A), Citrate-IONPs (B), and CNAIONPs (C).

CNA-IONPs were prepared similarly by mixing ferric and ferrous salts at a 2:1 molar
ratio with CNAs in deionized water (Figure 5.2C). The total iron ions and the carboxyl
groups of CNAs were adjusted in a molar ratio of 1:2. Ammonium hydroxide was added
to this mixed solution dropwise under nitrogen atmosphere and the reaction was allowed
to proceed at 85 C for 1 h. The solution was centrifuged at 3,000 g for 5 min to remove
precipitates and other water-insoluble impurities. CNA-IONPs in the supernatant were
dialyzed (MWCO 6

8 kDa), filtered (0.22 µm syringe filters), and collected by freeze

drying.
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5.2.4. Particle characterization
The particle size distribution was determined by DLS analysis (90Plus NanoParticle size
distribution analyzer, Brookhaven Instruments, Holtsville, NY, USA). Zeta potential was
measured with Zetasizer Nano ZS (Malvern Instruments, Worcestershire, UK). The
IONP loading content for CNA-IONPs was quantified by thermal gravimetric analysis
(TGA, Perkin-Elmer TGA7 Analyzer, Waltham, MA, USA) and inductively coupled
plasma mass spectrometry (ICP-MS, Agilent 7500cx, Santa Clara, CA, USA). TGA and
ICP-MS determined the amount of iron remaining from CNA-IONPs, following thermal
decomposition (100 ~ 600 ºC) and chemical digestion (HNO3:H2O2 = 2:1) of CNAs,
respectively.

5.2.5. Particle size and stability evaluation in aqueous media
Particle size and stability of Citrate-IONPs and CNA-IONPs (0.1 mg/mL, based on IONP
content) were first observed by dissolving the particles in water, PBS, and DMEM with
10% FBS and 1% Pen-Strep, using 1.5 mL microvials. Aqueous solubility, particle size,
and stability of Citrate-IONPs and CNA-IONPs were further characterized under various
media: in water at 1 mg/mL, 22 °C, for 30 h; in water at 1 mg/mL, 37 °C, for 30 h; in cell
culture medium at 1 mg/mL, 37 °C, for 30 h; and in cell culture medium at 1 mg/mL, 43
°C, for 30 h, as discussed in detail in the Results and Discussion section. DLS was used
to monitor time-dependent changes in particle size of all samples.
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5.2.6. Cytotoxicity assays
A mouse brain endothelial cell line (bEnd.3) was obtained from American Type Culture
Collection (CRL-2299). The cells were cultured in a humidified incubator (37 ºC and 5%
CO2) and used from passages 5 through 10. Cells were seeded on 96 well plates (4,000
cells/well) and incubated with DMEM supplemented with 10% FBS and 1% Pen-Strep
for 24 h. These cells were treated with Citrate-IONPs (0, 0.002, 0.02, 0.05, 0.1, and 0.2
mg/mL) and CNA-IONPs (0, 0.2, 0.5, 1, 5, and 10 mg/mL). Citrate-IONP and CNAIONP concentrations were based on cytotoxicity observed in preliminary experiments.
The cells were incubated with Citrate-IONPs or CNA-IONPs for 0.5, 3, 6, 12 and 30 h,
followed by washing the cells with PBS three times. After additional 24 h incubation in
fresh cell culture media, cell viability was determined using the resazurin dye assay.
Resazurin in PBS was added to the cell-containing wells to a final concentration of 100
µM. Cell plates were incubated for an additional 3 h as non-fluorescent resazurin was
converted to fluorescent resorufin by live cells (276, 277). Resorufin signals were
measured at λex 485 nm and λem530 nm. Cell viability was reported as % of control at the
same time.

5.2.7. Magnetic resonance imaging
Citrate-IONPs and CNA-IONPs were dispersed in water, PBS, and cell culture media
with two-fold serial dilutions ranging from 0.02 to 2.5 mg/mL (based on IONP content).
Citrate-IONP and CNA-IONP solutions (150 µL) were placed in a 96 well plate and
imaged on a 3.0 Tesla MR imager (Siemens Tim Trio, Erlangen, Germany) using a 10 cm
diameter surface coil to enhance the received signal. Multiple, T2-weighted fast spin echo
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images of all samples were acquired with different echo time (TE), to visualize the
dependence of the T2 relaxation time on the particle composition and dispersing media.
From the multi echo T2 images acquired at different echo times, we used a customdeveloped software code to derive T2 on a pixel-by-pixel basis. From these images we
estimated the average T2 within the wells of CNA-IONPs in the three media as a function
of particle concentration.

5.2.8. Evaluation of AMF-induced heating profiles and particle stability after AMF
exposure
The heating profiles of CNA-IONPs were evaluated in cell culture media (1, 2.5, and 5
mg/mL) under AMF induced by a Taylor Winfield induction power supply (TaylorWinfield Technologies MMF-3-135/400-2, Columbus, OH, USA) equipped with a 15
mm diameter, 5 turn solenoid. The AMF field parameters were set to 59.3 kA/m at 300
kHz for 30 minutes. The temperature of the medium was measured every 0.25 seconds
for 30 minutes using a Fluoroptic® thermometer (LumaSense Technologies, Santa Clara,
CA, USA). The initial medium temperature was 37 ºC. The CNA-IONP particle stability
was monitored in cell culture media (1, 2.5, and 5 mg/mL) for 30 h after 30 min AMF
using DLS.

5.2.9. Statistical analysis
One-way ANOVA followed by Tukey’s test was used to test for significant differences
on particle sizes of the samples with 37 and 43 °C incubation temperatures for 30 h (1
mg/mL) or different concentrations (1, 2.5 and 5 mg/mL) for 30 h after 0.5 h AMF
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compared to the particle size of sample at time 0 with 22 °C incubation temperatures (1
mg/mL). Two-way ANOVA followed by Bonferroni multiple comparisons was used to
test for significant differences among different concentration groups and times (GraphPad
Prism Version 3.00 for Windows, GraphPad Software, San Diego, CA). The results of the
statistical analysis for one-way ANOVA and two-way ANOVA will be reported as F(df
effect, df error) = F-value and P-value. Statistical significance was accepted at a level of
p < 0.05. All results are reported as mean ± standard deviation (SD).

Figure 5.3. Gel permeation chromatography (GPC) spectra of CNAs.
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5.3. Results and discussion
5.3.1. Preparation and characterization of Citrate-IONPs and CNA-IONPs
GPC analyses confirmed that CNAs were successfully formed with narrow dispersity
(Figure 5.3). Molecular weight of CNAs was 304,007 Da, indicating that approximately
32 PEG-p(Asp) block copolymer chains formed an individual CNA particle. No free
PEG-p(Asp) block copolymers (Mn = 9,600 Da) were seen after CNA synthesis,
although small molecular weight impurities (Mn = 2,859 Da) were observed. The particle
size of empty CNAs was 36 ± 5 nm. These results were consistent with our previous
observations for other CNAs (55, 56). The solution containing IONPs formed dark brown
precipitates immediately after NH4OH was added in the presence of either citric acid or
empty CNAs. In comparison to Citrate-IONPs, CNA-IONPs remained soluble in aqueous
solutions even after centrifugation. As a result, unreacted iron ions, aggregated IONPs,
and other impurities were readily removed from CNA-IONPs. Subsequent DLS
measurements showed that CNA-IONPs were 25 ± 3 nm, similar to empty CNAs,
indicating that the cross-linked core of CNAs effectively suppressed the growth of IONPs
inside the nanoassemblies, preventing aggregation. Citrate-IONPs were initially 90 ± 10
nm in water at 200 µg/mL, but their particle sizes varied as agglomeration and
precipitation occurred (discussed in detail in Particle stability section). CNA-IONPs
showed 25 ± 3 and 25 ± 1 % (wt%) IONP loading, determined by TGA and ICP-MS
analyses, respectively. Zeta potentials of Citrate-IONPs and CNA-IONPs in PBS at pH
7.4 were -29.5 ± 3.6 and -5.0 ± 0.6 mV, respectively. These results suggested that CNAIONPs effectively protected IONPs inside the carboxyl-rich nanoassembly core, shielding
the electric charge of IONP chelates with CNAs.
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5.3.2. Particle stability
Citrate-IONPs and CNA-IONPs were first dispersed in water, PBS, and cell culture
media at 0.1 mg/mL for solubility testing (Figure 5.4). Citrate-IONPs dispersed partially
in aqueous solutions, but the solutions were turbid (Figure 5.4A), forming precipitates
(Figure 5.4B, blue box). On the other hand, CNA-IONPs were stable in all aqueous
solutions: the letters ‘IO’ can be seen clearly through the brown solution in Figure 5.4A
and no precipitates are seen in Figure 5.4B (red box). Interestingly, Citrate-IONPs
remained at around 400 nm in the serum-containing cell culture medium at 37 ºC for 3 h,
but they ultimately precipitated in water, PBS, and DMEM (Figure 5.5A). It is surmised
that Citrate-IONPs in the cell culture medium might have bound to bovine serum albumin
(BSA) from 10% FBS, forming 400 nm complexes that dispersed in the solution as
previous studies reported that BSA stabilized metal oxide nanoparticles (278-280).
Nevertheless, rapid agglomeration in the cell culture medium to > 400 nm will still likely
limit biomedical applications of Citrate-IONPs. Previous research demonstrated that
IONPs smaller than 50 nm had a longer circulation time in blood than larger IONPs that
were rapidly cleared by the MPS (281).
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Figure 5.4. Citrate-IONPs and CNA-IONPs in aqueous solutions. (A: Turbidity of
sample solutions at 0.1 mg/mL; and B: Enlarged images of the bottom of a 1.5 mL glass
vial showing precipitates of Citrate-IONPs [blue box] but not CNA-IONPs [red box])

CNA-IONPs were stable in water and cell culture media at 22, 37, and 43 °C for 30 h,
and particle size remained unchanged between 25 ~ 29 nm in diameter (Figures 5.5A and
5.5B). There were no significant changes in the particle size of CNA-IONP from 1 to 5
mg/ml (Figure 5.5C). A previous study showed that the magnetic property of IONPs is
size-dependent and that the particle size is linearly correlated with the saturation
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Figure 5.5. Particle stability characterization results. Samples were incubated in DMEM
cell culture media with 10% FBS. (A: Time-dependent changes of particle sizes for
Citrate-IONPs [circles] and CNA-IONPs [squares] incubated at room temperature. The
asterisk (*) indicates that Citrate-IONPs started precipitating; B: Temperature effects on
particle sizes for CNA-IONPs incubated for 30 h (n = 6); and C: Concentration effects on
particle sizes of CNA-IONPs following 30 min AMF (n = 4))

magnetization of IONPs (282). As mentioned above, IONPs below 50 nm can circumvent
the MPS and have a longer circulation time (281). Several researchers demonstrated
plasma proteins rapidly bound to nanoparticle surfaces, forming a protein corona which
can change nanomaterial physicochemical properties and influence their fate in vivo
(232, 254, 283). In this study, the presence of 10% FBS in cell culture medium produced
no significant change in the particle size of CNA-IONPs over 30 h in a biologicallyrelevant medium compared with their size in water. In general, the small particle size that
remained constant for > 30 h is favorable for in vivo applications using CNA-IONPs
because particle size-induced changes in IONPs magnetic properties and biodistribution
will be minimal. Therefore, these results suggested that CNA-IONPs would be stable in
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blood in vivo, which will be beneficial especially for increasing their blood retention
time, and thus potentially improving blood-tumor barrier penetration for diagnosis and
therapy of tumors located away from the body surface such as brain (284).

5.3.3. Cytotoxicity of Citrate-IONPs and CNA-IONPs
Time-dependent cytotoxicity of Citrate-IONPs and CNA-IONPs was tested in a murine
brain endothelial cell line (bEnd.3) as shown in Figure 5.6. Citrate-IONPs caused a
significant decrease in cell viability at concentrations greater than 0.05 mg/mL, and cell
viability dropped rapidly at 0.1 mg/mL after 3 h (Figure 5.6A). This is consistent with
previous reports showing IONPs caused serious cytotoxicity in cells, limiting their
applications as imaging contrast agents (41), and significantly increased reactive oxygen
species (> 0.025 mg/mL) (285). Even FDA-approved MRI contrast agents, such as
Endorem® and Sinerem® (derivatized dextran coated IONPs), are reported to cause cell
growth inhibition over a 24 h period at 0.05 mg/mL (286), similar to the Citrate-IONPs
cytotoxic concentration in this study. Previous studies showed that IONP toxicity in vitro
was highly dependent on size, surface modification, charge, and cell type (287).
However, most IONPs started to show toxicity above 1 mg/mL in vitro despite their size,
surface modification, charge, or the cell type (41). On the contrary, CNA-IONPs caused
no cell death up to 10 mg/mL and 30 h exposure (Figure 5.6B). These results demonstrate
that CNA-IONPs significantly improved biocompatibility of IONPs entrapped inside the
nanoassemblies as opposed to citrate-IONP formulations.
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Figure 5.6. Biocompatibility characterization results. A mouse brain endothelial cell line
(bEnd.3) was incubated with either Citrate-IONPs (A) or CNA-IONPs (B) at different
concentrations and times (n = 4). The asterisks (*) indicate significant differences
(F(4,75) = 150, p < 0.0001) from the three lower concentrations (0.002, 0.02, and 0.05
mg/mL).

5.3.4. MRI of Citrate-IONPs and CNA-IONPs
Citrate-IONPs and CNA-IONPs showed concentration-dependent changes on T2weighted MR images (image darkening) (Figure 5.7). Citrate-IONPs showed contrast
patterns similar to CNA-IONPs in water, but Citrate-IONPs dispersed initially yet
agglomerated gradually in PBS and cell culture media, forming agglomerates on the
bottom of wells when placed in the magnetic field of the MR imager. Images acquired
transverse to the wells showed that Citrate-IONPs precipitated at the bottom of wells
producing zones of intense signal loss on T2 images (side-view images in Figure 5.7).
Citrate-IONPs showed a dark signal on the T2 images above 0.16 mg/mL in water.
Citrate-IONPs were observed to agglomerate faster in cell culture medium than PBS at
the same concentration (data not shown), and showed dark images above 0.63 mg/mL.
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On the contrary, CNA-IONPs were stable in water, PBS and cell culture media (Figure
5.4B, red box), showing concentration-dependent T2-weighted MRI contrast (Figure 5.7).
CNA-IONPs produced dark MR images as low as 0.04 mg/mL in water and 0.02 mg/mL
in cell culture medium. CNA-IONPs evenly distributed in the solution and produced
homogenous MR images. The average T2 within the wells of CNA-IONPs in water, PBS
and cell culture medium as a function of their concentration were estimated from these
images. Plots of relaxation rate (i.e. 1/T2) versus CNA-IONP concentration showed a
linear dependency with correlation coefficients nearly 1 in all three media (data not
shown). From the slope of 1/T2 vs particle concentration curves, we estimated CNAIONP relaxivities to be 70, 63 and 73/s/mM Fe in water, PBS and cell culture medium,
respectively. Previous research showed that IONPs have T2 relaxivities around 30 /s/mM
Fe (1, 39, 52). Contrast efficiency was considerably enhanced by CNA-IONPs compared
with Citrate-IONPs. We tried to estimate relaxivities for the T2* relaxation rates (1/T2*,
s-1) measurements in a similar way. However, the T2* was so low for the samples that the
measurements were not reliable. Nevertheless, the ratio of T2* relaxivity and T2
relaxivity (R2*/R2, mM-1s-1) would be high, indicating the potential of the CNA-IONPs
to strongly influence the contrast on either T2* or T2 weighted MRI. Previous clinical
investigation showed that IONPs with diameters less than 40 nm can accumulate at the
margins of human brain tumors resulting in improvement of their delineation on MRI
(73). Therefore, CNA-IONPs are expected to significantly improve contrast efficiency
and serve as excellent T2 contrast agents in future in vivo applications.
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Figure 5.7. Visual images and T2-weighted MRI of Citrate-IONPs and CNA-IONPs.
Serial dilutions of the samples were prepared on a 96-well plate, containing water, PBS,
and DMEM with 10% FBS. Side view images of transverse plane MRIs show dispersion
and precipitation of the Citrate-IONPs and lack of CNA-IONP precipitation in DMEM
with 10% FBS.

5.3.5. AMF-induced heating profiles and particle stability after AMF exposure
Another exciting application of IONPs is AMF-mediated remote heating hyperthermia.
CNA-IONPs in cell culture media generated heat in response to AMF, increasing the
solution temperature in a concentration-dependent manner (Figure 5.8). The solution
temperature reached equilibrium in 10 min at 40, 41 and 42 °C with 1, 2.5 and 5 mg/mL
CNA-IONPs, respectively. This temperature range is promising because previous results
demonstrated that cancer cells were susceptible to > 40 ºC and IONP-induced local
hyperthermia appeared effective to kill glioma T-9 cells in Fisher F344 rats (288, 289).
CNA-IONPs in cell culture media exposed to AMF for 30 min were subsequently
incubated for 30 h at 37 ºC, yet the AMF caused no adverse changes in particle sizes of
CNA-IONPs (Figure 5.5C). Although no large aggregates were formed, the particle sizes
of CNA-IONPs increased slightly at 2.5 and 5 mg/mL, following 30 minute AMF
exposure and subsequent 30 h at 37 ºC. Such an increase was not shown in 1 mg/mL
CNA-IONPs. We found that the particle sizes were consistent for all 1 mg/mL CNAIONPs incubated at 22, 37, and 43 ºC for 30 h continuously or after 30 min AMF
exposure. These results suggested that the increase in particle sizes of 2.5 and 5 mg/mL
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CNA-IONPs following 30 min AMF exposure might be attributed not to interparticular
aggregates during AMF-induced heat generation but to molecular vibration of IONPs
entrapped in CNAs, causing relaxation and rearrangement of block copolymer segments
in the CNA core. Despite the slight increase in the particle size, CNA-IONPs were
always smaller than 40 nm after 30 h at 37 ºC in cell culture media regardless of AMF
exposure, indicating that IONPs can remain entrapped stably inside CNAs without
compromising AMF-responsive magnetic properties. These results suggested that CNAIONPs would be a promising nanoscale tool to achieve localized hyperthermia in vivo, an
elegant thermal therapy that invokes little damage to critical organs or tissues such as the
central nervous system compared with whole body hyperthermia, which often leads to
potential toxicities to the brain (58), or to develop a multifunctional nanoparticle for
theranostic applications by delivering IONPs in combination with various therapeutic
agents (33, 190).

Figure 5.8. Representative heating profiles of CNA-IONPs in the presence of AMF.
Three concentrations (1, 2.5, and 5 mg/mL) were tested for fine-tuned remote heating
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with 30 minute applications of AMF. Control indicates the initial temperature of cell
culture medium containing no CNA-IONPs (37 ºC).

5.4. Conclusions
16B

CNA-IONPs,

block

copolymer

cross-linked

nanoassemblies

entrapping

superparamagnetic Fe3O4 iron oxide in a cross-linked core, showed controlled particle
size in biological conditions and less toxicity without loss of magnetic properties in
comparison to Citrate-IONPs, conventional iron oxide formulations stabilized with citric
acid. CNA-IONPs did not agglomerate in water, PBS, or cell culture media, maintaining
a clinically-relevant particle size (< 40 nm), suggesting that such stable and small CNAIONPs may achieve preferential accumulation in tumors and reduced macrophage uptake
in vivo. Cytotoxicity of CNA-IONPs was significantly lower than that of Citrate-IONPs,
causing no cell death up to 10 mg/mL using a murine brain endothelial cell line (bEnd.3).
For MRI contrast agent application, CNA-IONPs showed concentration-dependent T2weighted MRIs with correlation coefficients nearly 1 between CNA-IONP concentrations
and T2-weighted MRIs. CNA-IONPs considerably enhanced the T2 relaxivities
compared to Citrate-IONPs. CNA-IONPs retained the magnetic properties of IONPs,
which generated heat at mild hyperthermic temperatures (40 ~ 42 C) in the presence of
AMF. In conclusion, CNA-IONPs significantly improved particle stability and
biocompatibility of IONPs, and thus provide a promising iron oxide nanoparticle
formulation for MRI and AMF-induced remote hyperthermia with low toxicity and high
efficiency.

5.5. Unsolved problems
17B
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In the studies reported in this chapter, we successfully developed stable and
biocompatible CNA-IONPs, which showed their potential for MRI diagnosis and
therapeutic applications in the CNS. For biomedical application in the brain, whether
CNA-IONPs can cross the BBB needs to be determined. Furthermore, mild whole body
hyperthermia can increase BBB permeability, which provide the potential for IONPs to
cross the BBB using AMF-induced hyperthermia (58). Whether the flux of CNA-IONPs
across the BBB can be enhanced by taking advantage of unique properties of IONPs such
as AMF-induced hyperthermia need to be defined. In the next chapter, we will investigate
whether AMF-induced hyperthermia enhance the paracelullar and transcelullar flux of
CNA-IONPs across the BBB.

Reproduced with permission from Dan M, Scott DF, Hardy P, Wydra RA, Yokel RA,
Hilt JZ, Bae Y. Block copolymer cross-linked nanoassemblies improve particle stability
and biocompatibility of superparamagnetic iron oxide nanoparticles. Pharmaceutical
Research 2013, 30(2):552-61. Copyright © 2013 Springer Science+Business Media,
LLC. Author’s contributions: Dan M synthesized and characterized Citrate-IONPs and
CNA-IONPs and tested their stability and toxicity. Dan M and Bae Y drafted the
manuscript. Yokel RA revised the manuscripts critically. Scott DF carried out preparation
and characterization of CNAs and drafted the CNAs method section. Hardy PA carried
out MRI and drafted the method and results section of MRI. Wydra RJ and Hilt JZ
developed Citrate-IONPs synthesis method and supervised the synthesis of CitrateIONPs.
Copyright © Mo Dan 2013
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Chapter 6 Alternating magnetic field enhanced the blood brain barrier association
32B

and paracellular flux of superparamagnetic iron oxide nanoparticles

The hypothesis of this chapter is that AMF-induced hyperthermia would significantly
increase the paracellular and/or transcellular flux of IONPs, and influence the BBB cell
association with IONPs compared with conventional hyperthermia. We investigated the
effect of conventional hyperthermia and AMF-induced hyperthermia on BBB
permeability using two in vitro BBB models, bEnd.3 and Madin-Darby canine kidney
(MDCKII) cells. Results of this study will give us a better understanding how AMFinduced hyperthermia influences IONP association with BBB cells and flux across the
BBB, which will provide important information for the future application of IONP in the
CNS and insight into the difference between conventional hyperthermia and AMFinduced hyperthermia on the BBB permeability and IONPs flux.

6.1 Introduction
18B

The BBB’s tight junctions and drug efflux transporters play a crucial role in safeguarding
the brain from endogenous and exogenous compounds, including most therapeutics
circulating in the blood (28). One of the most promising approaches to overcome limited
drug flux to the CNS is the employment of multifunctional nanoparticles (290). However,
most published studies showed indirect evidence of nanoparticle flux across the BBB into
the brain by monitoring fluorescent and radioactive drugs (146, 147) or therapeutic
efficacy of drugs in animal models of brain tumors (148). A better understanding of
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nanoparticle association with and flux across biological barriers including the highly
regulated BBB is urgently needed.

One type of multifunctional nanoparticle, IONPs, has multiple bionanomedical
applications, such as diagnosis and therapy for the CNS (291). IONPs can be activated by
an AMF to generate controlled local hyperthermia (292). IONPs can also be used as T2
MRI contrast agents for pathologies in the CNS such as brain tumors (34). To achieve
CNS applications, the ability of IONPs to cross the BBB needs to be better understood.
A recent study evaluated the uptake and transport of different surface modified IONPs by
human-derived endothelial cells; no IONP flux across the BBB was observed under
normal conditions (293). However, the influence of AMF-induced local hyperthermia on
BBB permeability and IONP flux across the BBB has not been reported.

Numerous researchers showed mild whole body hyperthermia can increase BBB
permeability, which has potential for brain therapeutic application (58). However, whole
body hyperthermia led to heat stress in vivo and caused toxicity to the CNS such as
edema (58, 60). An IONP nanocarrier system can generate a local hyperthermia to
increase BBB permeability and brain accumulation of IONPs for diagnosis and therapy in
the CNS.

In the previous chapter, we developed CNA-IONPs, which are stable in cell culture
medium with and without AMF for at least 30 h. They produced

no observed

cytotoxicity in bEnd.3 cells when exposed up to 10 mg/mL for 30 h (292). CNA-IONPs
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significantly improved particle stability and biocompatibility of IONPs compared to
citrate-coated IONPs, and thus provide a promising iron oxide nanoparticle formulation
that retain paramagnetic properties for AMF-induced hyperthermia and T2 MRI
enhancement. We used CNA-IONPs as a IONP nanocarrier model to investigate our
hypothesis that AMF-induced hyperthermia would significantly increase the paracellular
and/or transcellular flux of IONPs, and influence the BBB cell association with IONPs
compared with conventional hyperthermia.

In this report the objective of the study was to elucidate the potential and mechanism of
AMF-induced hyperthermia to increase IONP flux across the BBB. We evaluated CNAIONP flux across, and effects on two in vitro BBB models (bEnd.3 and MDCKII cell
lines) at 37 °C, conventional hyperthermia at 43 °C (0.5 h) or AMF-induced
hyperthermia at 41 °C (0.5 h). The paracellular flux changes induced by conventional
hyperthermia at 43 °C up to 4 h were monitored by LY, a paracellular flux maker. Using
TEM, the cellular localization of the iron oxide core of the studied nanoparticles was
investigated. Conventional citrate-IONPs were used as a control.

6.2. Methods
19B

6.2.1. Lucifer yellow flux and transendothelial electrical resistance
To monitor flux through the paracellular pathway, Lucifer yellow (100 µM) (SigmaAldrich, St. Louis, MO), which fluxes across cells via this pathway, was added to the
medium on the donor side of the cells. Samples (100 µL) of the medium from the donor
chamber were collected at time zero and from the receiving chamber at different time
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points for LY concentration analysis. Fluorescence was determined in a SpectraMax M5
Multi-Mode Microplate Reader (Molecular devices, Sunnyvale, CA) at λex\λem = 450/530
nm and compared with a standard of Lucifer yellow in Dulbecco's Modified Eagle
Medium (DMEM, Mediatech, Manassas, VA) or minimum essential medium with
Earle’s salts (MEM, Mediatech, Manassas, VA) depending on cell lines and cell culture
conditions (Appendix B) (294). Transendothelial electrical resistance (TEER) of bEnd.3
or MDCKII Transwell® models was measured every other day using a RMA321Millicell-ERS voltohmmeter (Millipore Corp, Billerica, MA).

6.2.2. Evaluation of AMF-induced heating profiles and particle stability after AMF
exposure
The heating profiles of CNA-IONPs induced by AMF-activation of CNA-IONPs were
evaluated in cell culture media (2.5 mg/mL) in the Transwell® cell model under AMF
induced by a Taylor Winfield induction power supply (Taylor-Winfield Technologies
MMF-3-135/400-2, Columbus, OH) equipped with a 15 mm diameter, 5 turn solenoid.
The AMF field parameters were set to 33.4 kA/m at 300 kHz for 0.5 h. The temperature
of the medium in the Transwell® donor chamber was measured every 0.25 seconds for
0.5 h using a Fluoroptic® thermometer (LumaSense Technologies, Santa Clara, CA). The
initial medium temperature was 37 ºC. CNA-IONP stability was monitored for 30 h after
0.5 h at 37 ºC, 43 ºC and AMF using DLS analysis (90Plus NanoParticle size distribution
analyzer, Brookhaven Instruments, Holtsville, NY).
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6.2.3. Effects of AMF on CNA-IONP and Citrate-IONP cell association and flux
using bEnd.3 and MDCKII in vitro BBB models
Citrate-IONPs (0.05 mg/ml) or CNA-IONPs (2.5 mg/ml) were introduced into the donor
chamber at 37ºC or 43ºC or exposed to AMF for 0.5 h. All were then maintained at 37 ºC
for 30 h. Most clinical research showed conventional hyperthermia between 41 and 45 °C
can induce tumor cell death (190). Conventional hyperthermia at 43 °C was chosen to
compare with AMF-induced hyperthermia. AMF was induced by the Taylor Winfield
induction power supply described above. The AMF field parameters were set to 33.4
kA/m at 300 kHz. Samples (100 µL) were collected from the donor chamber at time 0
and from the receiving chamber at different time points. IONP cell uptake was terminated
by removal of the medium and addition of ice cold solution containing 137 mM NaCl and
10 mM HEPES at PH 7.4 (295). Cells were trypsinized using 0.25% trypsin-EDTA for 5
minutes at 37°C and the suspension centrifuged. The cell pellet was re-suspended with
DMEM. A trypan blue exclusion test was performed to assess cell viability. Protein
concentrations were measured using a bicinchoninic acid assay (BCA Protein Assay Kit,
Thermo Fisher Scientific, Waltham, MA). Iron concentrations in cells and samples were
measured by Ferrozine assay (Appendix B). All experiments were done three or four
times.
6.2.4. Effect of conventional hyperthermia on paracellular flux using a MDCKII in
vitro BBB model
The effect of hyperthermia on the paracellular pathway was tested using a MDCKII in
vitro BBB model. LY (100 µM) was added to the medium on the donor chamber of the
Transwell®. The cells were incubated for 0.5, 1, 2 and 4 h at 43 °C followed by

120

incubation at 37 °C till 6 h. Samples (100 µL) were collected from the donor chamber at
time 0 and from the receiving chamber up to 6 h. Cells were collected as described in the
above section. A trypan blue exclusion test was performed to assess cell viability at the
end of the experiment. LY concentrations were analyzed as described above. All
experiments were performed in triplicate wells and repeated once in triplicate wells.

6.2.5. Citrate-IONP and CNA-IONP cell localization using transmission electron
microscopy
bEnd.3 and MDCKII cells were seeded on 12 well plates (BD Falcon, San Jose,
California) at a density of 200,000 cells/cm2. A cell uptake experiment was performed 3
days after seeding. The cells were exposed to a cell culture medium containing 0.05
mg/mL Citrate-IONPs or 0.05 mg/mL CNA-IONPs for 2 h then quickly washed with ice
cold saline 3 times. The cells were fixed in 3.5% glutaraldehyde in 0.1M cacodylate
buffer, pH 7.4 for 1 h at 4 °C. Samples were dehydrated in ascending concentrations of
ethanol and embedded in Eponate 12. After polymerization, blocks were sectioned at 80
nm for TEM viewing in a Philips Tecnai 12 Biotwin electron microscope (FEI, Hillsboro,
Oregon).

6.2.6. The apparent permeability coefficient
The apparent permeability coefficient (Papp) of LY and CNA-IONPs exposed to 37ºC or
43ºC or AMF for 0.5 h followed by 30 h incubation at 37ºC was calculated using
GraphPad Prism (GraphPad Software, San Diego, CA). The first 6 h flux data were used
with R2 cutoff > 0.8. The Papp in (cm/s) was calculated using the equation: Papp =
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(ΔQ/Δt)/(area*CD) (296). ΔQ/Δt is the linear appearance rate obtained from the profile of
the transported amount of the substrate against time (mg/s). area is the surface area of the
cell monolayer (4.67 cm2 for a 6-well plate). CD is the initial donor concentration of LY
or nanoparticle (mg/mL).

6.2.7. Statistical analysis
Influx rates of LY and CNA-IONPs were calculated by linear regression using GraphPad
Prism. The first 6 h data were used with R2 cutoff > 0.8. Bartlett’s was used to test if
samples have equal variances. One-way ANOVA followed by Tukey’s test was used to
test for significant differences of Citrate-IONP and CNA-IONP cell association among
control, conventional hyperthermia and AMF-induced hyperthermia conditions. One-way
ANOVA followed by Tukey’s test was also used to test for significant differences of
apparent permeability coefficients of LY and CNA-IONP among control, conventional
hyperthermia and AMF-induced hyperthermia conditions. Two-way ANOVA followed
by Bonferroni multiple comparisons was used to test for significant flux differences
among the treatment groups and times using GraphPad Prism. The results of the
statistical analysis for one-way ANOVA and two-way ANOVA will be reported as F(df
effect, df error) = F-value and P-value. All results are reported as mean ± standard
deviation (SD). Statistical significance was accepted at p < 0.05.

6.3. Results
20B

6.3.1. Characterization and stability of Citrate-IONPs and CNA-IONPs
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AMF activation of CNA-IONPs in cell culture medium generated heat. The cell culture
media temperature reached equilibrium in 10 min at 41 °C with 2.5 mg/mL CNA-IONPs
(Figure 6.1A). IONP loading contents in CNAs were 25 ± 3 and 25 ± 1 wt % determined
by thermal gravimetric analysis and inductively coupled plasma mass spectrometry
analyses, respectively. DLS measurements showed that AMF-induced hyperthermia had
no effects on the CNA-IONP size at 30 h (Figure 6.1B). Citrate-IONPs were 90 ± 10 nm
in water at 200 µg/mL, but they agglomerated > 400 nm and precipitated in PBS and cell
culture medium (292). Furthermore, conventional hyperthermia at 43 °C and AMFinduced hyperthermia accelerated the agglomeration of Citrate-IONPs (> 800 nm).

6.3.2. Citrate-IONPs and CNA-IONPs flux and cell association using a bEnd.3 in
vitro BBB model
In order to study the flux of IONPs across the BBB, bEnd.3 cells were grown as a
monolayer on Transwell® inserts (Figure 6.2A). All the flux experiments were studied 710 days after cell seeding on the Transwell® insert, when TEER was > 120 Ω/cm2. The
Papp of Lucifer yellow was 3.81 ± 0.17 X 10-6 cm/s, similar to a previous report (Table
6.1) (297).
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Figure 6.1. Representative heating profiles of CNA-IONPs (2.5 mg/mL) in the
Transwell® cell model for fine-tuned remote heating with 0.5 h applications of AMF.
Control indicates the temperature of cell culture medium containing no CNA-IONPs (37
ºC) (A). Particle stability characterization results using DLS after exposure to 37 °C for
30 h (n = 6), 43 °C (0.5 h) followed by 37 °C for 30 h (n = 6) or AMF (0.5 h) followed by
37 °C for 30 h (n = 4) (B).

Table 6.1. The apical-to-basolateral apparent permeability coefficients of Lucifer yellow
and CNA-IONPs flux using bEnd.3 and MDCKII in vitro BBB models at 37°C for 6 h (n
= 3), 43°C (0.5 h) followed by 37°C (n = 3) for 6 h or AMF (0.5 h) followed by 37°C for
6 h (n = 4).
Papp
bEnd.3

LY X 10-6 (cm/s)

Transwell®

CNA-IONPs (2.5

model

mg/mL) X 10-6 (cm/s)

MDCKII

LY X 10-6 (cm/s)

Transwell®

CNA-IONPs (2.5

model

37 °C

43 °C (0.5 h)

AMF (0.5 h)

3.81 ± 0.17

4.04 ± 0.14

7.25 ± 0.28*

0.67± 0.09

0.67± 0.09

1.66 ± 0.37*

0.49 ± 0.03

0.49 ± 0.049

0.59 ± 0.04*

0.06 ± 0.01

0.056 ± 0.011

0.13 ± 0.02*

-6

mg/mL) X 10 (cm/s)

* Significantly different compared with 37 and 43 °C.
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Citrate-IONPs (0.05 mg/mL) and CNA-IONPs (2.5 mg/mL) were used in the flux study
according to our previous cytotoxicity study (292). The fluxes of Citrate-IONPs did not
increase over 30 h and they were similar in the control group (37 °C for 30 h),
conventional hyperthermia group (43 °C for 0.5 h followed by 37 °C for 30 h) and AMFinduced hyperthermia group (AMF for 0.5 h followed by 37 °C for 30 h) (Figure 6.2B).
However, Citrate-IONP cell association significantly increased in the conventional
hyperthermia and AMF-induced hyperthermia groups compared to control (F(2,6) = 24, P
< 0.0014) (Figure 6.2C). TEM was used to observe Citrate-IONPs localization in cells.
The agglomerated Citrate-IONPs (close to micrometer size) (Figure 6.3A) with their
primary size around 10 nm (Figure 6.3B) were observed inside the bEnd.3 cells.

CNA-IONPs showed very different cell association and flux patterns compared with
Citrate-IONPs. The flux of CNA-IONPs was significantly increased from 1 to 30 h in the
AMF-induced hyperthermia group compared with the control and conventional
hyperthermia groups (Figure 6.2D). The flux of CNA-IONPs was overall higher in the
conventional hyperthermia group then control; however, they were not significantly
different (Figure 6.2E). The Papp of LY and CNA-IONPs were similar in both the control
and conventional hyperthermia groups. However, the Papp of LY (F(2,7) = 280, P <
0.0001) and CNA-IONPs (F(2,7) = 19, P < 0.0016) in the AMF-induced hyperthermia
group significantly increased 90% and 148% respectively compared with control (Table
6.1). Trypan blue exclusion test results showed no observed cell death in any
experiments.

Meanwhile, analysis of iron concentration showed CNA-IONP cell

association or cell uptake increased, but not significantly, in the AMF-induced
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hyperthermia group compared with the control and conventional hyperthermia groups
analyzed by iron concentrations (Figure 6.2F). CNA-IONPs cell association was at least
10 times lower compared with Citrate-IONPs (Figure 6.2F vs. 6.2C; Figure 6.3C vs.
6.3B). Less CNA-IONP cell uptake agreed with our TEM results. After analysis of three
separately prepared TEM samples and two sections from each sample, CNA-IONPs were
found occasionally in three samples (Figure 6.3C).
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Figure 6.2. Citrate-IONP and CNAs-IONP flux across bEnd.3 cells and cell association
results. Schema of the Transwell® system and AMF used for flux studies (A). CitrateIONPs flux across bEnd.3 cells (B) and cell association with bEnd.3 cells (C) at 37°C (n
= 3) for 30 h, conventional hyperthermia at 43°C (0.5 h, n = 3) followed by 37°C for 30
h or AMF-induced hyperthermia (0.5 h, n = 3) followed by 37°C for 30 h. CNAs-IONPs
flux across bEnd.3 cells (D), liner regression of the first 6 h CNAs-IONPs flux data (E)
and bEnd.3 cell association (F) at 37°C (n = 3) for 30 h, conventional hyperthermia at
43°C (0.5 h, n = 3) followed by 37°C for 30 h or AMF-induced hyperthermia (0.5 h, n =
4) followed by 37°C for 30 h. * Significantly different compared to 37 °C in panel C
(F(2,6) = 24, P < 0.0014). * Significantly different compared to 37 °C and conventional
hyperthermia in panel D and E (F(2,48) = 121, P < 0.0001).

The LY results showed that the bEnd.3 BBB model showed high paracellular pathway
flux (Table 6.1), which may mimic a ‘leaky’ BBB such as the blood tumor barrier (BTB).
For this study, it was also crucial to use an in vitro model which can form tight junctions
to predict how AMF-induced hyperthermia increases CNA-IONP flux in vivo since
AMF-induced hyperthermia significantly increased the paracellular flux. After we tested
CNA-IONPs trafficking across the bEnd.3 monolayer, CNA-IONPs flux was investigated
using a ‘tighter’ BBB Transwell® model - MDCKII to gain better understanding how
conventional hyperthermia and AMF-induced hyperthermia influence the paracellular
pathway.

6.3.3. CNA-IONPs flux and cell association using MDCKII in vitro BBB model
MDCKII cells were grown as a monolayer on Transwell® inserts. Three to 4 days after
cell seeding when resistance was > 170 Ω/cm2 flux experiments were conducted. Lucifer
yellow Papp was at 0.49 ± 0.033 X 10-6 cm/s (Table 6.1).
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Figure 6.3. Transmission electron microscopy results of the cellular localization of the Citrate-IONPs (0.05 mg/ml) (A and B) and
CNA-IONPs (0.05 mg/ml) (C) in bEnd.3 cells at 2 h.

LY significantly increased in the AMF-induced hyperthermia group from 2 to 6 h
compared with the control and conventional hyperthermia groups (Figure 6.4A). CNAIONP flux increased in the AMF-induced hyperthermia group (Figure 6.4B). The Papp of
LY (F(2,7) = 7, P < 0.019) and CNA-IONPs (F(2,7) = 27, P < 0.0005) in the AMF group
increased 23% and 123%, respectively compared with control using MDCKII
Transwell® model (Table 6.1). The MDCKII cell uptake or cell association of CNAIONPs was also significantly increased in the AMF-induced hyperthermia group
compared to the control and conventional hyperthermia groups (F(2,7) = 10, P < 0.0081)
(Figure 6.4C). Trypan blue exclusion test results showed no observed cell death in any
experiments. In both MDCKII and bEnd.3 models, AMF-induced hyperthermia
significantly increased LY and CNA-IONP flux across the BBB monolayer but
conventional hyperthermia did not. Numerous studies showed that conventional
hyperthermia can increase BBB permeability, heat magnitude and duration dependently
(60, 298). Our results showed that conventional hyperthermia for 0.5 h did not change the
MDCKII in vitro BBB model permeability. The following study is to test the effect of
different hyperthermia durations on paracellular flux in order to have better
understanding of the differences between AMF-induced hyperthermia and conventional
hyperthermia.

6.3.4. Effect of conventional hyperthermia on paracellular flux using MDCKII in
vitro BBB model
The Papp of LY was 0.46 to 0.5 X 10-6 cm/s for the first 6 h after 0.5, 1, and 2 h exposure
at 43 °C followed by 37 °C for 6 h. However, after incubation at 43 °C for 4 h, the P app of
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LY significantly increased 22% (Papp, 0.61 ± 0.05 X 10-6 cm/s) compared with control
and similar to the Papp of LY in the AMF-induced hyperthermia group (Figure 6.5). The
trypan blue exclusion test results showed no observed cell death in any experiments after
4 h at 43 °C followed by 36 h at 37 °C.

6.4. Discussion
21B

Biocompatibility and stability in biological environments, such as cell culture medium or
blood, are crucial for nanoparticles to serve as good candidates as carriers across the BBB
(281, 291). In this study, we investigated Citrate-IONPs flux across the BBB at normal,
conventional hyperthermia and AMF-induced hyperthermia conditions. Citrate-IONPs
did not show any flux across bEnd.3 cells over 30 h. Citrate-IONPs agglomerated very
rapidly in cell culture medium to > 400 nm (292), which may be too large to cross the
BBB through the paracellular pathway (299). Even through Citrate-IONPs agglomerated
close to micrometer size in vitro, they were still able to be taken up by BBB cells. The
TEM results suggested that Citrate-IONPs were taken up by phagocytosis, consistent
with a previous report that phagocytosis could engulf particles as large as 20 µm (300).
Furthermore, citrate-IONP agglomerations were close to microsize and could not be
measured by DLS after conventional hyperthermia at 43 °C and AMF-induced
hyperthermia for 0.5 h. Citrate-IONPs agglomeration provided one of the explanations
for higher bEnd.3 cell association in the conventional hyperthermia and AMF-induced
hyperthermia groups. However, no transcytosis was observed over 30 h.
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Figure 6.5. The effect of conventional hyperthermia on paracellular flux results. LY flux
across MDCKII in vitro BBB model at 43 °C incubation for 0.5, 1, 2, and 4 h followed
by 37 °C till 6 h
It’s not surprising that Citrate-IONPs agglomerates did not show any flux over time
across the highly regulated BBB in vitro. A high concentration of Citrate-IONPs in BBB
cells related to toxicity, according to our previous research (292), and no transcytosis
suggests they lack potential therapeutic CNS applications.

CNAs improved IONPs stability (size < 40 nm, Figure 6.1B) and biocompatibility
without loss of AMF-induced hyperthermia and MRI T2 enhancement properties (292).
In this study, Citrate-IONPs and CNA-IONPs showed completely different patterns of
bEnd.3 cell association and flux across the BBB in vitro. CNA-IONP flux increased with
time across bEnd.3 cells at 37 °C. However, less than 6 % of CNA-IONPs from the donor
chamber crossed the bEnd.3 monolayer into receiving chambers over 30 h. Previous
research demonstrated that different charged IONP fluxes were also studied using a
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human brain derived BBB model. No IONPs fluxes were observed over 24 h under
normal conditions (293). AMF-induced hyperthermia doubled the Papp of CNA-IONPs in
the bEnd.3 model during the first 6 h. Thirty % of CNA-IONPs crossed the bEnd.3
monolayer at 30 h. The LY flux was also significantly increased which provides evidence
that AMF-induced hyperthermia opened the paracellular pathway to increase CNA-IONP
flux. The lack of observed cell death ruled out increased flux simply due to cell death.
Meanwhile, the cell uptake/association of CNA-IONPs was ~ 10 times lower then
Citrate-IONPs. The low cell uptake of CNA-IONPs was consistent with CNA-IONPs
crossing the BBB mainly through the paracellular pathway after AMF-induced
hyperthermia in the bEnd.3 in vitro BBB model. This is the first study showing that
AMF-induced hypothermia significantly increased CNA-IONPs flux across a BBB model
in vitro with low toxicity. AMF-induced hypothermia by IONPs is one approach to
potentially increase BBB permeability and IONPs flux for diagnosis and therapy in the
CNS.

The bEnd.3 cell as a BBB derived cell line suffers the problem that they (the junctions)
cannot be “tight” enough to fully recapitulate the normal in vivo BBB. Madin-Darby
canine kidney II (MDCKII) cells are known to form tight junctions very well with
paracellular flux <1.5% of the donor dose per hour measured by inulin (301). Therefore,
the non-cerebral cell line MDCKII was used as a surrogate in vitro BBB model (302) to
study nanoparticle flux (303). In the present paper, we used bEnd.3 and MDCKII cell
lines as two common in vitro BBB models to evaluate CNA-IONP uptake, cell effects
and CNA-IONP flux under AMF-induced hyperthermia and conventional hyperthermia
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conditions. After 0.5 h conventional hyperthermia treatment, CNA-IONP flux across the
bEnd.3 monolayer was overall higher, but not significantly, compared with control (37
°C), but no differences was observed using MDCKII cells. The P app of LY in the AMF
groups increased 90% in the bEnd.3 model v.s. 20% in the MDCKII model compared to
the control. AMF-induced hyperthermia increased the Papp of CNA-IONPs 148% in the
bEnd.3 model and 128% in the MDCKII model. In general, a similar trend was observed
with BBB permeability changes by AMF-induced hyperthermia using the two in vitro
BBB models. However, the ‘leaky’ bEnd.3 Transwell® model’s paracellular pathway
flux was more sensitive to conventional hyperthermia and AMF-induced hyperthermia
compared with MDCKII cells. Previous studies also showed a threshold at 43 °C for
BBB disruption induced by conventional hyperthermia in normal brain tissue (298, 304).
However, in a leaky BBB, such as the BTB, which was more sensitive to conventional
hyperthermia, permeability increases at a lower temperature (305). The bEnd.3
Transwell® model can provide insight on the effect of AMF-induced hyperthermia on
leaky BBB conditions such as the BTB. Even though MDCKII cells are not a blood-brain
barrier derived cell line, they were shown to be a good in vitro model to predict the extent
of brain exposure and the rate of brain uptake in vivo for several CNS drug candidates
(306). Comparisons of these two in vitro BBB models, MDCKII cells produce a better in
vitro model to predict whether AMF-induced hyperthermia changes paracellular flux in
normal brain tissue because they form tight junctions very well. Because of the unique
physicochemical properties and different cell association mechanisms of nanoparticles
compared with small drug candidates, further studies were needed to investigate the

135

correlation between nanoparticle flux across the bEnd.3 and MDCKII Transwell®
models and the BBB in vivo.

We also tested whether AMF-induced hyperthermia influences the cell association of
CNA-IONPs using both cell lines. AMF-induced hyperthermia increased CNA-IONPs
cell uptake/association in bEnd.3 cells and significantly increased cell uptake/association
in MDCKII cells. Several studies showed that mild hyperthermia induced by ultrasound
can enhance the intracellular uptake/association of polymeric micelles by increasing the
diffusion of micelles and/or ultrasound-induced perturbation of cell membranes (307,
308). We are not aware of any report on cell uptake/association enhancement by AMFinduced hyperthermia. Furthermore, the Papp of CNA-IONPs increased more than the Papp
of LY suggesting AMF-induced hyperthermia increased transcellular flux. How AMFinduced hyperthermia enhances CNA-IONP cell uptake and transcytosis needs to be
explored. Compared with MDCKII cells, CNA-IONP cell uptake by bEnd.3 cells was
~10 times higher. MDCKII cells have good paracellular permeability characteristics;
however, there are major differences between MDCKII epithelial and brain endothelial
cells, such as expression of different transporters (309). Taken together, different models
might be suitable to address different questions of BBB function. The brain endothelial
cell line bEnd.3 model might be suitable to address IONPs cell uptake and non-brain
derived MDCKII cells provide a good model to test BBB permeability.

The potential application of conventional hyperthermia to increase BBB permeability has
been investigated for decades (58, 60). However, the difference between conventional
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hyperthermia and AMF-induced hyperthermia on the BBB permeability was not studied
before. Our results showed that the Papp of LY and CNA-IONPs significantly increased
79% and 148%, respectively, in the AMF-induced hyperthermia group compared with the
conventional hyperthermia group. There was no significant difference between 37 °C and
43 °C groups, suggesting AMF-activation of CNA-IONPs increased the BBB
permeability not only by simple heating but also other factors such as IONP vibration or
IONP surface temperature vs. surroundings temperature. The temperature we measured
was the environmental temperature in the Transwell® rather than the surface temperature
of IONPs. Previous research showed that IONP surface temperature can be up to 20 °C
higher relative to the surrounding regions (310). The temperature on the surface of cells
may be higher than we measured using the temperature probe. Another possibility is that
CNA-IONPs can bind to the cell surface and vibrate under AMF, mechanically
increasing BBB permeability. Other research demonstrated that cell surface bound IONPs
can mechanically activate certain cell surface receptors (311). However, further research
needs to be done to investigate how CNA-IONPs associate with BBB cells and the role of
temperature and mechanical effects on BBB permeability.

We further tested how different durations of conventional hyperthermia exposure at 43
°C influence paracellular pathway compared with AMF-induced hyperthermia. Our
results showed that conventional hyperthermia (43 °C) did not influence the paracellular
flux up to 2 h and that flux significantly increased at 43 °C after 4 h. A previous whole
body hyperthermia study on rats also showed BBB permeability changes were highly
dependent on heat magnitude and duration. No BBB permeability change was observed
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(within 2 h) under whole body hyperthermia, but BBB permeability was increased after 4
h whole body hyperthermia (60). We did not observe any cell death even after 4 h
conventional hyperthermia at 43 °C. However, whole body hyperthermia leads to heat
stress in vivo causing numerous CNS toxicities such as edema, spontaneous
electroencephalogram and neuronal damage (312). Our results also showed that the Papp
of LY after conventional hyperthermia at 43 °C for 4 h was similar to the P app of LY at
AMF-induced hyperthermia for 0.5 h. AMF-induced hyperthermia can increase BBB
permeability similar to conventional hyperthermia at lower temperature and shorter time
without cell death in vitro. Previous research showed that half an hour AMF-induced
hyperthermia killed head and neck cancer cells in mice without harming any normal cells
(313). However, the toxicity of AMF-induced hyperthermia on the BBB in vivo needs to
be investigated. AMF-induced hyperthermia showed potential advantage to increase BBB
permeability more effectively with low toxicity compared with conventional
hyperthermia, suggesting potential therapeutic application.

6.5. Conclusions
2B

CNA-IONPs showed low flux across the BBB under normal conditions in both b.End3
and MDCKII in vitro BBB models. AMF-induced hyperthermia (0.5 h) enhanced CNAIONPs flux and cell association using both b.End3 and MDCKII BBB models in the
absence of cell death. However, conventional hyperthermia at 43 °C did not increase the
BBB permeability up to 2 h. AMF-induced hyperthermia at 41 °C (0.5 h) enhanced BBB
permeability similar to conventional hyperthermia at 43 °C for 4 h. Altogether these
results suggested that AMF-induced hyperthermia enhanced the BBB association and
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permeability of CNA-IONPs more effectively than conventional hyperthermia. AMFinduced hyperthermia provides an approach to deliver IONPs across the BBB with low
toxicity for potential therapeutic and diagnostic applications in the CNS.

Copyright © Mo Dan 2013
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Chapter 7 Conclusions and future studies
3B

With the rapid surge in the development of metal-based ENMs, it is critical to understand
how ENMs were handled in the biological system and to identify physicochemical
properties most relevant to their biological properties that best predict ENM response.
This information will guide researchers to design and engineer ENMs with desirable
properties to change their behavior in the biological system and avoid undesirable
outcomes. The guiding hypothesis for this dissertation is that the physicochemical
properties of metal-based ENMs change their pharmacokinetics, especially BBB
association and flux. In this dissertation, Chapters 3 and 4 used ceria ENMs as a metalbased ENM model to study their pharmacokinetics in blood and BBB association
properties. Then Chapters 5 and 6 developed an optimized multifunctional IONP for
potential biomedical application in the CNS according to the results from Chapters 3 and
4.

First, we proved our first hypothesis that ceria ENMs demonstrated different
pharmacokinetic profiles compared with the cerium ion. Furthermore, different sizes and
shapes of ceria ENMs showed size-dependent blood concentrations and blood circulation
time supporting our second hypothesis in chapter 3. Five nm ceria ENM showed
significantly higher blood concentration compared with the other 3 sizes ten min after
infusion. The high hydrophilicity of ENMs and small size may have contributed to slower
clearance from the blood (194, 314). Ceria ENMs larger than 5 nm were very rapidly
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cleared from circulating blood. Fifteen and thirty nm ceria ENMs showed different blood
cell association behavior compared with other sizes, which agrees with previous studies
that the critical size of ENMs plays a very important role on cell association and uptake
(83, 149, 150). After ceria ENMs distributed in the blood, our next hypothesis is that
ceria ENMs can associate with and flux across the BBB. The in situ brain perfusion
technique was used to study ceria ENM flux and brain vascular cell associations. This is
the first report of ceria ENM interaction with the BBB in vivo under conditions that
control ENM chemistry. Five nm ceria ENMs associated with the capillary luminal wall
rather than appearing inside the brain parenchyma. This result showed that the flux of
ceria ENMs across the healthy BBB is very limited. A recent published review
summarized the BBB permeability of metal and metal oxide ENMs and the results from
30 different metal-base ENM demonstrated bran entry is very challenging in general
(200). Most of these studies only analyzed the whole brain concentrations of ENMs. The
present study was the first study to specifically demonstrate ceria ENM distribution
between the BBB and brain parenchyma. These results provide important information to
design a ceria ENMs to cross the BBB for their therapeutic applications for
neurodegenerative diseases and their potential toxicity on the BBB cells. Meanwhile,
capillary luminal wall association provides the possibility for redistribution back to blood
which lead to nontraditional pharmacokinetic profiles, as we showed in our
pharmacokinetic study of different size ceria ENMs (259).

Second, we hypothesized that multifunctional CNA-IONPs will have optimized
physicochemical properties to improve the stability and biocompatibility of IONPs
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compared to the results from the citrate-coated ceria ENMs studies. The stability of
CNA-IONPs in cell culture medium was significantly improved with a size around 30 nm
compared with citrate-IONPs. Furthermore, CNAs significantly decreased the toxicity of
IONPs in vitro with enhanced superparamagnetic properties such as MRI T2 contrast and
hyperthermia abilities (196). CNA-IONPs with improved biocompatibility and stability in
biological environments serve as good candidates as carriers to cross the BBB (281, 291).
However, the study in chapter 4 showed that even in the absence of agglomeration, the
flux of metal-based ENMs across healthy BBB was very limited (199). In chapter 6, we
hypothesized that AMF-induced hyperthermia would significantly increase the
paracellular and/or transcellular flux of IONPs, and influence the BBB cell association
with IONPs compared with conventional hyperthermia. Our results showed that AMFinduced hyperthermia significantly increased CNA-IONP flux across the BBB, which
increased the paracellular and transcellular flux without apparent toxicity. AMF-induced
hyperthermia provides the potential to overcome some side effects of conventional
hyperthermia on the BBB. In summary, metal-based ENMs have different
pharmacokinetic behaviors because of their unique physicochemical properties compared
with their constituent metal. The stability and physicochemical properties of metal-based
ENMs are critical for their pharmacokinetics in blood and their biological barrier
association such as the BBB. Even though metal-based ENMs without special surface
modification have limited ability to cross the healthy BBB, researchers are taking
advantage of metal-based ENMs’ unique properties such as hyperthermia to enhance the
BBB flux of IONPs with low toxicity.
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The research presented in this dissertation provides a starting point for future studies. It
has been shown that ENMs are rapidly coated with plasma proteins and other circulating
substances, which create a corona around the ENM (254, 255). The protein coating of
citrate-coated ENMs might change their pharmacokinetics in blood and cell association.
We are not aware of any reports of ceria uptake into blood cells or platelets other than our
prior finding suggesting a small amount of a 30 nm ceria ENM might have entered red
blood cells after 1 h in vitro (7). A systematic research on different size ceria ENMs
association with proteins in the blood and blood cells will provide potential explanations
for their unique pharmacokinetic profiles in the blood. Furthermore, protein association
on the surface of ENMs is a dynamic process. It is crucial to investigate the dynamic
changes of the protein corona to predict the biological response changes of ENMs in vivo.
Because of the unique properties of ENMs, such as protein corona, adhesion and
phagocytic uptake compared with small molecules, new pharmacokinetic models should
be developed such as a PBPK to predict the time-dependent changes of ceria ENM
distribution in tissues and blood (232, 238). After blood distribution, ENM interaction
with biological barriers including cell association/ dissociation, cell uptake, and
transcytosis will determine their fate in biological systems. We observed the 5 nm ceria
associated on the surface of the BBB cells 2 min after infusion. A better understanding of
ENM interaction process with the BBB over time will provide evidence to explain the
nontraditional pharmacokinetic behavior such as concentrations increasing over time
after iv injection. This information will also help us to design optimized ENMs with
desirable biological properties such as the increased BBB association or prolonged
circulation times.
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With this fundamental information on the pharmacokinetics of metal-based ENMs in
hand, we developed a polymer based ENMs loaded with IONPs with improved stability
and biocompatibility in vitro (196). More studies are needed to investigate their
pharmacokinetics such as half-life and clearance in vivo, which are important for passive
targeting for certain organs (315). More importantly, for biomedical applications, it is
critical to test whether they can accumulate at target organs such as tumors, cross
biological barriers such as the BBB and their potential toxicity in vivo. ENMs with
different physicochemical properties cross the BBB through various mechanisms as
discussed in 2.3.3. However, little research has been reported on the paracellular and
transcellular flux of ENMs across the BBB and how the flux can be increased or
decreased by surface modification or unique properties of ENMs. Our results showed that
AMF-induced hyperthermia using IONPs can increase IONPs flux in vitro. However, this
monolayer BBB in vitro model cannot mimic the BBB in vivo. An in vivo study will be
needed to test whether AMF-induced hyperthermia can effectively open the BBB without
causing major toxicity. Our results also showed that AMF-induced hyperthermia
increased the BBB permeability more effectively in a ‘leaky’ BBB in vitro model. Since
the BBB will become leakier because of the brain tumor, the effect of AMF-induced
hyperthermia using IONPs on the blood tumor barrier permeability needs to be
investigated for their potential brain tumor therapeutic or diagnostic applications.

In conclusion, this work yielded valuable information in regards to metal-based ENMs
for brain delivery and ENMs in general. The pharmacokinetic study of ceria ENMs may
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be relevant to most citrate-coated metal-based ENMs and provide evidence that size plays
important role on ENMs’ fate in biological system. This points to the importance of
analyzing metal-based ENMs to identify their unique pharmacokinetics properties, which
determine their potential biomedical applications. It is also possible that ceria ENM
interaction with the BBB may be applied in other metal-based ENMs, which provides
important information for future applications of metal-based ENMs in the CNS. CNAIONPs demonstrated that CNAs have the potential to significantly improve the stability
and biocompatibility of metal-based ENMs, which are very important for any biomedical
applications. Metal-based ENMs are promising because of their unique properties
compared with other ENMs. AMF-induced hyperthermia using CNA-IONPs can increase
the BBB permeability, demonstrating the possibility of other metal-based ENMs
generating heat for this application.

Copyright © Mo Dan 2013
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Appendices
34B

This section contains the following additional information:

Appendix A: Abbreviations
Appendix B: Supplementary Information to chapter 6
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Appendix A Abbreviations
23B

ABC
AMF
BBB
CED
CNAs
CNS
CTAB
DIUF
DLS
EPR
FCC
Gd-DTPA

ICP-MS
ICV
IONPs
LM
EM
LRP1
LY
MCT
MPS
MRI
MRT
NIR
OCT
PEG-p(Asp)
PEPE
P-gp
PSD

ATP-binding cassette
Alternating magnetic field
Blood-brain barrier
Convention-enhanced delivery
Cross-linked nanoassemblies
Central nervous system
Hexadecyltri-methylammonium bromide
Deionized ultra filtered water
Dynamic light scattering

Enhanced permeability and retention
Face-centered cubic
Gadolinium-diethylenetriaminepentaacetic acid

TEER

Inductively coupled plasma mass spectrometry
Intra-cerebro-ventricular
Iron oxide nanoparticles
Light microscopy
Electron microscopy
Low-density lipoprotein receptor-related protein-1
Lucifer yellow
Monocarboxylate transporters
Mononuclear phagocyte system
Magnetic resonance imaging
Mean residence time
Near infra-red
Optical coherence tomography
Poly(ethylene glycol)-poly(aspartate)
Polyether-copolyester
P-glycoprotein
Particle size distribution
Transendothelial electrical resistance

TEM
Tf
TMC
TNF-α
XRD

Transmission electron microscopy
Transferrin
Trimethylated chitosan
Necrosis factor alpha
X–ray diffraction
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Appendix B Supplementary Information to chapter 6
B.6.1. Method
B.6.1.1. Materials
The chemicals used to prepare the Citrate-coated IONPs (Citrate-IONPs) and crosslinked nanoassemblies loaded with superparamagnetic iron oxide nanoparticles (CNAIONPs) have been described (292).

B.6.1.2. Preparation and characterization of Citrate-IONPs and CNA-IONPs
Citrate-IONPs and CNA-IONPs were synthesized using a previously reported method
(55, 186, 292). Briefly, ferric chloride hexahydrate (Fe3+) and ferrous chloride
tetrahydrate (Fe2+) were dissolved in deionized water (Fe3+ Fe2+ = 2:1), followed by
adding ammonium hydroxide dropwise under an N2 atmosphere at 85 ºC. Citric acid (2
equivalent) was then added to prepare Citrate-IONPs. After 1 h, the solution was placed
on a magnet to collect black brown particles, which were washed repeatedly using pure
ethanol (274, 275). Citrate-IONPs were dried overnight in a vacuum drying oven.
CNA-IONPs were prepared similarly by mixing ferric and ferrous salts at a 2:1 molar
ratio with CNAs in deionized water. The total iron ions and the carboxyl groups of CNAs
were adjusted in a molar ratio of 1:2. Ammonium hydroxide was added to this mixed
solution dropwise under nitrogen atmosphere and the reaction was allowed to proceed at
85 C for 1 h. The solution was centrifuged at 3,000 g for 5 min to remove precipitates
and other water-insoluble impurities. CNA-IONPs in the supernatant were filtered (0.22
µm syringe filters), dialyzed (MWCO 6

8 kDa), and collected by freeze drying. The

physico-chemical properties and stability of the Citrate-IONPs and CNA-IONPs were
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determined in our laboratories. All of the methods have been reported in our previous
report (292).

B.6.1.3. Cell lines and culture conditions
The immortalized mouse brain endothelial cell line bEnd.3 (American Type Culture
Collection, Manassas, VA) was cultured in Dulbecco's Modified Eagle Medium (DMEM,
Mediatech, Manassas, VA) with 10% fetal bovine serum (FBS, Atlanta Biologicals,
Lawrenceville, GA), 100 U/ml penicillin, and 100 mg/ml streptomycin (Invitrogen,
Grand Island, NY) at 37ºC in a humidified incubator with 5% CO2 and used from
passages 5 through 10. Madin-Darby canine kidney II (MDCKII) cells (European
Collection of Cell Cultures, Salisbury, UK) were cultured in minimum essential medium
with Earle’s salts (MEM, Mediatech, Manassas, VA) with 5% FBS, 100 U/ml penicillin,
and 100 mg/ml streptomycin at 37 ºC in a humidified incubator with 5% CO 2 and used
from passages 45 through 60.

B.6.1.4. Transwell cultures
bEnd.3 cells were seeded on Transwell® filters (polycarbonate 12 mm, pore size 3.0 µm,
Corning Costar, Lowell, MA) in a density of 200,000 cells/cm2. The flux assays were
performed 7-10 days after seeding (297). MDCKII cells were seeded on Transwell®
filters in a density of 200,000 cells/cm2 and the flux assays were performed 4 days after
seeding (296).
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B.6.1.5. Iron concentration analyzed by Ferrozine assay
A ferrozine assay for iron was carried out to determine the iron content of the
nanoparticle solutions, the cell culture media, the nanoparticle-loaded cells and the
control cells, (316, 317). The cell suspension or nanoparticle solution was diluted to
appropriate concentration. Fifty µL samples were mixed with 50 µL of 1.4 mM HCl and
20 µL ascorbic acid (2M), and then incubated at 70 °C for 1 hour. After the mixtures
cooled to room temperature, 30 µL of the iron detection reagent (6.5 mM ferrozine, 6.5
mM neocuproine, 2.5 M ammonium acetate and 1 M ascorbic acid dissolved in water)
was added to each sample. After 30 min, the solution in each tube was transferred into a
well of a 96 well plate and the absorbance measured at 550 nm on a microplate reader. A
standard curve was also prepared with 0, 0.1, 0.2, 0.5, 1, 2, 5 and 10 μg/mL iron and
treated in the same way.

B.6.1.6. The effect of temperature and CNA-IONPs concentrations on CNA-IONPs
flux using MDCKII Transwell® model
CNA-IONP and LY fluxes were also investigated with two concentrations (0.5 mg/ml
and 2.5 mg/ml CNA-IONP) at 37 and 43 °C (0.5 h). Samples (100 µL) were collected
from the donor chamber at time 0 and from the receiving chamber at 0.5, 0.75, 1, 2, 3, 4,
and 6 h. LY concentrations was analyzed as described in the method section of this report
and iron concentrations were analyzed as described above.
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B.6.2. Results
CNA-IONPs fluxes were studied at 37 °C and 43 °C (0.5 h) with two concentrations (0.5
mg/ml or 2.5 mg/ml). Neither temperature or concentration increased the flux of CNAIONPs and LY over 6 h and the total flux of CNA-IONPs was less than 0.2% of donor
chamber over 6 h (Figure B.6.1A& B.6.1B). The concentration independence of CNAIONP flux across the BBB provided evidence that CNA-IONPs cross the BBB through
non-diffusion mechanism. This very limited IONPs flux across the BBB was consistent
with a previous report. . They did not observe any IONPs flux over 24 h under normal
conditions using a human brain derived BBB model (293).

3

B

Control
37 C 0.5 mg/ml
37 C 2.5 mg/ml
43 C (0.5 h) 0.5 mg/ml
43 C (0.5 h) 2.5 mg/ml

mass amount
in the recieving chamber ( g)

% of donor chamber (LY)

A

2

1

0

2.0
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C (0.5 h) 2.5 mg/ml
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0.5
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4
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Figure B.6.1. LY (A) and CNA-IONP (B) flux across MDCKII transwell® model at two
different concentrations (0.5 and 2.5 mg/mL) and temperatures (37 and 43 °C) (n = 3 in
each group).

Copyright © Mo Dan 2013

151

References
1.

2.

3.

4.
5.

6.

7.

8.

9.

10.

11.

12.

13.

14.

J.M. Hu, Y.F. Qian, X.F. Wang, T. Liu, and S.Y. Liu. Drug-Loaded and
superparamagnetic iron oxide nanoparticle surface-embedded amphiphilic block
copolymer micelles for integrated chemotherapeutic drug delivery and MR
imaging. Langmuir. 28:2073-2082 (2012).
W.L. Jiang, H. Xie, D. Ghoorah, Y.L. Shang, H.J. Shi, F. Liu, X.L. Yang, and
H.B. Xu. Conjugation of Functionalized SPIONs with Transferrin for Targeting
and Imaging Brain Glial Tumors in Rat Model. PLoS One. 7: (2012).
J. Zeng, Q. Zhang, J. Chen, and Y. Xia. A comparison study of the catalytic
properties of Au-based nanocages, nanoboxes, and nanoparticles. Nano Lett.
10:30-35 (2010).
Q. Huo. A perspective on bioconjugated nanoparticles and quantum dots. Colloids
Surf B Biointerfaces. 59:1-10 (2007).
R.A. Sperlingand W.J. Parak. Surface modification, functionalization and
bioconjugation of colloidal inorganic nanoparticles. Philos Transact A Math Phys
Eng Sci. 368:1333-1383 (2010).
G. Sonavane, K. Tomoda, and K. Makino. Biodistribution of colloidal gold
nanoparticles after intravenous administration: Effect of particle size. Colloids
and Surfaces B-Biointerfaces. 66:274-280 (2008).
R.A. Yokel, R.L. Florence, J.M. Unrine, M.T. Tseng, U.M. Graham, P. Wu, E.A.
Grulke, R. Sultana, S.S. Hardas, and D.A. Butterfield. Biodistribution and
oxidative stress effects of a systemically-introduced commercial ceria engineered
nanomaterial. Nanotoxicology. 3:234-248 (2009).
S.S. Hardas, D.A. Butterfield, R. Sultana, M.T. Tseng, M. Dan, R.L. Florence,
J.M. Unrine, U.M. Graham, P. Wu, E.A. Grulke, and R.A. Yokel. Brain
distribution and toxicological evaluation of a systemically delivered engineered
nanoscale ceria. Toxicol Sci. 116:562-576 (2010).
A.S. Karakoti, N.A. Monteiro-Riviere, R. Aggarwal, J.P. Davis, R.J. Narayan,
W.T. Self, J. McGinnis, and S. Seal. Nanoceria as antioxidant: synthesis and
biomedical applications. JOM. 60:33-37 (2008).
R.W. Tarnuzzer, J. Colon, S. Patil, and S. Seal. Vacancy engineered ceria
nanostructures for protection from radiation-induced cellular damage. Nano
Letters. 5:2573-2577 (2005).
J. Niu, A. Azfer, L.M. Rogers, X. Wang, and P.E. Kolattukudy. Cardioprotective
effects of cerium oxide nanoparticles in a transgenic murine model of
cardiomyopathy. Cardiovasc Res. 73:549-559 (2007).
T. Xia, M. Kovochich, M. Liong, L. Madler, B. Gilbert, H. Shi, J.I. Yeh, J.I. Zink,
and A.E. Nel. Comparison of the mechanism of toxicity of zinc oxide and cerium
oxide nanoparticles based on dissolution and oxidative stress properties. ACS
Nano. 2:2121-2134 (2008).
D. Schubert, R. Dargusch, J. Raitano, and S.W. Chan. Cerium and yttrium oxide
nanoparticles are neuroprotective. Biochemical and Biophysical Research
Communications. 342:86-91 (2006).
N. Singh, C.A. Cohen, and B.A. Rzigalinski. Treatment of neurodegenerative
disorders with radical nanomedicine. Ann N Y Acad Sci. 1122:219-230 (2007).
152

15.

16.

17.

18.
19.
20.

21.

22.

23.
24.

25.
26.

27.

28.

29.

B. D'Angelo, S. Santucci, E. Benedetti, S. Di Loreto, R.A. Phani, S. Falone, F.
Amicarelli, M.P. Ceru, and A. Cimini. Cerium oxide nanoparticles trigger
neuronal survival in a human Alzheimer disease model by modulating BDNF
pathway Current Nanoscience. 5:167-176 (2009).
J. Chen, S. Patil, S. Seal, and J.F. McGinnis. Rare earth nanoparticles prevent
retinal degeneration induced by intracellular peroxides. Nat Nanotechnol. 1:142150 (2006).
M. Das, S. Patil, N. Bhargava, J.F. Kang, L.M. Riedel, S. Seal, and J.J. Hickman.
Auto-catalytic ceria nanoparticles offer neuroprotection to adult rat spinal cord
neurons. Biomaterials. 28:1918-1925 (2007).
E. Hodgson. A textbook of Modern Toxicology, John Wiley & Sons. Inc., 2004.
E.J. Park, J. Choi, Y.K. Park, and K. Park. Oxidative stress induced by cerium
oxide nanoparticles in cultured BEAS-2B cells. Toxicology. 245:90-100 (2008).
A. Thill, O. Zeyons, O. Spalla, F. Chauvat, J. Rose, M. Auffan, and A.M. Flank.
Cytotoxicity of CeO2 nanoparticles for Escherichia coli. Physico-chemical insight
of the cytotoxicity mechanism. Environmental Science and Technology. 40:61516156 (2006).
T.J. Brunner, P. Wick, P. Manser, P. Spohn, R.N. Grass, L.K. Limbach, A.
Bruinink, and W.J. Stark. In vitro cytotoxicity of oxide nanoparticles: comparison
to asbestos, silica, and the effect of particle solubility. Environmental Science and
Technology. 40:4374-4381 (2006).
H.J. Eom and J. Choi. Oxidative stress of CeO2 nanoparticles via p38-Nrf-2
signaling pathway in human bronchial epithelial cell, Beas-2B. Toxicology
Letters. 187:77-83 (2009).
W. Lin, Y.W. Huang, X.D. Zhou, and Y. Ma. Toxicity of cerium oxide
nanoparticles in human lung cancer cells. Int J Toxicol. 25:451-457 (2006).
E.-J. Park, W.-S. Cho, J. Jeong, J.-h. Yi, K. Choi, Y. Kim, and K. Park. Induction
of inflammatory responses in mice treated with cerium oxide nanoparticles by
intratracheal instillation. Journal of Health Science. 56:387-396 (2010).
H.E. Institute. Evaluation of human health risk from cerium added to diesel fuel,
Communication 9, Health Effects Institute, Boston, MA, 2001.
S.M. Hirst, A. Karakoti, S. Singh, W. Self, R. Tyler, S. Seal, and C.M. Reilly.
Bio-distribution and in vivo antioxidant effects of cerium oxide nanoparticles in
mice. Environ Toxicol. 28:107-118 (2013).
R.A. Yokel, T.C. Au, R. MacPhail, S.S. Hardas, D.A. Butterfield, R. Sultana, M.
Goodman, M.T. Tseng, M. Dan, H. Haghnazar, J.M. Unrine, U.M. Graham, P.
Wu, and E.A. Grulke. Distribution, elimination, and biopersistence to 90 days of a
systemically introduced 30 nm ceria-engineered nanomaterial in rats. Toxicol Sci.
127:256-268 (2012).
J. Bernacki, A. Dobrowolska, K. Nierwinska, and A. Malecki. Physiology and
pharmacological role of the blood-brain barrier. Pharmacological Reports.
60:600-622 (2008).
E. Barbu, E. Molnar, J. Tsibouklis, and D.C. Gorecki. The potential for
nanoparticle-based drug delivery to the brain: overcoming the blood-brain barrier.
Expert Opin Drug Del. 6:553-565 (2009).

153

30.
31.

32.

33.

34.

35.

36.

37.

38.

39.
40.

41.

42.

43.

J. Kreuter and S. Gelperina. Use of nanoparticles for cerebral cancer. Tumori.
94:271-277 (2008).
L. Chen, R.A. Yokel, B. Hennig, and M. Toborek. Manufactured aluminum oxide
nanoparticles decrease expression of tight junction proteins in brain vasculature.
Journal of Neuroimmune Pharmacology. 3:286-295 (2008).
X. He, H. Zhang, Y. Ma, W. Bai, Z. Zhang, K. Lu, Y. Ding, Y. Zhao, and Z. Chai.
Lung deposition and extrapulmonary translocation of nano-ceria after
intratracheal instillation. Nanotechnology. 21:285103 (2010).
J.S. Weinstein, C.G. Varallyay, E. Dosa, S. Gahramanov, B. Hamilton, W.D.
Rooney, L.L. Muldoon, and E.A. Neuwelt. Superparamagnetic iron oxide
nanoparticles: diagnostic magnetic resonance imaging and potential therapeutic
applications in neurooncology and central nervous system inflammatory
pathologies, a review. J Cerebr Blood F Met. 30:15-35 (2010).
M. Wankhede, A. Bouras, M. Kaluzova, and C.G. Hadjipanayis. Magnetic
nanoparticles: an emerging technology for malignant brain tumor imaging and
therapy. Expert Rev Clin Pharmacol. 5:173-186 (2012).
A.H. Lu, E.L. Salabas, and F. Schuth. Magnetic nanoparticles: synthesis,
protection, functionalization, and application. Angew Chem Int Ed Engl. 46:12221244 (2007).
M. Yanase, M. Shinkai, H. Honda, T. Wakabayashi, J. Yoshida, and T. Kobayashi.
Intracellular hyperthermia for cancer using magnetite cationic liposomes: Ex vivo
study. Japanese Journal of Cancer Research. 88:630-632 (1997).
M. Mahmoudi, S. Sant, B. Wang, S. Laurent, and T. Sen. Superparamagnetic iron
oxide nanoparticles (SPIONs): development, surface modification and
applications in chemotherapy. Adv Drug Deliv Rev. 63:24-46 (2011).
S.A. Meenach, K.W. Anderson, and J.Z. Hilt. Synthesis and characterization of
thermoresponsive poly(ethylene glycol)-based hydrogels and their magnetic
nanocomposites. J Polym Sci Pol Chem. 48:3229-3235 (2010).
A.K. Gupta and M. Gupta. Synthesis and surface engineering of iron oxide
nanoparticles for biomedical applications. Biomaterials. 26:3995-4021 (2005).
B. Novotna, P. Jendelova, M. Kapcalova, P. Rossner, K. Turnovcova, Y.
Bagryantseva, M. Babic, D. Horak, and E. Sykova. Oxidative damage to
biological macromolecules in human bone marrow mesenchymal stromal cells
labeled with various types of iron oxide nanoparticles. Toxicol Lett. 210:53-63
(2012).
M. Mahmoudi, H. Hofmann, B. Rothen-Rutishauser, and A. Petri-Fink. Assessing
the In Vitro and In Vivo Toxicity of Superparamagnetic Iron Oxide Nanoparticles.
Chem Rev (2011).
A. Beduneau, Z. Ma, C.B. Grotepas, A. Kabanov, B.E. Rabinow, N. Gong, R.L.
Mosley, H. Dou, M.D. Boska, and H.E. Gendelman. Facilitated monocytemacrophage uptake and tissue distribution of superparmagnetic iron-oxide
nanoparticles. PLoS One. 4:e4343 (2009).
S.A. Meenach, J.Z. Hilt, and K.W. Anderson. Poly(ethylene glycol)-based
magnetic hydrogel nanocomposites for hyperthermia cancer therapy. Acta
Biomaterialia. 6:1039-1046 (2010).

154

44.

45.

46.

47.

48.
49.

50.

51.

52.

53.

54.

55.

56.

M. Wagner, S. Wagner, J. Schnorr, E. Schellenberger, D. Kivelitz, L. Krug, M.
Dewey, M. Laule, B. Hamm, and M. Taupitz. Coronary MR angiography using
citrate-coated very small superparamagnetic iron oxide particles as blood-pool
contrast agent: initial experience in humans. J Magn Reson Imaging. 34:816-823
(2011).
M. Di Marco, C. Sadun, M. Port, I. Guilbert, P. Couvreur, and C. Dubernet.
Physicochemical characterization of ultrasmall superparamagnetic iron oxide
particles (USPIO) for biomedical application as MRI contrast agents. Int J
Nanomed. 2:609-622 (2007).
M. Safi, J. Courtois, M. Seigneuret, H. Conjeaud, and J.F. Berret. The effects of
aggregation and protein corona on the cellular internalization of iron oxide
nanoparticles. Biomaterials. 32:9353-9363 (2011).
K. Andreas, R. Georgieva, M. Ladwig, S. Mueller, M. Notter, M. Sittinger, and J.
Ringe. Highly efficient magnetic stem cell labeling with citrate-coated
superparamagnetic iron oxide nanoparticles for MRI tracking. Biomaterials
(2012).
D. Farrell, S.A. Majetich, and J.P. Wilcoxon. Preparation and characterization of
monodisperse Fe nanoparticles. J Phys Chem B. 107:11022-11030 (2003).
M. Kumagai, Y. Imai, T. Nakamura, Y. Yamasaki, M. Sekino, S. Ueno, K.
Hanaoka, K. Kikuchi, T. Nagano, E. Kaneko, K. Shimokado, and K. Kataoka.
Iron hydroxide nanoparticles coated with poly(ethylene glycol)-poly(aspartic acid)
block copolymer as novel magnetic resonance contrast agents for in vivo cancer
imaging. Colloid Surface B. 56:174-181 (2007).
D.H. Kim, E.A. Rozhkova, T. Rajh, S.D. Bader, and V. Novosad. Synthesis of
hybrid gold/iron oxide nanoparticles in block copolymer micelles for imaging,
drug delivery, and magnetic hyperthermia. IEEE T Magn. 45:4821-4824 (2009).
L.E. Euliss, S.G. Grancharov, S. O'Brien, T.J. Deming, G.D. Stucky, C.B. Murray,
and G.A. Held. Cooperative assembly of magnetic nanoparticles and block
copolypeptides in aqueous media. Nano Lett. 3:1489-1493 (2003).
J.F. Berret, N. Schonbeck, F. Gazeau, D. El Kharrat, O. Sandre, A. Vacher, and M.
Airiau. Controlled clustering of superparamagnetic nanoparticles using block
copolymers: Design of new contrast agents for magnetic resonance imaging. J Am
Chem Soc. 128:1755-1761 (2006).
B.S. Kim, J.M. Qiu, J.P. Wang, and T.A. Taton. Magnetomicelles: Composite
nanostructures from magnetic nanoparticles and cross-linked amphiphilic block
copolymers. Nano Lett. 5:1987-1991 (2005).
S. Kim, Y.Z. Shi, J.Y. Kim, K. Park, and J.X. Cheng. Overcoming the barriers in
micellar drug delivery: loading efficiency, in vivo stability, and micelle-cell
interaction. Expert Opin Drug Del. 7:49-62 (2010).
H.J. Leeand Y. Bae. Cross-linked nanoassemblies from poly(ethylene glycol)poly(aspartate) block copolymers as stable supramolecular templates for
particulate drug delivery. Biomacromolecules. 12:2686-2696 (2011).
D. Scott, J. Rohr, and Y. Bae. Nanoparticulate formulations of mithramycin
analogs for enhanced cytotoxicity. Int J Nanomed. 6:2757-2767 (2011).

155

57.

58.
59.

60.
61.
62.
63.
64.
65.
66.
67.
68.

69.

70.

71.

72.

73.

A. Ponta, S. Akter, and Y. Bae. Degradable cross-linked nanoassemblies as drug
carriers for heat shock protein 90 inhibitor 17-N-allylamino-17demethoxygeldanamycin. Pharmaceuticals. 4:1281-1292 (2011).
E.A. Kiyatkin and H.S. Sharma. Permeability of the blood-brain barrier depends
on brain temperature. Neuroscience. 161:926-939 (2009).
W. Gong, Z. Wang, N. Liu, W. Lin, X. Wang, D. Xu, H. Liu, C. Zeng, X. Xie, X.
Mei, and W. Lu. Improving efficiency of adriamycin crossing blood brain barrier
by combination of thermosensitive liposomes and hyperthermia. Biol Pharm Bull.
34:1058-1064 (2011).
H.S. Sharma and P.J. Hoopes. Hyperthermia induced pathophysiology of the
central nervous system. Int J Hyperthermia. 19:325-354 (2003).
B.B. Youan. Impact of nanoscience and nanotechnology on controlled drug
delivery. Nanomedicine (Lond). 3:401-406 (2008).
V. Wagner, A. Dullaart, A.K. Bock, and A. Zweck. The emerging nanomedicine
landscape. Nat Biotechnol. 24:1211-1217 (2006).
S. Aggarwal. What's fueling the biotech engine-2008. Nature Biotechnology.
27:987-993 (2009).
W.I. Choi, A. Sahu, Y.H. Kim, and G. Tae. Photothermal cancer therapy and
imaging based on gold nanorods. Ann Biomed Eng. 40:534-546 (2012).
B. Perks. The catalytic potential of gold nanoparticles was overlooked for years,
but researchers are making up for lost time, Chemistry World, 2010, pp. 48-50.
F. Michael. Experimental relations of gold (and other metals) to light. Phil Trans
Roy Soc London. 147:145 -181 (1857).
S. Lal, S.E. Clare, and N.J. Halas. Nanoshell-enabled photothermal cancer therapy:
impending clinical impact. Acc Chem Res. 41:1842-1851 (2008).
A.M. Gobin, M.H. Lee, N.J. Halas, W.D. James, R.A. Drezek, and J.L. West.
Near-infrared resonant nanoshells for combined optical imaging and photothermal
cancer therapy. Nano Lett. 7:1929-1934 (2007).
K.V. Katti, R. Kannan, K. Katti, V. Kattumori, R. Pandrapraganda, V. Rahing, C.
Cutler, E.J. Boote, S.W. Casteel, C.J. Smith, J.D. Robertson, and S.S. Jurrison.
Hybrid Gold Nanoparticles in Molecular Imaging and Radiotherapy. Czech J
Phys. 56:D23-D34 (2006).
R. Xu, J. Ma, X. Sun, Z. Chen, X. Jiang, Z. Guo, L. Huang, Y. Li, M. Wang, C.
Wang, J. Liu, X. Fan, J. Gu, X. Chen, Y. Zhang, and N. Gu. Ag nanoparticles
sensitize IR-induced killing of cancer cells. Cell Res. 19:1031-1034 (2009).
L.K. Limbach, Y. Li, R.N. Grass, T.J. Brunner, M.A. Hintermann, M. Muller, D.
Gunther, and W.J. Stark. Oxide nanoparticle uptake in human lung fibroblasts:
effects of particle size, agglomeration, and diffusion at low concentrations.
Environmental Science and Technology. 39:9370-9376 (2005).
S. Linkand M.A. El-Sayed. Spectral properties and relaxation dynamics of surface
plasmon electronic oscillations in gold and silver nanodots and nanorods. J Phys
Chem B. 103:8410-8426 (1999).
H.C. Huang, S. Barua, G. Sharma, S.K. Dey, and K. Rege. Inorganic
nanoparticles for cancer imaging and therapy. J Control Release. 155:344-357
(2011).

156

74.

75.

76.

77.

78.

79.

80.
81.

82.
83.

84.

85.

86.

87.

88.

J. You, G. Zhang, and C. Li. Exceptionally high payload of doxorubicin in hollow
gold nanospheres for near-infrared light-triggered drug release. ACS Nano.
4:1033-1041 (2010).
J.H. Park, G. von Maltzahn, L.L. Ong, A. Centrone, T.A. Hatton, E. Ruoslahti,
S.N. Bhatia, and M.J. Sailor. Cooperative nanoparticles for tumor detection and
photothermally triggered drug delivery. Adv Mater. 22:880-885 (2010).
R.K. Visaria, R.J. Griffin, B.W. Williams, E.S. Ebbini, G.F. Paciotti, C.W. Song,
and J.C. Bischof. Enhancement of tumor thermal therapy using gold nanoparticleassisted tumor necrosis factor-alpha delivery. Mol Cancer Ther. 5:1014-1020
(2006).
M. Mikhaylova, Y.S. Jo, D.K. Kim, N. Bobrysheva, Y. Andersson, T. Eriksson,
M. Osmolowsky, V. Semenov, and M. Muhammed. The effect of biocompatible
coating layers on magnetic properties of superparamagnetic iron oxide
nanoparticles. Hyperfine Interact. 156:257-263 (2004).
A.E. Nel, L. Madler, D. Velegol, T. Xia, E.M.V. Hoek, P. Somasundaran, F.
Klaessig, V. Castranova, and M. Thompson. Understanding biophysicochemical
interactions at the nano-bio interface. Nat Mater. 8:543-557 (2009).
A. Elder, S. Vidyasagar, and L. DeLouise. Physicochemical factors that affect
metal and metal oxide nanoparticle passage across epithelial barriers. Wiley
Interdiscip Rev Nanomed Nanobiotechnol. 1:434-450 (2009).
NIOSH. Strategic Plan for NIOSH Nanotechnology Research and Guidance, 2009.
P. Decuzzi, R. Pasqualini, W. Arap, and M. Ferrari. Intravascular Delivery of
Particulate Systems: Does Geometry Really Matter? Pharm Res-Dord. 26:235243 (2009).
S.M. Moghimi, A.C. Hunter, and J.C. Murray. Long-circulating and targetspecific nanoparticles: Theory to practice. Pharmacol Rev. 53:283-318 (2001).
P. Decuzzi, S. Lee, B. Bhushan, and M. Ferrari. A theoretical model for the
margination of particles within blood vessels. Annals of Biomedical Engineering.
33:179-190 (2005).
P. Decuzzi, B. Godin, T. Tanaka, S.Y. Lee, C. Chiappini, X. Liu, and M. Ferrari.
Size and shape effects in the biodistribution of intravascularly injected particles.
Journal of Controlled Release. 141:320-327 (2010).
M. Lundqvist, J. Stigler, G. Elia, I. Lynch, T. Cedervall, and K.A. Dawson.
Nanoparticle size and surface properties determine the protein corona with
possible implications for biological impacts. P Natl Acad Sci USA. 105:1426514270 (2008).
M.P. Monopoli, D. Walczyk, A. Campbell, G. Elia, I. Lynch, F.B. Bombelli, and
K.A. Dawson. Physical-Chemical Aspects of Protein Corona: Relevance to in
Vitro and in Vivo Biological Impacts of Nanoparticles. Journal of the American
Chemical Society. 133:2525-2534 (2011).
P.P. Karmali and D. Simberg. Interactions of nanoparticles with plasma proteins:
implication on clearance and toxicity of drug delivery systems. Expert Opin Drug
Del. 8:343-357 (2011).
I. Hamad, O. Al-Hanbali, A.C. Hunter, K.J. Rutt, T.L. Andresen, and S.M.
Moghimi. Distinct Polymer Architecture Mediates Switching of Complement

157

89.
90.

91.

92.
93.

94.

95.

96.

97.

98.

99.
100.

101.

102.

103.

Activation Pathways at the Nanosphere-Serum Interface: Implications for Stealth
Nanoparticle Engineering. ACS Nano. 4:6629-6638 (2010).
V.P. Torchilin. Passive and active drug targeting: drug delivery to tumors as an
example. Handb Exp Pharmacol:3-53 (2010).
F. Braet, R. Dezanger, M. Baekeland, E. Crabbe, P. Vandersmissen, and E. Wisse.
Structure and Dynamics of the Fenestrae-Associated Cytoskeleton of Rat-Liver
Sinusoidal Endothelial-Cells. Hepatology. 21:180-189 (1995).
S.M. Moghimi, C.J. Porter, I.S. Muir, L. Illum, and S.S. Davis. Non-phagocytic
uptake of intravenously injected microspheres in rat spleen: influence of particle
size and hydrophilic coating. Biochem Biophys Res Commun. 177:861-866
(1991).
S.M. Moghimi, A.C. Hunter, and J.C. Murray. Nanomedicine: current status and
future prospects. Faseb Journal. 19:311-330 (2005).
S.K. Hobbs, W.L. Monsky, F. Yuan, W.G. Roberts, L. Griffith, V.P. Torchilin,
and R.K. Jain. Regulation of transport pathways in tumor vessels: Role of tumor
type and microenvironment. P Natl Acad Sci USA. 95:4607-4612 (1998).
D.C. Drummond, O. Meyer, K. Hong, D.B. Kirpotin, and D. Papahadjopoulos.
Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors.
Pharmacol Rev. 51:691-743 (1999).
T. Lammers, V. Subr, K. Ulbrich, P. Peschke, P.E. Huber, W.E. Hennink, and G.
Storm. Simultaneous delivery of doxorubicin and gemcitabine to tumors in vivo
using prototypic polymeric drug carriers. Biomaterials. 30:3466-3475 (2009).
R. Weissleder, J.F. Heautot, B.K. Schaffer, N. Nossiff, M.I. Papisov, A.
Bogdanov, Jr., and T.J. Brady. MR lymphography: study of a high-efficiency
lymphotrophic agent. Radiology. 191:225-230 (1994).
S.M. Moghimi and B. Bonnemain. Subcutaneous and intravenous delivery of
diagnostic agents to the lymphatic system: applications in lymphoscintigraphy
and indirect lymphography. Adv Drug Deliv Rev. 37:295-312 (1999).
H.S. Choi, W. Liu, P. Misra, E. Tanaka, J.P. Zimmer, B. Itty Ipe, M.G. Bawendi,
and J.V. Frangioni. Renal clearance of quantum dots. Nat Biotechnol. 25:11651170 (2007).
T.M. Riddick. Control of colloidal stability through zeta potential. Vol. 1,
Livingston Publishing Co., Wynnewood, PA, 1968, pp. 320-331.
U. Gaur, S.K. Sahoo, T.K. De, P.C. Ghosh, A. Maitra, and P.K. Ghosh.
Biodistribution of fluoresceinated dextran using novel nanoparticles evading
reticuloendothelial system. Int J Pharm. 202:1-10 (2000).
T. Niidome, M. Yamagata, Y. Okamoto, Y. Akiyama, H. Takahashi, T. Kawano,
Y. Katayama, and Y. Niidome. PEG-modified gold nanorods with a stealth
character for in vivo applications. Journal of Controlled Release. 114:343-347
(2006).
T. Cao, T. Yang, Y. Gao, Y. Yang, H. Hu, and F. Li. Water-soluble NaYF4:Yb/Er
upconversion nanophosphors: Synthesis, characteristics and application in
bioimaging. Inorganic Chemistry Communications. 13:392-394 (2010).
G. Frasca, F. Gazeau, and C. Wilhelm. Formation of a three-dimensional
multicellular assembly using magnetic patterning. Langmuir. 25:2348-2354
(2009).
158

104.

105.

106.

107.

108.

109.

110.

111.
112.

113.
114.
115.
116.

117.
118.
119.

B. Chanteau, J. Fresnais, and J.F. Berret. Electrosteric enhanced stability of
functional sub-10 nm cerium and iron oxide particles in cell culture medium.
Langmuir. 25:9064-9070 (2009).
G. Goloverda, B. Jackson, C. Kidd, and V. Kolesnichenko. Synthesis of
ultrasmall magnetic iron oxide nanoparticles and study of their colloid and surface
chemistry. J Magn Magn Mater. 321:1372-1376 (2009).
Y. Park, R.D. Whitaker, R.J. Nap, J.L. Paulsen, V. Mathiyazhagan, L.H. Doerrer,
Y.Q. Song, M.D. Hurlimann, I. Szleifer, and J.Y. Wong. Stability of
Superparamagnetic Iron Oxide Nanoparticles at Different pH Values:
Experimental and Theoretical Analysis. Langmuir. 28:6246-6255 (2012).
M. Hatakeyama, H. Kishi, Y. Kita, K. Imai, K. Nishio, S. Karasawa, Y. Masaike,
S. Sakamoto, A. Sandhu, A. Tanimoto, T. Gomi, E. Kohda, M. Abe, and H.
Handa. A two-step ligand exchange reaction generates highly water-dispersed
magnetic nanoparticles for biomedical applications. J Mater Chem. 21:5959-5966
(2011).
A.H. Lu, E.L. Salabas, and F. Schuth. Magnetic nanoparticles: synthesis,
protection, functionalization, and application. Angew Chem Int Ed. 46:1222-1244
(2007).
H. Wolburg and A. Lippoldt. Tight junctions of the blood-brain barrier:
development, composition and regulation. Vascular Pharmacology. 38:323-337
(2002).
I.A. Simpson, A. Carruthers, and S.J. Vannucci. Supply and demand in cerebral
energy metabolism: the role of nutrient transporters. Journal of Cerebral Blood
Flow and Metabolism. 27:1766-1791 (2007).
U. Bickel, T. Yoshikawa, and W.M. Pardridge. Delivery of peptides and proteins
through the blood-brain barrier. Adv Drug Deliver Rev. 46:247-279 (2001).
R.A. Yokel. Blood-brain barrier flux of aluminum, manganese, iron and other
metals suspected to contribute to metal-induced neurodegeneration. Journal of
Alzheimer's Disease. 10:223-253 (2006).
S. Rapoport. Sites and functions of the blood-brain barrier., In Blood-brain barrier
in physiology and medicine, Raven Press, New York, 1976, pp. 43-84.
W. Pardridge. Introduction to the Blood-Brain Barrier: Methodology, Biology and
Pathology, Cambridge University Press, 1998.
B.V. Zlokovic. The Blood-Brain Barrier in Health and Chronic
Neurodegenerative Disorders. Neuron. 57:178-201 (2008).
D.M. Hermann and C.L. Bassetti. Implications of ATP-binding cassette
transporters for brain pharmacotherapies. Trends in Pharmacological Sciences.
28:128-134 (2007).
R. Gabathuler. Approaches to transport therapeutic drugs across the blood-brain
barrier to treat brain diseases. Neurobiology of Disease. 37:48-57 (2010).
W. Pardridge. Drug Targeting to the Brain. Pharm Res-Dord. 24:1733-1744
(2007).
W.A. Vandergrift, S.J. Patel, J.S. Nicholas, and A.K. Varma. Convectionenhanced delivery of immunotoxins and radioisotopes for treatment of malignant
gliomas. Neurosurg Focus. 20:E13 (2006).

159

120.

121.

122.

123.

124.

125.
126.
127.

128.

129.
130.

131.

132.

133.

134.

L.K. Fung, M.G. Ewend, A. Sills, E.P. Sipos, R. Thompson, M. Watts, O.M.
Colvin, H. Brem, and W.M. Saltzman. Pharmacokinetics of interstitial delivery of
carmustine, 4-hydroperoxycyclophosphamide, and paclitaxel from a
biodegradable polymer implant in the monkey brain. Cancer Res. 58:672-684
(1998).
D. Fortin, C. Gendron, M. Boudrias, and M.P. Garant. Enhanced chemotherapy
delivery by intraarterial infusion and blood-brain barrier disruption in the
treatment of cerebral metastasis. Cancer. 109:751-760 (2007).
C.A. Lipinski, F. Lombardo, B.W. Dominy, and P.J. Feeney. Experimental and
computational approaches to estimate solubility and permeability in drug
discovery and development settings. Adv Drug Deliver Rev. 64:4-17 (2012).
C.A. Lipinski, F. Lombardo, B.W. Dominy, and P.J. Feeney. Experimental and
computational approaches to estimate solubility and permeability in drug
discovery and development settings. Adv Drug Deliver Rev. 46:3-26 (2001).
M.O. Bradley, N.L. Webb, F.H. Anthony, P. Devanesan, P.A. Witman, S.
Hemamalini, M.C. Chander, S.D. Baker, L. He, S.B. Horwitz, and C.S. Swindell.
Tumor targeting by covalent conjugation of a natural fatty acid to paclitaxel. Clin
Cancer Res. 7:3229-3238 (2001).
W.M. Pardridge. Transport of Small Molecules through the Blood-Brain-Barrier Biology and Methodology. Adv Drug Deliver Rev. 15:5-36 (1995).
A.R. Jonesand E.V. Shusta. Blood-brain barrier transport of therapeutics via
receptor-mediation. Pharm Res-Dord. 24:1759-1771 (2007).
P. Zhang, L. Hu, Q. Yin, Z. Zhang, L. Feng, and Y. Li. Transferrin-conjugated
polyphosphoester hybrid micelle loading paclitaxel for brain-targeting delivery:
synthesis, preparation and in vivo evaluation. J Control Release. 159:429-434
(2012).
S.U. Shin, P. Friden, M. Moran, T. Olson, Y.S. Kang, W.M. Pardridge, and S.L.
Morrison. Transferrin-antibody fusion proteins are effective in brain targeting.
Proc Natl Acad Sci U S A. 92:2820-2824 (1995).
J. Kreuter. Influence of the surface properties on nanoparticle-mediated transport
of drugs to the brain. J Nanosci Nanotechno. 4:484-488 (2004).
C. Peetlaand V. Labhasetwar. Biophysical characterization of nanoparticleendothelial model cell membrane interactions. Molecular Pharmaceutics. 5:418429 (2008).
R.S. Dhanikula, T. Hammady, and P. Hildgen. On the Mechanism and Dynamics
of Uptake and Permeation of Polyether-Copolyester Dendrimers Across an In
Vitro Blood-Brain Barrier Model. J Pharm Sci-Us. 98:3748-3760 (2009).
J. Chang, Y. Jallouli, M. Kroubi, X.-b. Yuan, W. Feng, C.-s. Kang, P.-y. Pu, and
D. Betbeder. Characterization of endocytosis of transferrin-coated PLGA
nanoparticles by the blood-brain barrier. Int J Pharmaceut. 379:285-292 (2009).
C.C. Visser, S. Stevanovic, L.H. Voorwinden, P.J. Gaillard, D.J.A. Crommelin, M.
Danhof, and A.G. de Boer. Validation of the transferrin receptor for drug
targeting to brain capillary endothelial cells in vitro. Journal of Drug Targeting.
12:145-150 (2004).
J. Kreuter, P. Ramge, V. Petrov, S. Hamm, S.E. Gelperina, B. Engelhardt, R.
Alyautdin, H. von Briesen, and D.J. Begley. Direct evidence that polysorbate-80160

135.

136.

137.
138.
139.
140.
141.
142.
143.
144.
145.

146.

147.

148.

149.

150.

coated poly( butylcyanoacrylate) nanoparticles deliver drugs to the CNS via
specific mechanisms requiring prior binding of drug to the nanoparticles. Pharm
Res-Dord. 20:409-416 (2003).
J.M. Koziara, P.R. Lockman, D.D. Allen, and R.J. Mumper. Paclitaxel
nanoparticles for the potential treatment of brain tumors. Journal of Controlled
Release. 99:259-269 (2004).
I. Tamai, Y. Sai, H. Kobayashi, M. Kamata, T. Wakamiya, and A. Tsuji.
Structure-internalization relationship for adsorptive-mediated endocytosis of basic
peptides at the blood-brain barrier. J Pharmacol Exp Ther. 280:410-415 (1997).
N.J. Abbott, L. Ronnback, and E. Hansson. Astrocyte-endothelial interactions at
the blood-brain barrier. Nat Rev Neurosci. 7:41-53 (2006).
U. Knieseland H. Wolburg. Tight junctions of the blood-brain barrier. Cellular
and Molecular Neurobiology 20:57-76 (2000).
F. Herve, N. Ghinea, and J.M. Scherrmann. CNS delivery via adsorptive
transcytosis. AAPS J. 10:455-472 (2008).
H.L. Wong, X.Y. Wu, and R. Bendayan. Nanotechnological advances for the
delivery of CNS therapeutics. Adv Drug Deliv Rev. 64:686-700 (2012).
L.A. Bareford and P.W. Swaan. Endocytic mechanisms for targeted drug delivery.
Adv Drug Deliver Rev. 59:748-758 (2007).
S.D. Conner and S.L. Schmid. Regulated portals of entry into the cell. Nature.
422:37-44 (2003).
H. Hillaireau and P. Couvreur. Nanocarriers' entry into the cell: relevance to drug
delivery. Cellular and Molecular Life Sciences. 66:2873-2896 (2009).
G. Sahay, D.Y. Alakhova, and A.V. Kabanov. Endocytosis of nanomedicines.
Journal of Controlled Release. 145:182-195 (2010).
J. Rejman, V. Oberle, I.S. Zuhorn, and D. Hoekstra. Size-dependent
internalization of particles via the pathways of clathrin-and caveolae-mediated
endocytosis. Biochemical Journal. 377:159-169 (2004).
G. Tosi, A.V. Vergoni, B. Ruozi, L. Bondioli, L. Badiali, F. Rivasi, L. Costantino,
F. Forni, and M.A. Vandelli. Sialic acid and glycopeptides conjugated PLGA
nanoparticles for central nervous system targeting: In vivo pharmacological
evidence and biodistribution. Journal of Controlled Release. 145:49-57 (2010).
Y. Liu, J.F. Li, K. Shao, R.Q. Huang, L.Y. Ye, J.N. Lou, and C. Jiang. A leptin
derived 30-amino-acid peptide modified pegylated poly-L-lysine dendrigraft for
brain targeted gene delivery. Biomaterials. 31:5246-5257 (2010).
O. Veiseh, C. Sun, C. Fang, N. Bhattarai, J. Gunn, F. Kievit, K. Du, B. Pullar, D.
Lee, R.G. Ellenbogen, J. Olson, and M.Q. Zhang. Specific targeting of brain
tumors with an optical/magnetic resonance imaging nanoprobe across the bloodbrain barrier. Cancer Res. 69:6200-6207 (2009).
J. Jiang, G. Oberdorster, A. Elder, R. Gelein, P. Mercer, and P. Biswas. Does
nanoparticle activity depend upon size and crystal phase? Nanotoxicology. 2:3342 (2008).
B.D. Chithrani, A.A. Ghazani, and W.C.W. Chan. Determining the size and shape
dependence of gold nanoparticle uptake into mammalian cells. Nano Letters.
6:662-668 (2006).

161

151.

152.

153.

154.
155.

156.

157.

158.

159.

160.
161.
162.

163.

164.

B.D. Chithrani and W.C.W. Chan. Elucidating the mechanism of cellular uptake
and removal of protein-coated gold nanoparticles of different sizes and shapes.
Nano Letters. 7:1542-1550 (2007).
L.K. Limbach, Y.C. Li, R.N. Grass, T.J. Brunner, M.A. Hintermann, M. Muller,
D. Gunther, and W.J. Stark. Oxide nanoparticle uptake in human lung fibroblasts:
Effects of particle size, agglomeration, and diffusion at low concentrations.
Environ Sci Technol. 39:9370-9376 (2005).
J.O. Ferin, G. ; Penney, D. P. ; Soderholm, S. C. ; Gelein, R. ; Piper, H. C.
Increased pulmonary toxicity of ultrafine particles? I, Particle clearance,
translocation, morphology. Journal of aerosol science 21:381-384 (1990).
G. Oberdörster, A. Elder, and A. Rinderknecht. Nanoparticles and the brain: cause
for concern? J Nanosci Nanotechno. 9:4996-5007 (2009).
M.D. Howard, M. Jay, T.D. Dziubla, and X.L. Lu. PEGylation of nanocarrier
drug delivery systems: State of the art. Journal of Biomedical Nanotechnology.
4:133-148 (2008).
S. Ku, F. Yan, Y. Wang, Y. Sun, N. Yang, and L. Ye. The blood-brain barrier
penetration and distribution of PEGylated fluorescein-doped magnetic silica
nanoparticles in rat brain. Biochemical and Biophysical Research
Communications. In Press, Uncorrected Proof.
P. Calvo, B. Gouritin, H. Chacun, D. Desmaële, J. D'Angelo, J.-P. Noel, D.
Georgin, E. Fattal, J.P. Andreux, and P. Couvreur. Long-Circulating PEGylated
Polycyanoacrylate Nanoparticles as New Drug Carrier for Brain Delivery. Pharm
Res-Dord. 18:1157-1166 (2001).
Z.H. Wang, Z.Y. Wang, C.S. Sun, C.Y. Wang, T.Y. Jiang, and S.L. Wang.
Trimethylated chitosan-conjugated PLGA nanoparticles for the delivery of drugs
to the brain. Biomaterials. 31:908-915 (2010).
T. Cedervall, I. Lynch, S. Lindman, T. Berggard, E. Thulin, H. Nilsson, K.A.
Dawson, and S. Linse. Understanding the nanoparticle-protein corona using
methods to quantify exchange rates and affinities of proteins for nanoparticles. P
Natl Acad Sci USA. 104:2050-2055 (2007).
A. Crowe and E.H. Morgan. Iron and transferrin uptake by brain and
cerebrospinal fluid in the rat. Brain Res. 592:8-16 (1992).
E.H. Morgan and T. Moos. Mechanism and developmental changes in iron
transport across the blood-brain barrier. Dev Neurosci. 24:106-113 (2002).
A. Zensi, D. Begley, C. Pontikis, C. Legros, L. Mihoreanu, S. Wagner, C. Buchel,
H. von Briesen, and J. Kreuter. Albumin nanoparticles targeted with Apo E enter
the CNS by transcytosis and are delivered to neurones. Journal of Controlled
Release. 137:78-86 (2009).
D.E. Owens and N.A. Peppas. Opsonization, biodistribution, and
pharmacokinetics of polymeric nanoparticles. Int J Pharmaceut. 307:93-102
(2006).
M. Demeule, J.C. Currie, Y. Bertrand, C. Che, T. Nguyen, A. Regina, R.
Gabathuler, J.P. Castaigne, and R. Beliveau. Involvement of the low-density
lipoprotein receptor-related protein in the transcytosis of the brain delivery vector
Angiopep-2. Journal of Neurochemistry. 106:1534-1544 (2008).

162

165.

166.

167.

168.

169.
170.

171.

172.

173.

174.

175.

176.
177.

178.

179.

M. Demeule, A. Regina, C. Che, J. Poirier, T. Nguyen, R. Gabathuler, J.P.
Castaigne, and R. Beliveau. Identification and design of peptides as a new drug
delivery system for the brain. J Pharmacol Exp Ther. 324:1064-1072 (2008).
W. Ke, K. Shao, R. Huang, L. Han, Y. Liu, J. Li, Y. Kuang, L. Ye, J. Lou, and C.
Jiang. Gene delivery targeted to the brain using an Angiopep-conjugated
polyethyleneglycol-modified polyamidoamine dendrimer. Biomaterials. 30:69766985 (2009).
S. Linse, C. Cabaleiro-Lago, W.F. Xue, I. Lynch, S. Lindman, E. Thulin, S.E.
Radford, and K.A. Dawson. Nucleation of protein fibrillation by nanoparticles. P
Natl Acad Sci USA. 104:8691-8696 (2007).
I. Integrated Laboratory Systems. Chemical information profile for ceric oxide
[CAS No. 1306-38-3]. Supporting Nomination for Toxicological Evaluation by
the National Toxicology Program. In N. National Toxicology Program, Research
Triangle Park, NC (ed.), Research Triangle Park, NC., 2006, p. 21.
V.T. Davisand J.S. Thompson. Measurement of the electron affinity of cerium.
Phys Rev Lett. 88:073003 (2002).
F. Esch, S. Fabris, L. Zhou, T. Montini, C. Africh, P. Fornasiero, G. Comelli, and
R. Rosei. Electron localization determines defect formation on ceria substrates.
Science. 309:752-755 (2005).
M. Fronzi, A. Soon, B. Delley, E. Traversa, and C. Stampfl. Stability and
morphology of cerium oxide surfaces in an oxidizing environment: A firstprinciples investigation. Journal of Chemical Physics. 131: (2009).
J.E. Spanier, R.D. Robinson, F. Zheng, S.W. Chan, and I.P. Herman. Sizedependent properties of CeO2-y nanoparticles as studied by Raman scattering.
Phys Rev B. 64: (2001).
A. Karakoti, S. Singh, J.M. Dowding, S. Seal, and W.T. Self. Redox-active
radical scavenging nanomaterials. Chemical Society Reviews. 39:4422-4432
(2010).
M. Das, S. Patil, N. Bhargava, J.-F. Kang, L.M. Riedel, S. Seal, and J.J. Hickman.
Auto-catalytic ceria nanoparticles offer neuroprotection to adult rat spinal cord
neurons. Biomaterials. 28:1918-1925 (2007).
A. Corma, P. Atienzar, H. Garcia, and J.Y. Chane-Ching. Hierarchically
mesostructured doped CeO2 with potential for solar-cell use. Nat Mater. 3:394397 (2004).
E.G. Heckert, S. Seal, and W.T. Self. Fenton-like reaction catalyzed by the rare
earth inner transition metal cerium. Environ Sci Technol. 42:5014-5019 (2008).
X. He, H. Zhang, Y. Ma, W. Bai, Z. Zhang, K. Lu, Y. Ding, Y. Zhao, and Z. Chai.
Lung deposition and extrapulmonary translocation of nano-ceria after
intratracheal instillation Nanotechnology. 21:285103/285101-285103/285108
(2010).
S.M. Hirst, A. Karakoti, S. Singh, W. Self, R. Tyler, S. Seal, and C.M. Reilly.
Bio-distribution and in vivo antioxidant effects of cerium oxide nanoparticles in
mice. Environ Toxicol:1-12 (2011).
R.A. Yokel, M.T. Tseng, M. Dan, J.M. Unrine, U.M. Graham, P. Wu, and E.A.
Grulke. Biodistribution, biopersistence and associated toxicity of ceria engineered
nanomaterial Nanomedicine: Nanotechnology, Biology and Medicine (Submitted).
163

180.

181.

182.

183.

184.

185.
186.
187.

188.

189.

190.

191.
192.

193.
194.

Z.J. Deng, G. Mortimer, T. Schiller, A. Musumeci, D. Martin, and R.F. Minchin.
Differential plasma protein binding to metal oxide nanoparticles. Nanotechnology.
20: (2009).
P.R. Salacinski, C. McLean, J.E. Sykes, V.V. Clement-Jones, and P.J. Lowry.
Iodination of proteins, glycoproteins, and peptides using a solid-phase oxidizing
agent, 1, 3, 4, 6-tetrachloro-3α, 6α-diphenyl glycoluril (Iodogen). Analytical
biochemistry. 117:136-146 (1981).
J. Wang, M.F. Rahman, H.M. Duhart, G.D. Newport, T.A. Patterson, R.C.
Murdock, S.M. Hussain, J.J. Schlager, and S.F. Ali. Expression changes of
dopaminergic system-related genes in PC12 cells induced by manganese, silver,
or copper nanoparticles. Neurotoxicology. 30:926-933 (2009).
D. Walczyk, F.B. Bombelli, M.P. Monopoli, I. Lynch, and K.A. Dawson. What
the Cell "Sees" in Bionanoscience. Journal of the American Chemical Society.
132:5761-5768 (2010).
N. Mandzy, E. Grulke, and T. Druffel. Breakage of TiO2 agglomerates in
electrostatically stabilized aqueous dispersions. Powder Technology. 160:121-126
(2005).
N.S. Satarkar, D. Biswal, and J.Z. Hilt. Hydrogel nanocomposites: a review of
applications as remote controlled biomaterials. Soft Matter. 6:2364-2371 (2010).
R.A. Frimpongand J.Z. Hilt. Magnetic nanoparticles in biomedicine: synthesis,
functionalization and applications. Nanomedicine (Lond). 5:1401-1414 (2010).
D.L. Thorek, A.K. Chen, J. Czupryna, and A. Tsourkas. Superparamagnetic iron
oxide nanoparticle probes for molecular imaging. Ann Biomed Eng. 34:23-38
(2006).
L. Geraets, A.G. Oomen, J.D. Schroeter, V.A. Coleman, and F.R. Cassee. Tissue
distribution of inhaled micro- and nano-sized cerium oxide particles in rats:
results from a 28-day exposure study. Toxicol Sci. 127:463-473 (2012).
R.A. Yokel, M.T. Tseng, M. Dan, J.M. Unrine, U.M. Graham, P. Wu, and E.A.
Grulke. Biodistribution and biopersistence of ceria engineered nanomaterials: size
dependence. Nanomedicine. 9:398-407 (2013).
R. Cavaliere, E.C. Ciocatto, B.C. Giovanella, C. Heidelberger, R.O. Johnson, M.
Margottini, B. Mondovi, G. Moricca, and A. Rossi-Fanelli. Selective heat
sensitivity of cancer cells. Biochemical and clinical studies. Cancer. 20:13511381 (1967).
K.M. Krishnan. Biomedical nanomagnetics: a spin through possibilities in
imaging, diagnostics, and therapy. IEEE T Magn. 46:2523-2558 (2010).
A.C. Silva, T.R. Oliveira, J.B. Mamani, S.M.F. Malheiros, L. Malavolta, L.F.
Pavon, T.T. Sibov, E. Amaro, A. Tannus, E.L.G. Vidoto, M.J. Martins, R.S.
Santos, and L.F. Gamarra. Application of hyperthermia induced by
superparamagnetic iron oxide nanoparticles in glioma treatment. International
Journal of Nanomedicine. 6:591-603 (2011).
Z.R. Stephen, F.M. Kievit, and M. Zhang. Magnetite nanoparticles for medical
MR imaging. Mater Today. 14:330-338 (2011).
M. Semmler-Behnke, W.G. Kreyling, J. Lipka, S. Fertsch, A. Wenk, S. Takenaka,
G. Schmid, and W. Brandau. Biodistribution of 1.4- and 18-nm gold particles in
rats. Small. 4:2108-2111 (2008).
164

195.

196.

197.

198.

199.

200.

201.
202.

203.

204.

205.
206.

207.

208.

H.J. Weinmann, R.C. Brasch, W.R. Press, and G.E. Wesbey. Characteristics of
gadolinium-DTPA complex: a potential NMR contrast agent. AJR Am J
Roentgenol. 142:619-624 (1984).
M. Dan, D.F. Scott, P.A. Hardy, R.J. Wydra, J.Z. Hilt, R.A. Yokel, and Y. Bae.
Block copolymer cross-linked nanoassemblies improve particle stability and
biocompatibility of superparamagnetic iron oxide nanoparticles. Pharm Res.
30:552-561 (2013).
A. Ito, M. Shinkai, H. Honda, K. Yoshikawa, S. Saga, T. Wakabayashi, J.
Yoshida, and T. Kobayashi. Heat shock protein 70 expression induces antitumor
immunity during intracellular hyperthermia using magnetite nanoparticles. Cancer
Immunology Immunotherapy. 52:80-88 (2003).
A. Ito, M. Shinkai, H. Honda, and T. Kobayashi. Heat-inducible TNF-alpha gene
therapy combined with hyperthermia using magnetic nanoparticles as a novel
tumor-targeted therapy. Cancer Gene Therapy. 8:649-654 (2001).
M. Dan, M.T. Tseng, P. Wu, J.M. Unrine, E.A. Grulke, and R.A. Yokel. Brain
microvascular endothelial cell association and distribution of a 5 nm ceria
engineered nanomaterial. Int J Nanomedicine. 7:4023-4036 (2012).
R. Yokel, E. Grulke, and R. Macphail. Metal-based nanoparticle interactions with
the nervous system: the challenge of brain entry and the risk of retention in the
organism. Wiley Interdiscip Rev Nanomed Nanobiotechnol (2013).
V.M. Runge. Notes on "Characteristics of gadolinium-DTPA complex: a potential
NMR contrast agent". AJR Am J Roentgenol. 190:1433-1434 (2008).
B. Wang, W.Y. Feng, M. Wang, J.W. Shi, F. Zhang, H. Ouyang, Y.L. Zhao, Z.F.
Chai, Y.Y. Huang, Y.N. Xie, H.F. Wang, and J. Wang. Transport of intranasally
instilled fine Fe2O3 particles into the brain: Micro-distribution, chemical states,
and histopathological observation. Biological Trace Element Research. 118:233243 (2007).
B.B. Weksler, E.A. Subileau, N. Perriere, P. Charneau, K. Holloway, M. Leveque,
H. Tricoire-Leignel, A. Nicotra, S. Bourdoulous, P. Turowski, D.K. Male, F.
Roux, J. Greenwood, I.A. Romero, and P.O. Couraud. Blood-brain barrierspecific properties of a human adult brain endothelial cell line. FASEB J.
19:1872-1874 (2005).
J. Lodhia, G. Mandarano, N. Ferris, P. Eu, and S. Cowell. Development and use
of iron oxide nanoparticles (Part 1): Synthesis of iron oxide nanoparticles for MRI.
Biomed Imaging Interv J. 6:e12 (2010).
M. Lattuada and T.A. Hatton. Functionalization of monodisperse magnetic
nanoparticles. Langmuir. 23:2158-2168 (2007).
R. Guo, Y. Song, G.L. Wang, and R.W. Murray. Does core size matter in the
kinetics of ligand exchanges of monolayer-protected Au clusters? J Am Chem
Soc. 127:2752-2757 (2005).
G.H. Woehrle, L.O. Brown, and J.E. Hutchison. Thiol-functionalized, 1.5-nm
gold nanoparticles through ligand exchange reactions: Scope and mechanism of
ligand exchange. J Am Chem Soc. 127:2172-2183 (2005).
J. Papademetriou, C. Garnacho, D. Serrano, T. Bhowmick, E.H. Schuchman, and
S. Muro. Comparative binding, endocytosis, and biodistribution of antibodies and

165

209.

210.

211.

212.
213.

214.

215.

216.

217.
218.

219.
220.

221.

222.
223.

antibody-coated carriers for targeted delivery of lysosomal enzymes to ICAM-1
versus transferrin receptor. J Inherit Metab Dis. 36:467-477 (2013).
J.E. Riviere. Pharmacokinetics of nanomaterials: an overview of carbon
nanotubes, fullerenes and quantum dots. Wiley Interdiscip Rev Nanomed
Nanobiotechnol. 1:26-34 (2009).
R. Hardman. A toxicologic review of quantum dots: Toxicity depends on
physicochemical and environmental factors. Environmental Health Perspectives.
114:165-172 (2006).
E.V. Batrakova and A.V. Kabanov. Pluronic block copolymers: evolution of drug
delivery concept from inert nanocarriers to biological response modifiers. J
Control Release. 130:98-106 (2008).
J.R. Kanwar, G. Mahidhara, and R.K. Kanwar. Recent advances in nanoneurology
for drug delivery to the brain. Current Nanoscience 5:441-448 (2009).
T. Masui, H. Hirai, N. Imanaka, G. Adachi, T. Sakata, and H. Mori. Synthesis of
cerium oxide nanoparticles by hydrothermal crystallization with citric acid.
Journal of Materials Science Letters. 21:489-491 (2002).
C. Pan, D. Zhang, and L. Shi. CTAB assisted hydrothermal synthesis, controlled
conversion and CO oxidation properties of CeO2 nanoplates, nanotubes, and
nanorods. Journal of Solid State Chemistry. 181:1298-1306 (2008).
H.-X. Mai, L.-D. Sun, Y.-W. Zhang, R. Si, W. Feng, H.-P. Zhang, H.-C. Liu, and
C.-H. Yan. Shape-selective synthesis and oxygen storage behavior of ceria
nanopolyhedra, nanorods, and nanocubes. Journal of Physical Chemistry B
109:24380-24385 (2005).
Q. Wu, F. Zhang, P. Xiao, H. Tao, X. Wang, Z. Hu, and Y. Lu. Great influence of
anions for controllable synthesis of CeO2 nanostructures: From nanorods to
nanocubes. Journal of Physical Chemistry C. 112:17076-17080 (2008).
F. Zhang, Q. Jin, and S.-W. Chan. Ceria nanoparticles: Size, size distribution, and
shape. Journal of Applied Physics. 95:4319-4326 (2004).
K. Bjondahl. Differences in liver weight, mortality in cerium-treated mice and
144Ce levels in blood, liver, urine and faeces at various intervals after treatment
with nafenopin and pregnenolone 16-alpha-carbonitrile (PCN). Medical Biology.
54:454-460 (1976).
Y.I. Moskalev. [Experiments on distribution of Ce 144]. Med Radiol (Mosk).
4:52-58 (1959).
K. Takada and M. Fujita. Effects of DTPA on the excretion and tissue distribution
of 144Ce administered subcutaneously, intramuscularly and intravenously in rats.
J Radiat Res (Tokyo). 14:187-197 (1973).
B.A. Rzigalinski, I. Danelison, E.T. Strawn, C.A. Cohen, and C. Liang.
Nanoparticles for cell engineering - A radical concept. In C.S.S.R. Kumar (ed.),
Nanotechnologies for the Life Sciences, Vol. 9 Tissue, Cell and Organ
Engineering, Wiley-VCH, Hoboken, New Jersey, 2006, pp. 361-387.
B.A. Rzigalinski, K. Meehan, R.M. Davis, Y. Xu, W.C. Miles, and C.A. Cohen.
Radical nanomedicine. Nanomedicine (Lond). 1:399-412 (2006).
S.M. Hirst, A.S. Karakoti, R.D. Tyler, N. Sriranganathan, S. Seal, and C.M.
Reilly. Anti-inflammatory Properties of Cerium Oxide Nanoparticles. Small.
5:2848-2856 (2009).
166

224.

S.S. Hardas, D.A. Butterfield, R. Sultana, M.T. Tseng, M. Dan, R.L. Florence,
J.M. Unrine, U.M. Graham, P. Wu, E.A. Grulke, and R.A. Yokel. Brain
distribution and toxicological evaluation of a systemically delivered engineered
nanoscale ceria. Toxicological Sciences 116:562-576 (2010).

225.

226.

227.

228.

229.

230.

231.

232.
233.

234.

235.

236.
237.

Y. Nakamura, Y. Tsumura, Y. Tonogai, T. Shibata, and Y. Ito. Differences in
behavior among the chlorides of seven rare earth elements administered
intravenously to rats. Fundam Appl Toxicol. 37:106-116 (1997).
M. Geiser, B. Rothen-Rutishauser, N. Kapp, S. Schurch, W. Kreyling, H. Schulz,
M. Semmler, V. Im Hof, J. Heyder, and P. Gehr. Ultrafine particles cross cellular
membranes by nonphagocytic mechanisms in lungs and in cultured cells. Environ
Health Perspect. 113:1555-1560 (2005).
B.M. Rothen-Rutishauser, S. Schurch, B. Haenni, N. Kapp, and P. Gehr.
Interaction of fine particles and nanoparticles with red blood cells visualized with
advanced microscopic techniques. Environ Sci Technol. 40:4353-4359 (2006).
J. Wang, G. Zhou, C. Chen, H. Yu, T. Wang, Y. Ma, G. Jia, Y. Gao, B. Li, J. Sun,
Y. Li, F. Jiao, Y. Zhao, and Z. Chai. Acute toxicity and biodistribution of
different sized titanium dioxide particles in mice after oral administration. Toxicol
Lett. 168:176-185 (2007).
R.S. Yang, L.W. Chang, J.P. Wu, M.H. Tsai, H.J. Wang, Y.C. Kuo, T.K. Yeh,
C.S. Yang, and P. Lin. Persistent tissue kinetics and redistribution of
nanoparticles, quantum dot 705, in mice: ICP-MS quantitative assessment.
Environ Health Perspect. 115:1339-1343 (2007).
W.T. Al-Jamal, K.T. Al-Jamal, A. Cakebread, J.M. Halket, and K. Kostarelos.
Blood circulation and tissue biodistribution of lipid--quantum dot (L-QD) hybrid
vesicles intravenously administered in mice. Bioconjug Chem. 20:1696-1702
(2009).
H.C. Fischer, L. Liu, K.S. Pang, and W.C.W. Chan. Pharmacokinetics of
nanoscale quantum dots: in vivo distribution, sequestration, and clearance in the
rat Advanced Functional Materials. 16:1299-1305 (2006).
M. Li, K.T. Al-Jamal, K. Kostarelos, and J. Reineke. Physiologically based
pharmacokinetic modeling of nanoparticles. ACS Nano. 4:6303-6317 (2010).
S.H. Brewer, W.R. Glomm, M.C. Johnson, M.K. Knag, and S. Franzen. Probing
BSA binding to citrate-coated gold nanoparticles and surfaces. Langmuir.
21:9303-9307 (2005).
R.F. Uren and C.A. Hoefnagel. Lymphoscintigraphy. In J.F. Thompson, D.L.
Morton, and B.B.R. Kroon (eds.), Textbook of melanoma, Martin Dunitz, New
York, 2004, pp. 339-364.
S. Kim, Y.T. Lim, E.G. Soltesz, A.M. De Grand, J. Lee, A. Nakayama, J.A.
Parker, T. Mihaljevic, R.G. Laurence, D.M. Dor, L.H. Cohn, M.G. Bawendi, and
J.V. Frangioni. Near-infrared fluorescent type II quantum dots for sentinel lymph
node mapping. Nat Biotechnol. 22:93-97 (2004).
M.R.T.N. Tozer. Clinical pharmacokinetics and pharmacodynamics-comcepts and
applications, Wolters Kluwer, 2009.
J.J. DiStefano, 3rd. Noncompartmental vs. compartmental analysis: some bases
for choice. Am J Physiol. 243:R1-6 (1982).

167

238.

239.
240.
241.

242.

243.

244.

245.

246.

247.

248.

249.

250.
251.

252.

R.S. Yang, L.W. Chang, C.S. Yang, and P. Lin. Pharmacokinetics and
physiologically-based pharmacokinetic modeling of nanoparticles. J Nanosci
Nanotechnol. 10:8482-8490 (2010).
S.D. Liand L. Huang. Pharmacokinetics and biodistribution of nanoparticles. Mol
Pharm. 5:496-504 (2008).
J.F. Nyland and E.K. Silbergeld. A nanobiological approach to nanotoxicology.
Hum Exp Toxicol. 28:393-400 (2009).
H.A. Lee, T.L. Leavens, S.E. Mason, N.A. Monteiro-Riviere, and J.E. Riviere.
Comparison of quantum dot biodistribution with a blood-flow-limited
physiologically based pharmacokinetic model. Nano Lett. 9:794-799 (2009).
M. Dan, P. Wu, E.A. Grulke, U.M. Graham, J.M. Unrine, and R.A. Yokel. Ceria
engineered nanomaterial distribution in and clearance from blood: Size matters.
Nanomedicine. 7:95-110 (2012).
T. Xia, M. Kovochich, M. Liong, L. Madler, B. Gilbert, H. Shi, J.I. Yeh, J.I. Zink,
and A.E. Nel. Comparison of the mechanism of toxicity of zinc oxide and cerium
oxide nanoparticles based on dissolution and oxidative stress properties. ACS
Nano. 2:2121-2134 (2008).
J. Choi, V. Reipa, V.M. Hitchins, P.L. Goering, and R.A. Malinauskas.
Physicochemical characterization and in vitro hemolysis evaluation of silver
nanoparticles Toxicological Sciences. 123:133-143 (2011).
J.L. Viota, K. Rudzk, Á. Trueba, I. Torres-Aleman, and Á.V. Delgado.
Electrophoretic characterization of insulin frowth Factor (IGF-1) functionalized
magnetic nanoparticles. Langmuir. 27:6426-6432 (2011).
R.A. Bronen and G. Sze. Magnetic-resonance-imaging contracst agents - theory
and application to the central - nervous - system. Journal of Neurosurgery.
73:820-839 (1990).
J.S. Crossgrove, D.D. Allen, B.L. Bukaveckas, S.S. Rhineheimer, and R.A. Yokel.
Manganese distribution across the blood-brain barrier. I. Evidence for carriermediated influx of managanese citrate as well as manganese and manganese
transferrin. NeuroToxicology. 24:3-13. (2003).
J.S. Crossgrove and R.A. Yokel. Manganese distribution across the blood-brain
barrier III. The divalent metal transporter-1 is not the major mechanism mediating
brain manganese uptake. Neurotoxicology. 25:451-460 (2004).
J.S. Crossgrove and R.A. Yokel. Manganese distribution across the blood-brain
barrier. IV. Evidence for brain influx through store-operated calcium channels.
NeuroToxicology. 26:297-307 (2005).
Q.R. Smith. Brain perfusion systems for studies of drug uptake and metabolism in
the central nervous system. Pharmaceutical Biotechnology. 8:285-307 (1996).
D. Triguero, J. Buciak, and W.M. Pardridge. Capillary depletion method for
quantification of blood-brain barrier transport of circulating peptides and plasma
proteins. Journal of Neurochemistry. 54:1882-1888 (1990).
Y. Takasato, S.I. Rapoport, and Q.R. Smith. An in situ brain perfusion technique
to study cerebrovascular transport in the rat. American Journal of Physiology.
247:H484-H493 (1984).

168

253.

254.
255.

256.

257.

258.
259.

260.

261.

262.

263.
264.
265.
266.
267.

268.

C.C.a.D.G. Levitt. Capillary permeability to small solutes. In Handbook of
Physiology. The Cardiovascular System. Microcirculation., Am. Physiol. Soc.,
Bethesda, MD, 1984.
D.E. Owens and N.A. Peppas. Opsonization, biodistribution, and
pharmacokinetics of polymeric nanoparticles. Int J Pharm. 307:93-102 (2006).
Z.J. Deng, G. Mortimer, T. Schiller, A. Musumeci, D. Martin, and R.F. Minchin.
Differential plasma protein binding to metal oxide nanoparticles. Nanotechnology.
20:455101/455101-455101/455109 (2009).
W.H. De Jong, W.I. Hagens, P. Krystek, M.C. Burger, A.J. Sips, and R.E.
Geertsma. Particle size-dependent organ distribution of gold nanoparticles after
intravenous administration. Biomaterials. 29:1912-1919 (2008).
L. Garza-Ocanas, D.A. Ferrer, J. Burt, L.A. Diaz-Torres, M. Ramirez Cabrera,
V.T. Rodriguez, R. Lujan Rangel, D. Romanovicz, and M. Jose-Yacaman.
Biodistribution and long-term fate of silver nanoparticles functionalized with
bovine serum albumin in rats. Metallomics. 2:204-210 (2010).
J.M. Koziara, P.R. Lockman, D.D. Allen, and R.J. Mumper. In situ blood-brain
barrier transport of nanoparticles. Pharm Res-Dord. 20:1772-1778 (2003).
M. Dan, P. Wu, E.A. Grulke, U.M. Graham, J.M. Unrine, and R.A. Yokel. Ceriaengineered nanomaterial distribution in, and clearance from, blood: size matters.
Nanomedicine (Lond). 7:95-110 (2012).
C. Wilhelm, F. Gazeau, J. Roger, J.N. Pons, and J.C. Bacri. Interaction of anionic
superparamagnetic nanoparticles with cells: Kinetic analyses of membrane
adsorption and subsequent internalization. Langmuir. 18:8148-8155 (2002).
R.E. Serda, J. Gu, J.K. Burks, K. Ferrari, C. Ferrari, and M. Ferrari. Quantitative
Mechanics of Endothelial Phagocytosis of Silicon Microparticles. Cytometry Part
A. 75A:752-760 (2009).
S. Tanabe, Y. Shimohigashi, Y. Nakayama, T. Makino, T. Fujita, T. Nose, G.
Tsujimoto, T. Yokokura, M. Naito, T. Tsuruo, and T. Terasaki. In vivo and in
vitro evidence of blood-brain barrier transport of a novel cationic argininevasopressin fragment 4-9 analog. J Pharmacol Exp Ther. 290:561-568 (1999).
Y.S. Kang and W.M. Pardridge. Brain delivery of biotin bound to a conjugate of
neutral avidin and cationized human albumin. Pharm Res. 11:1257-1264 (1994).
N. Strazielle and J.F. Ghersi-Egea. Choroid plexus in the central nervous system:
biology and physiopathology. J Neuropathol Exp Neurol. 59:561-574 (2000).
Z. Redzic. Molecular biology of the blood-brain and the blood-cerebrospinal fluid
barriers: similarities and differences. Fluids Barriers CNS. 8:3 (2011).
W. Zheng. Toxicology of choroid plexus: Special reference to metal-induced
neurotoxicities. Microscopy Research and Technique. 52:89-103 (2001).
J.K. Räty, T. Liimatainen, T. Wirth, K.J. Airenne, T.O. Ihalainen, T. Huhtala, E.
Hamerlynck, M. Vihinen-Ranta, A. Närvänen, S. Ylä-Herttuala, and J.M.
Hakumäki. Magnetic resonance imaging of viral particle biodistribution in vivo.
Gene Therapy. 13:1440-1446 (2006).
S. Salmaso, J.S. Pappalardo, R.R. Sawant, T. Musacchio, K. Rockwell, P. Caliceti,
and V.P. Torchilin. Targeting glioma cells in vitro with ascorbate-conjugated
pharmaceutical nanocarriers. Bioconjug Chem. 20:2348-2355 (2009).

169

269.
270.
271.

272.

273.

274.

275.

276.

277.

278.

279.

280.

281.

282.

T. Kobayashi. Cancer hyperthermia using magnetic nanoparticles. Biotechnol J.
6:1342-1347 (2011).
C. Rumenapp, B. Gleich, and A. Haase. Magnetic nanoparticles in magnetic
resonance imaging and diagnostics. Pharm Res. 29:1165-1179 (2012).
R.R. Qiao, C.H. Yang, and M.Y. Gao. Superparamagnetic iron oxide
nanoparticles: from preparations to in vivo MRI applications. J Mater Chem.
19:6274-6293 (2009).
M. Wagner, S. Wagner, J. Schnorr, E. Schellenberger, D. Kivelitz, L. Krug, M.
Dewey, M. Laule, B. Hamm, and M. Taupitz. Coronary MR Angiography Using
Citrate-Coated Very Small Superparamagnetic Iron Oxide Particles as Blood-Pool
Contrast Agent: Initial Experience in Humans. J Magn Reson Imaging. 34:816823 (2011).
B. Chanteau, J. Fresnais, and J.F. Berret. Electrosteric enhanced stability of
functional sub-10 nm cerium and iron oxide particles in cell culture medium.
Langmuir. 25:9064-9070 (2009).
S.A. Meenach, J.Z. Hilt, and K.W. Anderson. Poly(ethylene glycol)-based
magnetic hydrogel nanocomposites for hyperthermia cancer therapy. Acta
Biomater. 6:1039-1046 (2010).
R.A. Frimpong, J. Dou, M. Pechan, and J.Z. Hilt. Enhancing remote controlled
heating characteristics in hydrophilic magnetite nanoparticles via facile coprecipitation. J Magn Magn Mater. 322:326-331 (2010).
J. O'Brien, I. Wilson, T. Orton, and F. Pognan. Investigation of the Alamar Blue
(resazurin) fluorescent dye for the assessment of mammalian cell cytotoxicity.
Eur J Biochem. 267:5421-5426 (2000).
M.L. Forrest, J.A. Yanez, C.M. Remsberg, Y. Ohgami, G.S. Kwon, and N.M.
Davies. Paclitaxel prodrugs with sustained release and high solubility in
poly(ethylene glycol)-b-poly(epsilon-caprolactone) micelle nanocarriers:
pharmacokinetic disposition, tolerability, and cytotoxicity. Pharm Res. 25:194206 (2008).
R. Tantra, J. Tompkins, and P. Quincey. Characterisation of the de-agglomeration
effects of bovine serum albumin on nanoparticles in aqueous suspension. Colloid
Surface B. 75:275-281 (2010).
Z.E. Allouni, M.R. Cimpan, P.J. Hol, T. Skodvin, and N.R. Gjerdet.
Agglomeration and sedimentation of TiO2 nanoparticles in cell culture medium.
Colloid Surface B. 68:83-87 (2009).
L. Foucaud, M.R. Wilson, D.M. Brown, and V. Stone. Measurement of reactive
species production by nanoparticles prepared in biologically relevant media.
Toxicol Lett. 174:1-9 (2007).
T. Neuberger, B. Schöpf, H. Hofmann, M. Hofmann, and B. von Rechenberg.
Superparamagnetic nanoparticles for biomedical applications: Possibilities and
limitations of a new drug delivery system. J Magn Magn Mater. 293:483-496
(2005).
L.C. Varanda, M. Jafelicci, P. Tartaj, K. O' Grady, T. Gonzalez-Carreno, M.P.
Morales, T. Munoz, and C.J. Serna. Structural and magnetic transformation of
monodispersed iron oxide particles in a reducing atmosphere. J Appl Phys.
92:2079-2085 (2002).
170

283.

284.

285.

286.

287.
288.

289.

290.

291.

292.

293.

294.

295.

Z.J. Deng, G. Mortimer, T. Schiller, A. Musumeci, D. Martin, and R.F. Minchin.
Differential plasma protein binding to metal oxide nanoparticles. Nanotechnology.
20:455101-455109 (2009).
A.J. Cole, A.E. David, J. Wang, C.J. Galbán, H.L. Hill, and V.C. Yang.
Polyethylene glycol modified, cross-linked starch-coated iron oxide nanoparticles
for enhanced magnetic tumor targeting. Biomaterials. 32:2183-2193 (2011).
M.I. Khan, A. Mohammad, G. Patil, S.A. Naqvi, L.K. Chauhan, and I. Ahmad.
Induction of ROS, mitochondrial damage and autophagy in lung epithelial cancer
cells by iron oxide nanoparticles. Biomaterials. 33:1477-1488 (2012).
C.C. Berry, S. Wells, S. Charles, and A.S. Curtis. Dextran and albumin
derivatised iron oxide nanoparticles: influence on fibroblasts in vitro.
Biomaterials. 24:4551-4557 (2003).
S.J. Soenen and M. De Cuyper. Assessing iron oxide nanoparticle toxicity in vitro:
current status and future prospects. Nanomedicine. 5:1261-1275 (2010).
M. Yanase, M. Shinkai, H. Honda, T. Wakabayashi, J. Yoshida, and T. Kobayashi.
Intracellular hyperthermia for cancer using magnetite cationic liposomes: Ex vivo
study. Jpn J Cancer Res. 88:630-632 (1997).
A.C. Silva, T.R. Oliveira, J.B. Mamani, S.M.F. Malheiros, L. Malavolta, L.F.
Pavon, T.T. Sibov, E. Amaro, A. Tannus, E.L.G. Vidoto, M.J. Martins, R.S.
Santos, and L.F. Gamarra. Application of hyperthermia induced by
superparamagnetic iron oxide nanoparticles in glioma treatment. Int J Nanomed.
6:591-603 (2011).
A. Agarwal, N. Lariya, G. Saraogi, N. Dubey, H. Agrawal, and G.P. Agrawal.
Nanoparticles as Novel Carrier for Brain Delivery: A Review. Current
Pharmaceutical Design. 15:917-925 (2009).
S. Bhaskar, F. Tian, T. Stoeger, W. Kreyling, J.M. de la Fuente, V. Grazu, P.
Borm, G. Estrada, V. Ntziachristos, and D. Razansky. Multifunctional
Nanocarriers for diagnostics, drug delivery and targeted treatment across bloodbrain barrier: perspectives on tracking and neuroimaging. Part Fibre Toxicol. 7:3
(2010).
M. Dan, D.F. Scott, P.A. Hardy, R.J. Wydra, J.Z. Hilt, R.A. Yokel, and Y. Bae.
Block Copolymer Cross-Linked Nanoassemblies Improve Particle Stability and
Biocompatibility of Superparamagnetic Iron Oxide Nanoparticles. Pharm Res
(2012).
B.H. Kenzaoui, C.C. Bernasconi, H. Hofmann, and L. Juillerat-Jeanneret.
Evaluation of uptake and transport of ultrasmall superparamagnetic iron oxide
nanoparticles by human brain-derived endothelial cells. Nanomedicine. 7:39-53
(2012).
Y.H. Zhou, W.R. Harris, and R.A. Yokel. The influence of citrate, maltolate and
fluoride on the gastrointestinal absorption of aluminum at a drinking waterrelevant concentration: A Al-26 and C-14 study. Journal of Inorganic
Biochemistry. 102:798-808 (2008).
Y.Z. Zhouand R.A. Yokel. The chemical species of aluminum influences its
paracellular flux across and uptake into Caco-2 cells, a model of gastrointestinal
absorption. Toxicol Sci. 87:15-26 (2005).

171

296.

297.

298.

299.
300.
301.

302.

303.

304.

305.

306.

307.
308.
309.
310.

D. Nozinic, A. Milic, L. Mikac, J. Ralic, J. Padovan, and R. Antolovic.
Assessment of macrolide transport using PAMPA, Caco-2 and MDCKII-hMDR1
assays. Croat Chem Acta. 83:323-331 (2010).
R.C. Brown, A.P. Morris, and R.G. O'Neil. Tight junction protein expression and
barrier properties of immortalized mouse brain microvessel endothelial cells.
Brain Res. 1130:17-30 (2007).
M. Nakagawa, K. Matsumoto, H. Higashi, T. Furuta, and T. Ohmoto. Acute
effects of interstitial hyperthermia on normal monkey brain--magnetic resonance
imaging appearance and effects on blood-brain barrier. Neurol Med Chir (Tokyo).
34:668-675 (1994).
S. Krol. Challenges in drug delivery to the brain: Nature is against us. Journal of
Controlled Release:145-155 (2012).
R.N. Germain. An innately interesting decade of research in immunology. Nature
Medicine. 10:1307-1320 (2004).
A.E. van Herwaarden, E. Wagenaar, B. Karnekamp, G. Merino, J.W. Jonker, and
A.H. Schinkel. Breast cancer resistance protein (Bcrp1/Abcg2) reduces systemic
exposure of the dietary carcinogens aflatoxin B1, IQ and Trp-P-1 but also
mediates their secretion into breast milk. Carcinogenesis. 27:123-130 (2006).
E. Hellinger, S. Veszelka, A.E. Toth, F. Walter, A. Kittel, M.L. Bakk, K. Tihanyi,
V. Hada, S. Nakagawa, T.D. Duy, M. Niwa, M.A. Deli, and M. Vastag.
Comparison of brain capillary endothelial cell-based and epithelial (MDCKMDR1, Caco-2, and VB-Caco-2) cell-based surrogate blood-brain barrier
penetration models. Eur J Pharm Biopharm. 82:340-351 (2012).
F. Fazlollahi, S. Angelow, N.R. Yacobi, R. Marchelletta, A.S. Yu, S.F. HammAlvarez, Z. Borok, K.J. Kim, and E.D. Crandall. Polystyrene nanoparticle
trafficking across MDCK-II. Nanomedicine. 7:588-594 (2011).
E. Moriyama, M. Salcman, and R.D. Broadwell. Blood-Brain-Barrier Alteration
after Microwave-Induced Hyperthermia Is Purely a Thermal Effect .1.
Temperature and Power Measurements. Surg Neurol. 35:177-182 (1991).
T. Uzuka, H. Takahashi, and R. Tanaka. Interstitial hyperthermia with intraarterial injection of adriamycin for malignant glioma. Neurol Med-Chir. 46:19-23
(2006).
Q. Wang, J.D. Rager, K. Weinstein, P.S. Kardos, G.L. Dobson, J.B. Li, and I.J.
Hidalgo. Evaluation of the MDR-MDCK cell line as a permeability screen for the
blood-brain barrier. Int J Pharmaceut. 288:349-359 (2005).
N. Rapoport. Ultrasound-mediated micellar drug delivery. Int J Hyperther.
28:374-385 (2012).
Z. Gao, H.D. Fain, and N. Rapoport. Ultrasound-enhanced tumor targeting of
polymeric micellar drug carriers. Mol Pharm. 1:317-330 (2004).
I. Wilhelm, C. Fazakas, and I.A. Krizbai. In vitro models of the blood-brain
barrier. Acta Neurobiol Exp. 71:113-128 (2011).
H. Huang, S. Delikanli, H. Zeng, D.M. Ferkey, and A. Pralle. Remote control of
ion channels and neurons through magnetic-field heating of nanoparticles. Nat
Nanotechnol. 5:602-606 (2010).

172

311.

312.

313.

314.

315.

316.

317.

R.J. Mannix, S. Kumar, F. Cassiola, M. Montoya-Zavala, E. Feinstein, M.
Prentiss, and D.E. Ingber. Nanomagnetic actuation of receptor-mediated signal
transduction. Nat Nanotechnol. 3:36-40 (2008).
H.S. Sharma, A. Sharma, H. Mossler, and D.F. Muresanu. Neuroprotective effects
of cerebrolysin, a combination of different active fragments of neurotrophic
factors and peptides on the whole body hyperthermia-induced neurotoxicity:
modulatory roles of co-morbidity factors and nanoparticle intoxication. Int Rev
Neurobiol. 102:249-276 (2012).
H.S. Sharma and A. Sharma. Nanowired drug delivery for neuroprotection in
central nervous system injuries: modulation by environmental temperature,
intoxication of nanoparticles, and comorbidity factors. Wiley Interdiscip Rev
Nanomed Nanobiotechnol. 4:184-203 (2012).
U. Gaur, S.K. Sahoo, T.K. De, P.C. Ghosh, A. Maitra, and P.K. Ghosh.
Biodistribution of fluoresceinated dextran using novel nanoparticles evading
reticuloendothelial system. Int J Pharmaceut. 202:1-10 (2000).
J.M. Rabanel, V. Aoun, I. Elkin, M. Mokhtar, and P. Hildgen. Drug-Loaded
Nanocarriers: Passive Targeting and Crossing of Biological Barriers. Curr Med
Chem. 19:3070-3102 (2012).
M.T. Basel, S. Balivada, H. Wang, T.B. Shrestha, G.M. Seo, M. Pyle, G.
Abayaweera, R. Dani, O.B. Koper, M. Tamura, V. Chikan, S.H. Bossmann, and
D.L. Troyer. Cell-delivered magnetic nanoparticles caused hyperthermiamediated increased survival in a murine pancreatic cancer model. Int J
Nanomedicine. 7:297-306 (2012).
J. Riemer, H.H. Hoepken, H. Czerwinska, S.R. Robinson, and R. Dringen.
Colorimetric ferrozine-based assay for the quantitation of iron in cultured cells.
Anal Biochem. 331:370-375 (2004).

173

VITA
6B3

MO DAN
Birthplace: Baoji, China

EDUCATION
2008 - present

Ph.D. candidate in Pharmaceutical Sciences, College of Pharmacy,
University of Kentucky, Lexington, KY

2008 - 2010

M.S. in Toxicology, Graduate Center for Toxicology, University of
Kentucky, Lexington, KY

2005 - 2008

M.S. in Pharmaceutics, College of Pharmacy, Shanghai Jiao Tong
University, Shanghai, China

2001 - 2005

B.S. in Pharmacy, College of Pharmacy, Sun Yat-Sen University,
Guangzhou, China

PROFESSIONAL EXPERIENCES
2008 – 2013

Research Assistant – College of Pharmacy, University of Kentucky

2005 – 2008

Research Assistant – College of Pharmacy, ShangUniversity of
Kentucky

2005 – 2006

Undergraduate Research – College of Pharmacy, Sun Yat-Sen
University,

HONORS AND AWARDS
National Cancer Institute - Cancer Nanotechnology Training Center Predoctoral
Fellowship, 2011-2013.
Medical Device Speciality Section Awards for the 52nd Annual Meeting of the
Society of Toxicology, 2013.
Peter G. Glavinos, Jr., Ph.D. Fall Graduate Student Travel Award, 2012.
Globalization of Pharmaceutics Education Network (GPEN) Meeting 2012
student award, Melbourne, Australia (GPEN-sponsored student presenter), 2012.
Society of Toxicology student travel award for the 51st Annual Meeting of the
Society of Toxicology, 2012.
174

Student symposium award for the 13th International Neurotoxicology Association
Meeting and the 11th International Symposium on Neurobehavioral Methods and
Effects in Occupational and Environmental Health (NEUREOH), Xi’an, China, 2011.
Karri Casner Environmental Sciences Fellowship for the 49th Annual Meeting of
the Society of Toxicology, 2010.
Outstanding Graduate Award, Sun Yat-Sen University (top 5%), 2005.
Excellent Party Member, Sun Yat-Sen University (Only student from the School of
Pharmacy to receive the award), 2005.
Excellent student scholarship, Sun Yat-Sen University (top 5%), 2001-2005.
Excellent League Member of Sun Yat-Sen University, 2003-2004.
Excellent student leader of Sun Yat-Sen University, 2002-2003.

PUBLICATIONS
1. Scott D, Baebout Y, Wydra R, Dan M, Yokel R, Hilt J, Bae Y. Block Copolymer
Self-assembled and Cross-linked Nanoassemblies for Combination Delivery of Iron
Oxide and Doxorubicin. Accepted.
2. Dan M, Scott D, Hardy P, Wydra R, Yokel R, Hilt J, Bae Y. Block copolymer crosslinked nanoassemblies improve particle stability and biocompatibility of
superparamagnetic iron oxide nanoparticles. Pharmaceutical Research. 2013, 30(2):
552-61.
3. Yokel RA, Tseng MT, Dan M, Unrine JM, Uschi M. Graham UM, Wu P, Grulke EA.
Biodistribution and biopersistence of ceria engineered nanomaterials: Size
dependence. Nanomedicine: Nanotechnology, Biology, and Medicine. 2013, 9(3),
398-407.
4. Dan M, Tseng M, Wu P, Unrine JM, Grulke EA, Yokel RA. Brain microvascular
endothelial cell association and distribution of a 5 nm ceria engineered nanomaterial.
International Journal of Nanomedicine, 2012, 7, 4023-4036.
5. Dan M, Wu P, Grulke EA, Graham UM, Unrine JM, Yokel RA. Ceria engineered
nanomaterial distribution in and clearance from blood: Size matters. Nanomedicine,
2012, 7(1), 95-110.
6. Hardas SS, Sultana R, Warrier G, Dan M, Florence RL, Wu P, Grulke EA, Tseng
MT, Unrine JM, Graham UM, Yokel RA, Butterfield DA. Rat brain pro-oxidant
effects of peripherally administered 5 nm ceria 30 days after exposure.
Neurotoxicology. 2012, 28(7).
7. Yokel RA, Au TC, MacPhail R, Hardas SS, Butterfield DA, Sultana R, Goodman M,
Tseng MT, Dan M, Haghnazar H, Unrine JM, Uschi M. Graham UM, Wu P, Grulke
EA. Distribution, elimination and biopersistence to 90 days of a systemicallyintroduced 30 nm ceria engineered nanomaterial in rats. Toxicological Sciences,
2012, 127 (1), 256-268.
8. Hardas SS, Butterfield DA, Sultana R, Tseng MT, Dan M, Florence RL, Unrine JM,
Graham UM, Wu P, Grulke EA, Yokel RA. Brain distribution and hippocampal
oxidative stress effects of a systemically-introduced 5 nm ceria engineered
nanomaterial. Toxicological Sciences, 2010, 116 (2): 562-576.
9. Chu X, Zhao T, Zhang Y, Zhao A, Zhou M, Zheng X, Dan M, Jia W. Determination
of 13 free fatty acids in pheretima using ultra-performance LC-ESI-MS.
Chromatographia, 2009, 69(7): 645-652.
175

10. He L, Shen P, Fu Q, Li J, Dan M, Wang X, Jia W. Nephro-protective effect of
Kangqianling decoction on chronic renal failure rats. Journal of Ethnopharmacology,
2009, 122(2): 367-373.
11. Dan M, Su M, Gao X, Zhao T, Zhao A, Xie G, Qiu Y, Zhou M, Liu Z, Jia W.
Metabolite profiling of Panax notoginseng using UPLC-ESI-MS. Phytochemistry,
2008, 69(11):2237-44.
12. Dan M, Xie G, Gao X, Long X, Su M, Zhao A, Zhao T, Zhou M, Qiu Y, Jia W. A
rapid ultra performance liquid chromatography- electrospray ionization mass
spectrometry method for the analysis of saponins in the adventitious roots of Panax
notoginseng. Phytochemical Analysis, 2009, 20(1):68-76.
13. Gao X, Dan M, Zhao A, Xie G, Jia W. Simultaneous determination of nine saponins
in flower buds of Panax notoginseng using high performance liquid chromatography.
Biomed Chromatogr, 2008, 22(3): 244-9.
14. Zhang Y, Dan M, Wu J, Yang H, Huang H, Qi Y, Wei S, Okuyama T,Nakajima K.
Study on the chromatographic fingerprinting of Schisandra chinensis (Turcz.) Baill.
by LC coupled with principal component analysis. Chromatographia, 2008, 68(2):
101- 104.
15. Wang X, Zhao T, Gao X, Dan M, Zhou M, Jia W. Simultaneous determination of 17
ginsenosides in rat urine by ultraperformance liquid chromatography - mass
spectrometry with solid-phase extraction. Analytica Chimica Acta, 2007, 594(2): 265273.
16. Dan M, Gao XF, Xie GX, Liu Z, Zhao AH, Jia W. Application of metabolomics in
the research of plant metabolites. Zhongguo Zhong Yao Za Zhi. 2007, 32(22):2337

PRESENTATIONS
3/13 Dan, M., Dickerson, M.T., Hardy, P.A., Bae, Y., Yokel, R.A. Superparamagnetic
iron oxide loaded cross-linked nanoassemblies improve tumor accumulation and
magnetic resonance imaging in vivo. Presented at the 52ed Annual Meeting of the Society
of Toxicology, March 11-14, San Antonio. Abstract Number/Poster Board number: 522
Poster Board -340
11/12 Dan, M., Dziubla, T.D., Bae, Y., Scott, D.F., Hilt, J.Z., Yokel, R.A. Hyperthermia
and anti-PECAM-1 surface modification increase Fe3O4 nanoparticle flux across the
blood brain barrier in vitro and in vivo. Presented at Globalization of Pharmaceutics
Education Network Meeting 2012, Nov 28- Dec 01, Melbourne, Australia. Selected
GPEN-sponsored presenter.
10/12 Dan, M., Cochran, D.B., Dziubla, T.D., Yokel, R.A. Study of Anti-PECAM-1 iron
oxide nanoparticle flux across the blood brain barrier in vitro and in vivo. Presented at
2012 American Association of Pharmaceutical Scientist Annual Meeting and Exposition,
Oct 14-18, Chicago.
09/12 Dan, M., Dziubla, T.D., Bae, Y., Scott, D.F., Hilt, J.Z., Yokel, R.A. Hyperthermia
and anti-PECAM-1 surface modification increase Fe3O4 nanoparticle flux across blood
brain barrier cells. Presented at the 6th International Conference on Nanotoxicology, Sep
4-7, Beijing, China.

176

07/12 Dan, M., Bae, Y., Dziubla, T.D., Scott, D.F., Hilt, J.Z., Yokel, R.A. The effect of
Fe3O4 nanoparticle-induced hyperthermia on the blood brain-barrier association and
permeability. Presented at 39th Annual Meeting & Exposition of the Controlled Release
Society, July 15-18, Québec City, Québec, Canada.
05/12 Dan, M., Bae, Y., Dziubla, T.D., Scott, D.F., Hilt, J.Z., Yokel, R.A. Hyperthermia
increase Fe3O4 nanoparticle flux across blood brain barrier cells. Presented at Markey
Cancer Research Day, May 16, Lexington, KY, USA.
03/12 Dan, M., Tseng, M.T., Wu, P., Unrine, J.M., Grulke, E.A., Yokel, R. A. Brain
entry rate and capillary endothelial cell association of ceria engineered nanoparticles.
Presented at the 51th Annual Meeting of the Society of Toxicology, March 11-15, San
Francisco. Abstract Number/Poster Board number: 321 Poster Board -450
06/11 Dan, M., Wu, P., Tseng, M.T., Graham, U.M., Florence, R.L., Unrine, J.M.,
Grulke, E.A., Yokel, R. A. Pharmacokinetics of ceria engineered nanomaterials after
intravenous administration: effect of particle size. Presented at the 43th annual
Pharmaceutics Graduate Student Research Meeting, June 23-25, Madison, Wisconsin.
06/11 Dan, M., Wu, P., Unrine, J.M., Grulke, E.A., Yokel, R. A. Ceria engineered
nanoparticle association with the blood-brain barrier using in situ bran perfusion.
Presented at a joint conference of the 13th International Neurotoxicology Association
Meeting and the 11th International Symposium on Neurobehavioral Methods and Effects
in Occupational and Environmental Health, June 5-10, Xi’an, China.
03/11 Dan, M., Wu, P., Tseng, M.T., Graham, U.M., Florence, R.L., Unrine, J.M.,
Grulke, E.A., Yokel, R. A. Biodistribution and persistence of four sizes of ceria
engineered nanomaterials after intravenous administration. Presented at the 50 th Annual
Meeting of the Society of Toxicology, March 6-10, Washington D.C. Abstract
Number/Poster Board number: 2065 Poster Board -715.
03/10 Dan, M., Tseng, M.T., Florence, R.L., Tiu, G., Unrine, J.M., Graham, U.M.,
Sultana, R., Hardas, S.S., Helm, M., Butterfield, D.A., Wu, P., Grulke, E.A., Yokel, R. A.
Short- and long-term biodistribution and oxidative stress effects of a systemicallyintroduced 5 nm ceria engineered nanomaterial. Presented at the 49 th Annual Meeting of
the Society of Toxicology, March 7-11, Salt Lake City, UT.
Abstract Number/Poster Board number: 277 Poster Board -633
Mo Dan
Author’s signature
06/14/2013
Date

177

